<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2026-02-09 09:55:09 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena L. Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>102</td>
          <td>48</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, Sara Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>135</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Veres, Colin J. Chu, Anita Gola, R. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, J. Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="Sepsis is a life-threatening condition arising from a dysregulated host response to infection, characterized by a complex interplay between pro-inflammatory and anti-inflammatory immune mechanisms. B cells, that are key components of humoral immunity, are essential for antibody production, antigen presentation, and immune modulation. Sepsis is commonly associated with B cell lymphopenia, particularly in severe cases, as evidenced by a marked reduction in circulating B cells in both adult and pediatric patients. However, the mechanisms driving this depletion have not been completely understood, particularly in pediatric sepsis. In this study, we employed single-cell RNA sequencing (scRNA-seq) to profile peripheral blood leukocytes from pediatric patients with sepsis (three with mild and three with severe condition) alongside four healthy controls. Our analysis revealed a broad depletion of immune cells in sepsis, with B cells showing the most pronounced reduction and the strongest capacity to discriminate between mild and severe disease states. Subset-level analysis identified significant loss and transcriptional reprogramming of natural killer-like B cells (ΝΚΒ), MHC IIhighnaïve, and MHC IIlownaïve B cells in severe sepsis, accompanied by signatures indicative of intrinsic and extrinsic apoptosis, disrupted differentiation, and enhanced migratory potential. Importantly, we identified and validated the population of NKB cells in both pediatric and adult cohorts, broadening the known landscape of B cell phenotypes in human sepsis. We also explored intercellular communications, focusing on B cell-neutrophil interactions, given the notable neutrophilia observed, revealing potential crosstalk that may contribute to the overall immune dysregulation in sepsis. Collectively, these findings offer new insights into the cellular and molecular drivers of immune dysfunction in pediatric sepsis, shedding light on B cell depletion as a central feature of disease severity. This work lays the foundation for future diagnostic and therapeutic strategies targeting B cell-mediated immunity in septic children. The study was registered on ClinicalTrials.gov (NCT04103268), with registration date on 2019-09-23, before the first patient was enrolled.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bce54efd110fde03077139b1afa9c1f4e6856c6b" target='_blank'>
              Single-cell analysis of B cell dysregulation in pediatric sepsis stratified by disease severity
              </a>
            </td>
          <td>
            Fahd Alhamdan, Stefano Gianoli, Koichi Yuki, S. Koutsogiannaki
          </td>
          <td>2025-12-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/046a4759f61fd2ed00479ddd2426526fb3c7aa64" target='_blank'>
              Myeloid reprogramming by poly(I:C) recruits progenitor-exhausted CD8+ T cells and sensitizes rhabdoid tumors to PD-1 blockade
              </a>
            </td>
          <td>
            Valeria Manriquez, Sofia Cavada-Silva, Kévin Beccaria, L. L. Niborski, Amaury Leruste, W. Richer, Mathias Vandenbogaert, Zhi-Yan Han, C. Sedlik, Jordan Denizeau, Jeremy Mesple, Zoé Fusilier, L. Laëtitia Lesage, Jérémie Goldstein, Yohan Gerber-Ferder, Stéphanie Fitte-Duval, Federico Marziali, R. Mena-Osuna, Jimena Tosello-Boari, Rachida Bouarich-Bourimi, Maria Florencia Pacini, Y. Missolo-Koussou, Mylène Bohec, Sylvain Baulande, Philippe Benaroch, J. Helft, Hélène D Moreau, J. Waterfall, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5984ff16cfe613f763f0430e61d72c3b4c0bbf01" target='_blank'>
              The breast tumor microenvironment exploits eosinophil plasticity to suppress their anti-tumor activity
              </a>
            </td>
          <td>
            Zofia Varyova, M. Pohin, Gracie J. Mead, Libby K. Jennings, Valeria da Costa, Sarah Spear, I. McNeish, A. Schwenzer, Adrian L. Harris, Audrey Gérard, Kim S. Midwood
          </td>
          <td>2026-01-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e10756da93e249564dafc2b41fce10c7b1ebac2e" target='_blank'>
              Dual PD-L1/TIGIT blockade induces PNAd⁺ HEV-like vessels and CD62L⁺ lymphocyte recruitment, driving rhabdoid tumor rejection
              </a>
            </td>
          <td>
            Stéphanie Fitte-Duval, Sofia Cavada Silva, R. Mena-Osuna, Owen Hoare, L. L. Niborski, Jordan Denizeau, Laëtitia Lesage, W. Richer, C. Sedlik, Kévin Beccaria, Maëva Veyssière, Rachida Bouarich-Bourimi, Jérémie Goldstein, Federico Marziali, Jimena Tosello Boari, J. Masliah-Planchon, Zhi-Yan Han, Dario Rocha, Mylène Bohec, Sylvain Baulande, J. Waterfall, Valeria Manriquez, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4⁺ T-cells, and CD8⁺ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS–ICOSL pathway, and are enriched for ICOS⁺ Th1-like CD4⁺ T cells and ICOSLhigh cDC1s. CD8⁺ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon-γ–responsive program that sustains CD8⁺ T-cell function and prevents dysfunction. Functionally, ICOSL⁺ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6a060eabfcbbb0a36b483e2912054f711b0272" target='_blank'>
              Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
              </a>
            </td>
          <td>
            Mehdi Chaib, M. Aminu, Shelley M Herbrich, Mahshid Arabi, Yue Xuan, Akshay V. Basi, Anna Casasent, Marc D. Macaluso, Kenneth H. Hu, Matthew M. Gubin, Xi Chen, James J. Mancuso, Sreyashi Basu, Sonali Jindal, Jared K. Burks, S. Watowich, Jia Wu, James P. Allison, Padmanee Sharma
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="Glioblastoma (GBM), the most frequent and aggressive primary brain tumor, remains refractory to all current therapies including surgical resection, chemotherapy, radiotherapy and immunotherapy. Immunosuppressive mechanisms in the GBM tumor microenvironment contribute to the lack of anti-tumor adaptive immunity. We found that a subset of tumor associated macrophages (TAMs) can be repolarized into an anti-tumor phenotype via agonist stimulation of the retinoic acid-inducible gene I (RIGI), a cytosolic double-stranded RNA pattern recognition receptor (PRR). In silico analysis of adult GBM datasets available in the public domain revealed that RIGI expression by a subset of activated TAMs positively correlated with patient survival. Studies in syngeneic mouse models of GBM showed that intratumoral delivery of stem-loop RNA 14 (SLR14), a RIG-I agonist, improved the efficacy of chemotherapy, radiotherapy and immunotherapy treatments, beyond the effects of other nuclei acid sensor agonists. We found that RIGI+ macrophages are the main drivers of SLR14 effect, combining activation of TAMs and priming of functional cytotoxic CD8+ T lymphocytes and NK cells. The anti-GBM effect of SLR14 is opening a significant new avenue for adult GBM treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1342f808c2fd345588c30c0266370e6a04636995" target='_blank'>
              RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma
              </a>
            </td>
          <td>
            Han Xu, Sungwoon Lee, Felipe Leser, Olga Fedorova, Peiwen Lu, Eric Song, Mehdi Touat, Anne Eichmann, Akiko Iwasaki, A. Pyle, Jean-Leon Thomas
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Improving responses to cancer immunotherapies requires deeper insight into the cellular mechanisms governing T cell-mediated anti-tumor immunity. TMEM33 is an endoplasmic reticulum-resident transmembrane protein enriched across multiple tumor types, with reported functions in anti-viral immunity as well as calcium and lipid homeostasis, yet its role in tumor immunosurveillance remains unknown. Using murine genetic models, we demonstrate that host TMEM33 constrains anti-tumor CD8+ T cell responses. Constitutive Tmem33-/- mice exhibited delayed melanoma tumor growth and increased CD8+ T cell infiltration. Antigen-specific CD8+ compartments in tumors of Tmem33-/- mice showed TCF-1+PD-1+ progenitor-exhausted cell (Tpex) enrichment, elevated effector function and reduced exhaustion, alongside improved effector memory expansion and T-bet expression in draining lymph nodes. We highlight that TMEM33 functions intrinsically within the T cell compartment, as TMEM33 deletion (1) enhanced polyclonal activation of naive CD8+ T cells ex vivo, (2) promoted preferential Tpex accumulation among adoptively transferred naive OT-I cells in B16F10-OVA tumors and draining lymph nodes, and (3) improved the potency of ex vivo-expanded OT-I cells in controlling tumor growth during adoptive cell therapy. Finally, in a large, prospectively recruited metastatic melanoma cohort, lower TMEM33 expression in patient CD8+ T cells significantly correlated with improved survival and elevated TCF-7 (encoding TCF-1). Collectively, our findings define TMEM33 as a formerly unrecognized intrinsic determinant of tumor-directed CD8+ T cell fate that limits Tpex maintenance, and restrains cell therapy responses, suggesting that its modulation may strengthen immunotherapeutic efficacy. One sentence summary TMEM33 intrinsically limits progenitor exhausted CD8+ T cells, scales anti-tumor responses and predicts melanoma patient survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b5c85fa3ccdffaf374a3f09dd7d217b43c30d4c" target='_blank'>
              TMEM33 deletion potentiates anti-tumor CD8+ T cell immunity
              </a>
            </td>
          <td>
            M. T. Jackson, Tianming Zhao, G. Milotay, I. Pedroza-Pacheco, Yanshu Cai, Claire Willis, S. Phyu, Bruno Beernaert, Jamie TW Kwon, Hala Estephan, Vinnycius Pereira Almeida, Maria Aggelakopoulou, Silvia Panetti, Christian Zierhut, Tim Elliott, Eleni Adamopoulou, J. Rehwinkel, Malcolm JW Sim, Amit Grover, Dmitry I. Gabrilovich, Benjamin P. Fairfax, E. Honoré, D. Withers, John C. Christianson, Eileen E. Parkes
          </td>
          <td>2026-01-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c11565e00df96d730b6130fa5ba4b31516b47635" target='_blank'>
              PI3Kδ promotes T cell effector differentiation and plasticity during chronic infection
              </a>
            </td>
          <td>
            Andrea C. Pichler, J. Cannons, Dominic P. Golec, Julie M. Reilley, Dan Corral, Eduard Ansaldo, Qin Xu, Subrata Paul, Paul Schaughency, Francisco A. Otaizo-Carrasquero, Stacie M. Anderson, Anshu Deewan, Dorian B. McGavern, Pamela L. Schwartzberg
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival. Pilcher et al. present a single-cell transcriptomics-based immune atlas of participants with newly diagnosed multiple myeloma, reporting on the association of cell types, gene expression and intercellular interactions with disease progression phenotypes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f88dd8011aa8686433c4d02b3a0e4dfd59a9255" target='_blank'>
              A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
              </a>
            </td>
          <td>
            William C. Pilcher, Lijun Yao, Edgar Gonzalez-Kozlova, Yered H. Pita-Juárez, Dimitra Karagkouni, Chaitanya R. Acharya, Marina E. Michaud, Mark Hamilton, Shivani Nanda, Yizhe Song, Kazuhito Sato, Julia Wang, Sarthak Satpathy, Yuling Ma, Jessica Schulman, D. D’souza, R. Jayasinghe, Denis J Ohlstrom, Katherine E. Ferguson, Giulia Cheloni, Mojtaba Bakhtiari, Nick Pabustan, K. Nie, J. Foltz, Isabella Saldarriaga, Rania Alaaeldin, Eva Lepisto, Rachel Chen, M. Fiala, Beena E. Thomas, April Cook, Junia Vieira Dos Santos, Chiang I-ling, Igor Figueiredo, J. Fortier, Michael Slade, Stephen T. Oh, Michael P. Rettig, Emilie I. Anderson, Ying Li, Surendra Dasari, Michael A. Strausbauch, Vernadette A. Simon, , I-ling Chiang, N. Kalavros, Jennifer Rogers, T. Dawson, Brian H. Lee, G. Kelly, Laura A Walker, Nicolas F. Fernandez, John Leech, Jarod Morgenroth-Rebin, K. Angeliadis, Matthew A. Wyczalkowski, Song Cao, Omar Ibrahim, Roderick Lin, T. Fehniger, Andrew J. Houston, E. Radkevich, Adeeb H Rahman, Zhihong Chen, A. Laganà, John F. DiPersio, J. Rosenblatt, S. Kim-Schulze, S. Lonial, Shaji K. Kumar, Swati S. Bhasin, T. Kourelis, M. Dhodapkar, Ravi Vij, D. Avigan, H. Cho, George Mulligan, Li Ding, Sacha Gnjatic, Ioannis S. Vlachos, Manoj K. Bhasin
          </td>
          <td>2026-01-01</td>
          <td>Nature Cancer</td>
          <td>0</td>
          <td>111</td>
        </tr>

        <tr id="Natural killer (NK) cells are integral to the innate immune system, playing a crucial role in immune surveillance and the rapid response to virally infected and tumor cells. Epigenetic gene expression regulation significantly influences NK cell function and differentiation. Using a high-throughput small-molecule drug screening approach, we identified bromodomain and extra-terminal domain (BET) inhibitors (BETi) as potent modulators of NK cell function, reducing proinflammatory cytokine secretion while increasing markers of NK cell maturation and cytotoxicity. During NK lineage specification from hematopoietic stem cells, we demonstrated that BETi reduced NK cell fate and promoted increased myeloid cell differentiation. Moreover, differentiated NK cell types had more functionally differentiated gene expression programs. Thus, BET proteins are crucial for both mature NK cell functions and controlling NK cell lineage development from progenitors in the bone marrow. These findings suggest that BETi can fine-tune NK cell responses, offering promising therapeutic potential for cancer immunotherapy and the treatment of inflammatory and autoimmune diseases. Our study underscores the critical role of BET inhibitors in regulating NK cell function and opens new avenues for targeted immune modulation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e1b914c2c6315017334ad728068ea592de3c5137" target='_blank'>
              Bromodomain and extra-terminal protein inhibitors modulate natural killer cell function and differentiation
              </a>
            </td>
          <td>
            Eric S. Geanes, Gage Greening, Maria Aggelakopoulou, Linh-Huyen Truong, Santosh Khanal, C. LeMaster, Marc Herman, Rebecca McLennan, P. Borrow, Todd Bradley
          </td>
          <td>2026-01-03</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>72</td>
        </tr>

        <tr id="Dogs play a major role in sustaining transmission of Leishmania infantum to people, thus prevention and treatment of canine leishmaniosis (CanL) to reduce transmission represents an unmet public health need. Although advances have been made in understanding how immunopathology correlates to infectiousness as CanL progresses, the immune mechanisms underlying transition between disease stages and terminal decline remain ill-defined. To address this knowledge gap, we generated a comprehensive atlas of peripheral immune cells from control dogs and naturally-infected dogs using single-cell RNA sequencing. The LeishDog Atlas captures the cellular and transcriptional complexity underlying CanL, tracing shifts in immune composition and gene expression across progressive, well-defined disease stages. Notably, we identified distinct myeloid, CD4+ and CD8+ T cell phenotypes and transcriptional states associated with disease progression. This resource provides a valuable framework for understanding systemic immune dysregulation in CanL, including determinants of T cell exhaustion and myeloid cell activation, and establishes a foundation for comparative, translational, and mechanistic studies of CanL immunopathology and transmissibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8412687f28e64e4d6b2558529c494e2ee4440eca" target='_blank'>
              A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis
              </a>
            </td>
          <td>
            Danielle P. Uhl, Daniel J. Holbrook, Max C Waugh, S. Dey, Najmeeyah Brown, Karen I. Cyndari, Jacob J. Oleson, Paul M. Kaye, Christine A. Petersen
          </td>
          <td>2025-12-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/59359ad678fb5970076eddf100c364fea7a28f75" target='_blank'>
              Adrenergic signaling induces a pro-tumorigenic B cell state in colorectal cancer
              </a>
            </td>
          <td>
            Meike S. Thijssen, Simone L. Schonkeren, Linde Coolkens, Yuchi Zou, Lieve Temmerman, Joëlle de Vaan, M. Idris, Jorunn Vrancken, Kim Wouters, Nathalie Vaes, Marion J. Gijbels, Sharon Scardellato, Erwin Wijnands, Willine J. van de Wetering, F. Verhaegen, L. J. Dubois, Erik Biessen, Carmen López Iglesias, Kim M Smits, A. Bardelli, Stefano Casola, W. Boesmans, V. Melotte
          </td>
          <td>2026-01-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a82efc5b2c9cc4922bf6d2b205d9310648f4f84" target='_blank'>
              Single-cell multiomics reveals epigenetic rewiring of splenic memory B cells in murine malaria reinfection
              </a>
            </td>
          <td>
            Montserrat Coronado, Á. Vincelle-Nieto, Isabel G. Azcárate, S. Pérez-Benavente, A. Puyet, Amalia Díez, José M. Bautista, A. Reyes-Palomares
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fab0829fa668d3f68087f51374ae0be2ba943151" target='_blank'>
              Perturbational single-cell profiling of patient tumors defines lineage- and context-specific programs of innate immune resistance
              </a>
            </td>
          <td>
            C. Perry, A. Frey, Y. Fei, J. Wang, P. Costa, H. N. Amin, S. Ghadermarzi, D. Levine, W. Tong, A. Koda, M. Mackie, M. He, Y. Nie, K. Clulo, F. Ouerghi, J. Wei, T. Cordero Dumit, M. Yaskolko, M. Ding, A. Caldera, O. Kyrysyuk, L. Lum, J. W. Allen, W. Guo, A. Naqash, A. Elliot, A. Vanderwalde, M. Capelletti, T. Adeyelu, S. Barry, M. Hugaboom, A. Bacchiocchi, H. Kluger, M. Bosenberg, A. Iwasaki, D. Braun, J. Clune, D. van Dijk, K. Olino, J. Ishizuka
          </td>
          <td>2025-12-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Xenotransplantation of gene-edited pig kidneys offers a promising solution to the shortage of kidneys for organ transplantation. We recently performed a gene-edited pig kidney transplantation into a living human recipient with end-stage kidney disease. Here, using transcriptomics, proteomics, metabolomics and multiplexed imaging, we conducted high-dimensional immune profiling in this individual. Despite profound depletion of circulating T cells, early T cell-mediated rejection occurred within 1 week after transplantation, likely driven by subtherapeutic immunosuppression and the presence of residual CD8+ T cells in lymph nodes. This T cell-mediated rejection event was reversed by intensified immunosuppression. After treatment, adaptive immunity remained suppressed, whereas innate immune activation, characterized by sustained monocyte and macrophage activity along with elevated levels of interleukin-1 beta and granulocyte–macrophage colony-stimulating factor, persisted. Comparative transcriptomic analysis showed that xenograft rejection profiles resembled those typically observed in human allograft rejection, while also revealing unique innate immune signatures. We did not detect antibody-mediated rejection. The levels of circulating pig donor-derived cell-free DNA rose during the initial rejection episode and declined with treatment, supporting the potential of cell-free DNA measurements as a noninvasive biomarker of xenograft rejection. These findings define the distinct immune landscape of kidney xenotransplantation and highlight the need for regimens targeting both innate and adaptive immunity to improve outcomes. High-dimensional immune profiling of a living recipient of a pig-to-human xenotransplant provides insight into the immune landscape of xenotransplantation and directions for improved immunosuppression strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4d98f157c93f6286ac76303fb8e8b35d2f6f44e7" target='_blank'>
              Immune profiling in a living human recipient of a gene-edited pig kidney
              </a>
            </td>
          <td>
            Guilherme T. Ribas, André F. Cunha, Jonathan P Avila, A. Giarraputo, Leela Morena, Karina Lima, R. B. Gassen, Jia-Yun Chen, Jia-Ren Lin, Sandro Santagata, Claire T Avillach, B. Ryback, Martin S Lindner, S. Bercovici, Ivy A. Rosales, Tatsuo Kawai, H. Nakaya, Robert B Colvin, Thiago J. Borges, Leonardo V. Riella
          </td>
          <td>2026-01-01</td>
          <td>Nature Medicine</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Type 2 diabetes mellitus (T2DM) worsens stroke outcomes, but the underlying mechanisms linking T2DM to systemic immune dysfunction remain unclear. We investigated whether T2DM alters bone marrow (BM) hematopoiesis and dysregulate immune signaling following ischemic stroke in mice. Single-cell RNA sequencing, GeoMx digital spatial profiling (DSP), nCounter, and flow cytometry were used to analyze BM cells from control (db/+, Ctrl) and diabetic (db/db, T2DM) mice underwent experimental stroke or sham surgery. Diabetes caused marked structural remodeling of BM, with reduced cellularity and imbalance of hematopoietic lineages. Pseudotime trajectory analysis revealed impaired differentiation and maturation signatures of hematopoietic progenitor cells (HPC1) and granulocytes, and overactivation toward monocytes in diabetes after stroke. CellChat analysis demonstrated reorganization of intercellular communication, with hematopoietic progenitor cells (HPC1) and monocytes emerging as dominant signaling hubs through upregulated MIF, SIRP, and THBS pathways. AUCell enrichment indicated increased glycolysis and oxidative phosphorylation but reduced interferon-γ (IFN-γ) signaling, reflecting metabolic activation coupled with immune dysregulation. DSP and nCounter further confirmed upregulation of genes in the MIF, SIRP and THBS pathways in CD115⁺ monocytes and Ly6G⁺ neutrophils, indicating proinflammatory and migratory activation in diabetic bone marrow. Our data suggest that T2DM reprograms hematopoiesis and signaling networks, leading to maladaptive myeloid responses and impaired immune regulation after stroke. This maladaptive BM environment amplifies inflammation and limits repair, linking diabetic metabolic stress to worsened ischemic outcomes. Targeting bone marrow immune dysfunction may offer a therapeutic strategy to improve stroke recovery in diabetic patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ab79f630ee108b9ad79cdd23cb73d99a2673e4d" target='_blank'>
              Type 2 diabetes Reprograms Bone Marrow Hematopoiesis and Dysregulates Immune Signaling in Response to Stroke
              </a>
            </td>
          <td>
            Hongxia Zhang, Wanjun Gu, Kailin Yu, Chia-Ling Tu, Wenhan Chang, Jialing Liu
          </td>
          <td>2025-12-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B-cell malignancies, but its success in acute myeloid leukemia (AML) remains limited. Durable responses depend on the formation of long-lived memory T cells, whereas T cell exhaustion contributes to non-response and relapse. In patients with AML who achieved remission after cord blood transplantation, we here first observe enrichment of memory T cells with high expression of the chemokine receptor CXCR4. Next, we show that engineering CAR-T cells to co-express CXCR4 enhances their persistence and anti-leukemic activity in patient-derived xenograft models. Using single-cell profiling and metabolic analysis, we find that CXCR4 promotes memory-associated transcriptional programs, reduces exhaustion, and supports oxidative metabolism. These effects are observed with CAR-T cells targeting CD25 or CD96 as AML-associated targets. Our results indicate that CXCR4 strengthens CAR-T cell memory and durability, offering a strategy to improve immunotherapy outcomes in AML and beyond. CAR-T cell efficacy is often limited by the inability to maintain a memory T cell program. Here, the authors show that intrinsic CXCR4 expression enhances CAR-T cell persistence and memory differentiation in acute myeloid leukemia.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2a1a8fac6df24e06173a348494a1e7d9ae0ffe6" target='_blank'>
              CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting
              </a>
            </td>
          <td>
            Ari Itoh-Nakadai, Minggao Liang, Michiho Shindo, Chen Bibi, Mariko Tomizawa-Murasawa, Saera Fujiki, Akiko Kaneko, Emi Kanamaru, Mari Hashimoto, Hiroshi Kajita, Yoshinari Ando, Miki Kojima, Jonathan Moody, Makoto Iwasaki, S. Takagi, Ryo Nakagawa, Saumya Agrawal, Hanae Amitani-Iijima, Kaori Sato, Yuriko Sorimachi, Nahoko Suzuki, Takehiro Fukami, Kazuharu Hanada, Satoshi Morita, Kazushige Katsura, Takehisa Matsumoto, Maiko Kobayashi, Masahiko Kato, Yasuyuki Negishi, Mikako Shirouzu, Y. Najima, K. Takubo, C. Hon, N. Uchida, Shuichi Taniguchi, Y. Momozawa, P. Carninci, Leonard D. Shultz, Yoriko Saito, Michiel J. L. de Hoon, Jay W. Shin, Fumihiko Ishikawa
          </td>
          <td>2026-01-26</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="Immune rejection poses a major challenge in organ transplantation, with tissue-resident memory T (TRM) cells playing a critical role in graft rejection. This study investigated the impact of CCR8 on TRM cells using single-cell RNA sequencing (scRNA-seq), flow cytometry, and immunohistochemistry. The results show that CCR8 expression was upregulated on CD8⁺ TRM cells after transplantation, peaking on day 7. Blocking or knocking out CCR8, as well as neutralizing CCL1 and CCL8, significantly reduced CD8⁺ TRM cell accumulation in the graft and their cytokine production. These treatments prolonged graft survival, alleviated rejection severity, and impaired the ability of CD8⁺ TRM cells to produce GZMB, IFN-γ, and IL-2. Single-cell analysis of skin transplantation revealed that loss of CCR8 disrupted macrophage–T cell interactions, particularly CD8⁺ TRM–macrophage crosstalk, while enhancing CD40, PD-L1, and NRG signaling. These findings suggest that targeting CCR8 to limit the accumulation and function of CD8⁺ TRM cells may be an effective strategy to alleviate transplant rejection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/90971d5b49b0f0a4e21364a3098badc63c73195f" target='_blank'>
              Single-cell analysis indicating CCR8 modulates CD8+ tissue-resident memory T cells to attenuates rejection in transplantation
              </a>
            </td>
          <td>
            Xueteng Wang, Xinqiang Li, Hailun Cai, Zhuoyu Jia, Xin Zhou, Ruidong Ding, Meiying Song, Huan Liu, Feng Wang, Bin Wu, Kai Zhao, Shipeng Li, Bei Zhang, Dahong Teng, Jinzhen Cai
          </td>
          <td>2025-12-16</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7bd9aca00aac6bc3a28be72ae84077e7863c3375" target='_blank'>
              FAK Inhibition Remodels the Metastatic ECM and Restores CD8⁺ T Cell Trafficking and Immunosurveillance
              </a>
            </td>
          <td>
            Nicole D. Barth, Bo Peng, Michael Papanicolaou, Fatemeh Ahmadi Moughari, Camille L. Duran, Christopher S. McGinnis, John C. Dawson, E. Webb, Morwenna Muir, Fraser Laing, Yookyung Jung, Xue-Yan He, Ansu Satpathy, M. Egeblad, Syed Haider, R. Natrajan, Maja H. Oktay, D. Entenberg, V. Brunton
          </td>
          <td>2026-01-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>54</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d1635d5db962d98f76f1b83fc5632d8a21ccd0a2" target='_blank'>
              Interleukin-6 restricts pre-thymic T cell lineage commitment of progenitors driving loss of SIV control
              </a>
            </td>
          <td>
            Saleem Anwar, Naseem Sadek, Christian M. Beusch, Ahmet F. Coskun, Mohamed S. Abdel-Hakeem, R. P. Johnson, Frank J. T. Staal, Vijayakumar Velu, Mirko Paiardini, Brandon F. Keele, Guido Silvestri, David E. Gordon, J. Tomalka, Sheikh Abdul Rahman
          </td>
          <td>2026-02-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Despite advances in treatment, >50% of patients with advanced melanoma are unresponsive to current therapies. Using the B78-D14 melanoma model (GD2+/MHC-I⁻/MHC-II+), we can cure mice with a regimen that includes radiation therapy (RT) in combination with immunocytokine (IC; anti-GD2 monoclonal antibody linked to IL-2) while establishing immunological memory. We interrogated the role of T cells in the antitumor and memory responses following RT+IC. We show a requirement for CD4, but not CD8 T cells, to achieve both the initial and memory responses. Upon IC-induced cell-cell contact, subsets of CD4 T cells, including Foxp3⁺ T regulatory cells, trogocytose GD2 from tumor cells, acquire cytotoxic granules, and kill tumor cells. These results were confirmed using human tumor cell lines. These findings reveal that CD4⁺ T regulatory cells, upon immunologically-induced binding to tumor cells, can trogocytose tumor antigens and directly kill tumor cells, redefining their potential role in antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77253e2042c64402b4c27c711448fdd4c49c02c6" target='_blank'>
              Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing
              </a>
            </td>
          <td>
            AK Erbe, Arika S. Feils, Anqi Gao, Sabrina N. VandenHeuvel, Simon Boyenga, Alina A. Hampton, M. Heck, Jen Zaborek, Dan Spiegelman, N. Tsarovsky, A. Hoefges, A. Pieper, Peter M. Carlson, Mildred A. Felder, Ravi B Patel, S. Gillies, Alexa R. Heaton, Zachary S. Morris, Huy Q. Dinh, A. Rakhmilevich, Paul M. Sondel
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>54</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8779b2bf6cba17b1530e13526c071bfe44406db3" target='_blank'>
              Regulatory T cells clonally expand and contribute to stromal cell function in fibrotic response to synthetic implants
              </a>
            </td>
          <td>
            Joscelyn C. Mejías, Kavita Krishnan, Anna Ruta, A. S. Ramanujam, Elise F. Gray-Gaillard, Locke Davenport Huyer, David R Maestas, Sushma Nagaraj, Frank Haoning Yu, Alexandra N. Rindone, Peter Abraham, Maria Browne, E. Fertig, Drew M. Pardoll, Jennifer H. Elisseeff
          </td>
          <td>2026-01-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Simple Summary Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide, and many patients do not respond well to immunotherapy. In this study, we identified a unique group of macrophages—called NFKBIZ+ M0 macrophages—that are enriched in patients non-responsive to anti-PD-1 treatment. These macrophages are activated by hypoxia and release factors such as VEGFA and HBEGF that promote new blood vessel formation and tumor growth. They also produce inflammatory molecules that suppress the immune system, helping the tumor evade immune attack. Further analysis revealed that specific signaling pathways (FOSB–VEGFA and FOS–HBEGF) drive this harmful macrophage behavior. Our findings uncover a new mechanism linking hypoxia, angiogenesis, and immune evasion to treatment resistance in HCC and suggest potential therapeutic targets to improve immunotherapy outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ce50b60fe1db2dee500e6f910be7f3a05fceb0c3" target='_blank'>
              Single-Cell Transcriptomic Profiling Reveals That Macrophage-Induced Angiogenesis Contributes to Immunotherapy Resistance in Hepatocellular Carcinoma
              </a>
            </td>
          <td>
            Xinyu Pan, Baolin Liao, Zhijie Hu, Yuanyan Xiong
          </td>
          <td>2026-01-01</td>
          <td>Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9bc787e32b19937cc86d82b167fee2834cae712" target='_blank'>
              T CELLS PROMOTE THE GROWTH OF SMALL-CELL LUNG CARCINOMA VIA AN IL-6/CD74 AXIS
              </a>
            </td>
          <td>
            Maya Baron, Zoé Ginestet, Debadrita Bhattacharya, Myung Chang Lee, Alexandros P. Drainas, Clara L. Poupault, Y. Nishiga, Alec E. Dallas, B. Nabet, Julien Sage
          </td>
          <td>2025-12-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="B cells are key drivers of immune dysregulation across systemic autoimmune diseases. Among their progeny, plasmablasts occupy a uniquely revealing niche: short-lived, highly proliferative intermediates that mirror real-time B-cell activation. Their appearance in peripheral blood integrates antigenic stimulation, cytokine-driven differentiation, and aberrant germinal-center dynamics, transforming them into sensitive indicators of ongoing immunological activity. This review synthesizes current knowledge on plasmablast biology and highlights disease-specific phenotypes across systemic lupus erythematosus (SLE), primary Sjögren disease (pSjD), IgG4-related disease (IgG4-RD), ANCA-associated vasculitis (AAV), and rheumatoid arthritis (RA). We incorporate molecular insights from single-cell technologies that have uncovered previously unrecognized plasmablast subsets, metabolic states, and interferon-related signatures with prognostic and mechanistic value. Beyond descriptive immunology, plasmablasts are emerging as dynamic biomarkers capable of informing real-time clinical decisions. One of the most robustly supported applications is the prognostic interpretation of plasmablast kinetics following B-cell-depleting therapies, where early reconstitution patterns consistently predict relapse across multiple autoimmune conditions. As clinical immunology shifts from static serological markers toward kinetic, cell-based monitoring, plasmablast quantification offers a path toward precision immune surveillance. Integrating plasmablast dynamics into routine care may ultimately allow clinicians to anticipate disease flares, time therapeutic reinforcements, and transition from reactive management to preventive intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3381319626eb89d0a494c21128b6154270c46d9f" target='_blank'>
              Plasmablasts as Translational Biomarkers in Autoimmune Diseases: From Cellular Dynamics to Clinical Decision-Making
              </a>
            </td>
          <td>
            M. Soyfoo, J. Sarrand
          </td>
          <td>2026-01-01</td>
          <td>Current Issues in Molecular Biology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Current therapies for inflammatory bowel disease (IBD) often fail to achieve complete remission and are associated with systemic toxicity owing to their broad immunosuppressive effects. To overcome these limitations, we developed a bioengineered extracellular vesicle (EV) platform that modulates key immune signaling pathways to efficiently restore the T-cell balance in inflamed intestinal tissues. EVs derived from Wharton’s jelly mesenchymal stem cells were engineered to display PD-L1 on their surface and encapsulate miR-27a-3p. Surface PD-L1 engages the PD-1 checkpoint in activated T cells, attenuating T-cell receptor signaling via SHP2-mediated dephosphorylation of ZAP70 and AKT. In parallel, miR-27a-3p suppresses prohibitin 1 (PHB1), a mitochondrial regulator of Th17 cell bioenergetics and inflammatory function, thereby reducing Th17 polarization and increasing the number of FOXP3⁺ regulatory T cells. These dual-targeting EVs preferentially localized to inflamed intestinal tissues via chemokine (CCR2/CXCR4) and PD-1-dependent mechanisms. In humanized mouse models of colitis, these EVs attenuated mucosal inflammation, suppressed effector T-cell responses, and preserved epithelial integrity. In IBD patient-derived colonoid cultures, PD-L1/miR-27a-3p EVs maintained epithelial viability and barrier integrity without inducing cytotoxicity or structural disruption. Transcriptomic and single-cell analyses revealed the downregulation of inflammatory and exhaustion signatures, along with the enrichment of regulatory subsets. Collectively, this study presents a cell-free immunotherapeutic approach that reprograms T cells in inflamed tissues through the PD-1 and mitochondrial signaling pathways while maintaining intestinal epithelial integrity, offering a promising therapeutic strategy for IBD and other T cell-driven inflammatory disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/21a759c51278c1cf53050a54d395a9872336d71e" target='_blank'>
              Engineered extracellular vesicles reprogram T cells by targeting PD-1 and PHB1 signaling in inflammatory bowel disease
              </a>
            </td>
          <td>
            Mi-Kyung Oh, Hyun Sung Park, Dong-Hoon Chae, Aaron Yu, Jae Han Park, Jiyoung Heo, Keonwoo Cho, Jiho Kim, Byeonghwi Lim, Jun-Mo Kim, Jordan Axelrad, Kyung Ku Jang, Jong Pil Im, S. Koh, Byung-Soo Kim, Kyung-Rok Yu
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9d522a0c1e585eda2d8238200dfededee05868fa" target='_blank'>
              Leveraging TNFR2 for antitumour immunity: T reg depletion and myeloid reprogramming versus T cell costimulation
              </a>
            </td>
          <td>
            L. Mårtensson, P. Holmkvist, Kirstie Cleary, Carolin Svensson, M. Semmrich, Niyaz Yoosuf, Alexandra Gabriela Ferreira, M. Kovacek, Mimoza Boden, Therese Blidberg, Osman Dadas, J. Mattsson, David Ermert, Elin Birgersson, Vincentiu Pitic, Martin C Taylor, Mona Yazdani, Ulla-Carin Tornberg, Ingrid Karlsson, Sean H Lim, S. Beers, Mark Cragg, B. Frendéus, I. Teige
          </td>
          <td>2026-01-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b58655f2ee5e1833c4162ee24f906c63fe582479" target='_blank'>
              Gene expression profiling of dendritic cell tolerance dysfunction in women with Systemic lupus erythematosus
              </a>
            </td>
          <td>
            Ana Laura Hernández-Ledesma, E. L. Coss-Navarrete, S. Salazar-Magaña, Diego Ramírez-Espinosa, L. Tinajero-Nieto, Estefania Torres-Valdez, A. Peña-Ayala, Guillermo Félix-Rodriguez, G. Frontana-Vázquez, Jair Santiago García Sotelo, G. Trynka, F. Rosetti, S. L. Fernandez-Valverde, María Gutiérrez-Arcelus, D. Alpízar-Rodríguez, Alejandra Medina-Rivera
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="Glioblastoma (GBM) remains one of the most lethal brain tumors, characterized by extensive immune evasion and a macrophage-dominated tumor microenvironment (TME). However, the molecular determinants governing tumor-associated macrophage (TAM) states and their immunoregulatory functions remain poorly understood. We integrated bulk- and single-cell transcriptomic datasets (TCGA, CGGA, Ivy GAP, and Brain Immune Atlas) to systematically characterize the expression, prognostic relevance, and immune contexture of the myeloid biomarker membrane-spanning 4-domain A6A, MS4A6A, in GBM. Differential expression, survival, and pathway enrichment analyses were performed. Single-cell mapping and CellChat modeling delineated MS4A6A-associated TAM subpopulations, intercellular communication networks, and ligand–receptor signaling dynamics. Spatial transcriptomic validation and pharmacogenomic modeling were conducted to assess anatomic enrichment and therapeutic vulnerabilities. High MS4A6A expression predicted unfavorable survival and correlated with increased stromal and immune infiltration. Single-cell analyses localized MS4A6A predominantly to TAMs, especially Regulatory- and Ribo-TAM states enriched for antigen presentation, T-cell regulation, and ribosomal biogenesis pathways. CellChat analysis revealed that MS4A6A-high TAMs exhibited markedly enhanced communication with CD4+ T cells and Tregs through upregulated PGE2–PTGER2/PTGER4, PECAM1–CD38, and THBS1–CD36 signaling axes, implicating MS4A6A in prostaglandin-driven immune suppression. Spatial profiling confirmed preferential localization of MS4A6A within perivascular and angiogenic niches. Pharmacogenomic prediction indicated that MS4A6A-high tumors were more sensitive to ERK, mTOR, and CDK4/6 inhibition. MS4A6A defines a macrophage-centered, immunosuppressive ecosystem in GBM, mediated by the activation of the PGE2 signaling axis. These findings position MS4A6A both as a prognostic biomarker and as a potential therapeutic node linking myeloid reprogramming to actionable pathway vulnerabilities in glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2aace77685200c650b039b4e217d58ff78ecf5af" target='_blank'>
              The Myeloid Biomarker MS4A6A Drives an Immunosuppressive Microenvironment in Glioblastoma via Activation of the PGE2 Signaling Axis
              </a>
            </td>
          <td>
            Jianan Chen, Qiong Wu, Anders E. Berglund, Robert J. Macaulay, James J. Mulé, Arnold B. Etame
          </td>
          <td>2025-12-20</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Lung adenocarcinoma (LUAD) exhibits substantial heterogeneity in tumor immune microenvironment (TIME) composition, shaping disease progression and therapeutic response. Here, we integrated transcriptomic and clinical data from TCGA‐LUAD to develop a TIME‐associated prognostic model. LASSO Cox regression identified eight key genes—S100P, CPLX2, CD200R1, LINC01857, CLEC7A, CLEC17A, COL6A5, and CX3CR1‐ that yielded a risk score separating patients into two groups with distinct immune states. High‐risk tumors were characterized by diminished CD4+ Th1 and CD8+ T cell infiltration, expansion of M2 macrophages, and cytokine profiles consistent with immune suppression, whereas low‐risk tumors displayed immune‐active features, including elevated IL‐27 signaling. Single‐cell RNA sequencing of a murine LUAD model revealed that early tumors featured a T cell‐enriched microenvironment with elevated IL‐27 signaling, whereas late tumors acquired a macrophage‐driven immunosuppressive landscape. Interstitial macrophages acquired an M2‐like phenotype, upregulated PD‐L1, and suppressed CD4+ and CD8+ T cell activity through the CD86‐CTLA4 and SELPLG‐SELL axes. Functionally, IL‐27 blockade accelerated tumor growth, whereas recombinant IL‐27 restrained tumor progression and enhanced PD‐L1/CTLA‐4 blockade efficacy by augmenting Th1 and cytotoxic T cell responses. These findings define a TME‐based prognostic classifier and position IL‐27 as a stage‐dependent therapeutic target that restores T cell immunity and boosts checkpoint blockade efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2cc2066e706ddd6bc43aa3abe99cd395ec53999b" target='_blank'>
              A tumor Microenvironment‐Derived Prognostic Model Guides IL‐27 as a Therapeutic Strategy to Restore T Cell Immunity in Lung Adenocarcinoma
              </a>
            </td>
          <td>
            Gaopu Xie, Donglin Cai, Gang Zhang, Hongda Zhao, Xu Wang, Li Zhu, Jing Ni, Xia Yi, Jun Liang, Mengmeng Liang
          </td>
          <td>2026-01-01</td>
          <td>Advanced Biology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Human gastrointestinal (GI) tissues are a major site of HIV-1 viral persistence, but the nature of the GI reservoir remains poorly described. To characterize the GI HIV reservoir, we profiled cells from GI tissue and matched peripheral blood mononuclear cells from ten people with HIV on antiretroviral therapy using single cell RNA sequencing. We identified distinct compartment-specific patterns of gene expression, highlighting key differences between blood and colon CD4 T cell populations. vRNA+ cells from both blood and GI tissue were heterogeneous and found in multiple subtypes of CD4 T cells, although vRNA+ cells were particularly enriched in cells with Th17 or Treg17 phenotypes. Transcriptomic comparison of HIV vRNA+ and vRNA- T cells revealed 116 differentially expressed genes that were associated with HIV infection including ZBED2, MAF and IL17F. These data provide novel information regarding the GI-resident HIV reservoir and suggest that compartment-specific patterns of gene expression are associated with HIV infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5304bb5c0336b41afad4253045c39c12a29c6255" target='_blank'>
              Single cell characterization of the gastrointestinal HIV reservoir reveals heterogeneous cellular phenotypes.
              </a>
            </td>
          <td>
            Jackson J Peterson, Shipra Chandel, K. James, Elizabeth S Bennett, V. Wu, Cory H White, Brigitte Allard, Matthew L Clohosey, Taylor Whitaker, Caroline E. Baker, Susan Pedersen, A. Peery, Cynthia L Gay, Michael R. Betts, David M. Margolis, N. Archin, Edward P Browne
          </td>
          <td>2025-12-23</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/71b827598caa3b92c66b1747f1e4d291bdfd16d5" target='_blank'>
              Multi-omics Analysis of Human Blood Cells Reveals Unique Features of Age-associated Type2 CD8 Memory T cells
              </a>
            </td>
          <td>
            Hiroyuki Matsui, Marlene Cervantes, Mir M. Khalid, Alan Tomusiak, Varun B. Dwaraka, Jorge Landgrave-Gomez, Prasanna Vadhana Ashok Kumaar, Qingwen Chen, Jesica Lasky-Su, Jake Stone, Ritesh Tiwari, Ryan Kwok, Shuntaro Ichikawa, Benjamin D. Ambrose, Rebeccah Riley, G. Hormazabal, Ariel Floro, Andreea Cristina Alexandru, Ryan Smith, B. Schilling, Herbert Kasler, Eric Verdin
          </td>
          <td>2026-01-07</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, where immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies, show limited efficacy with heterogeneous patient responses. The tumor microenvironment (TME) and tumor subclonal heterogeneity significantly influence immune evasion and therapeutic resistance. This study aimed to identify distinct tumor subpopulations in ESCC, characterize their roles in immunosuppression, and determine their association with ICI responsiveness. We analyzed single-cell multi-omics data from tumor specimens and peripheral blood mononuclear cells (PBMCs) of 12 ESCC patients receiving neoadjuvant therapy. Using bioinformatics tools (Seurat, CellChat), we identified tumor subpopulations, inferred cell-cell communication, and validated functional mechanisms via in vitro assays (cell culture, flow cytometry, western blotting), patient-derived organoid (PDO) co-culture systems, and humanized mouse models. Clinical correlations were assessed using bulk transcriptome data, survival analysis, and multi-cohort validation (GEO datasets, IMvigor210 cohort). A distinct HCAR2+ epithelial subclone was identified, characterized by high PD-L1 expression, immunosuppressive cell interactions (e.g., PD-L1/PD-1 axis with exhausted NK-like T cells), and enrichment in pathways driving immune evasion (STAT3, IL-6, PI3K-AKT-mTOR). HCAR2+ cells upregulated PD-L1 via STAT3 activation, impairing CD8+ T cell cytotoxicity and antigen presentation. Clinically, HCAR2+ infiltration correlated with poor prognosis, increased copy number variations (CNVs), high tumor mutational burden (TMB), and enhanced sensitivity to neoadjuvant anti-PD-1 therapy in vivo. Multi-cohort analysis confirmed HCAR2 expression as a predictive biomarker for favorable ICI response, associated with reduced immune exclusion and TIDE scores. HCAR2+ tumor subclones orchestrate an immunosuppressive TME via PD-L1-mediated CD8+ T cell exhaustion while paradoxically conferring sensitivity to PD-L1 blockade. HCAR2 expression serves as a dual biomarker for poor prognosis and ICI responsiveness, offering a novel molecular target for stratifying ESCC patients who may benefit from neoadjuvant immune checkpoint therapy. Targeting the HCAR2-STAT3-PD-L1 axis could enhance immunotherapy efficacy in this aggressive cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/391709fc125e2c7c8c2299a2a4763881267ce47e" target='_blank'>
              HCAR2 Orchestrates an Immunosuppressive Niche and Determines Checkpoint Inhibitor Responsiveness in Esophageal Squamous Cell Carcinoma
              </a>
            </td>
          <td>
            Zekun Li, Guangcong Shen, Xiaoqing Ma, Chenyang Meng, Diliyaer Abudukeremu, Rui Zhao, Zuoyu Chen, Qiang Song, Xiaofan Guo, Tianxing Zhou, Chao Xu, Bo Ni, Yueying Shan, Boyang Fu, Yiheng Chen, Zhansheng Jiang, Yongjie Xie, Kaiyuan Wang, Liangliang Wu, Xiuchao Wang
          </td>
          <td>2025-12-19</td>
          <td>Biological Procedures Online</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="The distal small intestine plays vital roles in host physiology by regulating nutrient and fluid homeostasis. Despite being impacted in Crohn’s disease and a major target for a range of infections, we know relatively little about the complexity of cellular responses and cell-cell communication in the ileum during infection. Single cell and spatial transcriptomics have emerged as powerful technologies to study tissue heterogeneity in the gut, but these tools have focused on the large intestine, in part due to the accessibility of this tissue for biopsies and its importance in cancer. Here we present GutPath, an atlas of over 500,000 single cells with RNA and protein expression profiles for 91 cell states in the ileum across diverse infectious archetypes. We show that GutPath accurately captures established immune responses to infection while revealing pathogen-specific responses in enterocytes. To highlight the discovery potential of this atlas, we identify a novel enterocyte cell state present during Yersinia pseudotuberculosis infection that is spatially linked to bacterial load and tissue pathology. GutPath establishes a much-needed resource for the immunology community that will accelerate the study of the transcriptional diversity of cellular landscapes in the small intestine.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a85741cbbf7153bca08bae9c2d936894041ad45" target='_blank'>
              Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions
              </a>
            </td>
          <td>
            Andrew Hart, Maria I. Merolle, Christian Howard, Breanne E. Haskins, I. Cohn, Suhas Bobba, Rui Xiao, Yi Yang, Ken Cadwell, Junjie Ma, H. Yano, Xiaoxiao Hou, Bethan A. Wallbank, Daniel Cutillo, Ivaylo I. Ivanov, Boris Striepen, Sunny Shin, Igor E. Brodsky, David Artis, Christopher A. Hunter, D. Beiting
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Purpose
Colorectal cancer (CRC) lung metastases exhibit high recurrence rates after resection, underscoring the need for improved therapeutic strategies. This study aimed to characterize the tumor microenvironment (TME) of CRC lung metastases and identify the factors associated with recurrence.


Materials and Methods
Fifteen CRC patients who underwent lung metastasectomy were enrolled. Multiplex immunohistochemistry (IHC), whole exome sequencing, transcriptome profiling, and single-cell RNA sequencing (scRNA-seq) were conducted on matched tumor, adjacent and distant normal lung tissues. Immune cell populations and gene expression profiles were analyzed and correlated with clinical recurrence outcomes.


Results
Exome and transcriptome analyses revealed frequent TP53, KRAS, and APC mutations. Most tumors corresponded to consensus molecular subtypes 2 and 4, characterized by immune-depleted and fibrotic features. Tumors showed downregulation of effector T and NK cell signatures. IHC revealed reduced density and increased distance of CD8+ T cells and macrophages from the epithelial cells. scRNA-seq demonstrated increased regulatory T cells and decreased NK and effector T cells in tumor. Tumor-associated macrophages (TAMs), particularly SPP1 (osteopontin)-expressing subsets, were markedly enriched in tumor and correlated with suppressed effector T cella activity. High SPP1 expression was associated with early recurrence and poor overall survival. Patients with recurrence had higher proportion of PD-1+ CD8+ T cells in adjacent normal tissues.


Conclusion
Immunosuppressive features including enrichment of SPP1+ TAMs and depletion of effector T and NK cells contribute to recurrence after CRC lung metastasectomy. Therapeutic strategies targeting both TAMs and T cells may enhance clinical outcomes in this patient population.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ae972bf762bae15538dd4da3de79b673b4d58b2d" target='_blank'>
              Immunosuppressive Tumor Microenvironment in Colorectal Cancer Lung Metastases: Implications for Recurrence After Metastasectomy.
              </a>
            </td>
          <td>
            Minsuk Kwon, Minkyue Shin, M. An, Y.J. Jeon, T. Hong, Jung Kyong Shin, S. Lim, Yoonah Park, Y. Cho, Seung-Tae Kim, Y. Choi, Jeeyun Lee
          </td>
          <td>2025-12-17</td>
          <td>Cancer research and treatment</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="Background Serum amyloid A (SAA), an acute-phase pro-inflammatory protein, is overexpressed in several cancers and is involved in shaping pro-tumor responses. We have previously reported that lung cancer stem cells secrete SAA, which contributes to tumor progression by inhibition of TH1 immunity. Here, we extended our studies to examine the mechanism of SAA mediated immunosuppression in both antigen-presenting cells (APCs) and the subsequent activation of T cells. Methods & results Using ex vivo co-culture systems and in vivo mice models, we found that SAA impaired dendritic cell and macrophage activation and drove macrophages toward an M2 phenotype with reduced antigen presentation. Lung cancer cells overexpressing SAA also consistently showed impaired CD8+ T cell infiltration and cytotoxicity, while SAA neutralization were efficient at enhancing CD8+ T cell activation and response to anti-tumor immunity. Mechanistically, we found that the immunosuppressive phenotype induced by SAA on APCs is mediated in part by CD36. Critically, inhibiting SAA by neutralization antibody recovered APC activity and enhanced T cell-dependent tumor control. Conclusion our results identify SAA as an important immunosuppressive mediator in the tumor microenvironment, implying that the SAA neutralizing antibody may be a potential target for the improvement of lung cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f10076dc13711bdee9c69a81615daf0299024df" target='_blank'>
              SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer
              </a>
            </td>
          <td>
            Mei Huang, Run Shi, Cong Xu, Yihan Zhang, Xiaoyue Du, S. Wen, Chunbin Wang, F. Jiang, Guoren Zhou, Xin Wang, Bo Shen
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Radiotherapy is a critical modality in cancer treatment, not only to eradicate cancer cells but also to trigger anti-tumor immunity. Interleukin-21 (IL-21), an immunomodulatory cytokine with potential in cancer therapy, has unexplored synergy with radiotherapy. Our study, leveraging human cancer databases and tissue microarrays, identified a positive correlation between IL-21 and radiotherapy outcomes, particularly in tumor microenvironment (TME) activation. In mouse tumor models, IL-21 combined with radiation significantly enhances TME, boosting CD8+ T cell activation and function, reducing tumor burden, and extending survival. Single-cell transcriptome sequencing revealed that the combination of IL-21 and radiation increased the cytotoxicity of effector and memory CD8+ T cells and prevented their exhaustion. These effects were further validated in humanized mice, where IL-21 combined with radiation reduced A549 tumor growth and enhanced CD8+ T cell function. Post-neoadjuvant radiotherapy samples from patients with esophageal cancer showed a positive correlation between IL-21 levels and CD8+ T cell infiltration. Our findings suggest that IL-21 is a promising adjuvant to radiotherapy, potentially improving the treatment efficacy through TME enhancement. This study provides a foundation for future clinical exploration of IL-21 for enhancing radiotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/42bba82008c61c07a67483aebafda8e002ff3cb9" target='_blank'>
              IL-21 enhances the cytotoxicity of intratumoral CD8+ T cells improving radiation efficacy.
              </a>
            </td>
          <td>
            Xinyang Li, Xueqi Xie, Baochao Wei, Xiaozheng Sun, Minxin Chen, Rufei Liu, Q. Tao, Yiheng Huang, Qian Wang, Shuangshuang Ma, Ling Wei, Rong Xiao, Zhaoyun Liu, Jinming Yu, Meng Wu, Dawei Chen
          </td>
          <td>2026-01-08</td>
          <td>JCI insight</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2227a7d7f1704d0d84703010e3af2b4bec3d96b9" target='_blank'>
              PRDM1 Drives Chemoradiotherapy-associated Enrichment of Adaptive NK Cells in Cervical Cancer
              </a>
            </td>
          <td>
            Meng Wan, Tangwu Zhong, Wenyang Shi, Jianyu Shen, Wei Zhang, Yizhe Sun
          </td>
          <td>2026-02-01</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Background Oncolytic herpes simplex virus (oHSV) therapy is a live virus-based immunotherapy that lyses tumor cells which release antigens and activate antitumor immunity. oHSV therapy has been shown to increase ATP production and release of extracellular ATP (eATP). In the extracellular tumor microenvironment, eATP functions as an immune-activating damage-associated molecular pattern but is hydrolyzed to extracellular adenosine (eADO), which can be immune-suppressive. eADO is generated by the sequential action of ectoenzymes CD39 and CD73 (NT5E). Here, we examined the role of immunosuppressive eADO signaling in regulating antitumor immune efficacy of oHSV. Methods We evaluated changes in eADO signaling in vitro and in patient specimens after virotherapy. A genetic CD73 knock-out mouse model and blocking antibodies were used to assess the impact of CD73 on virotherapy in two different solid tumor models. Single-cell RNA sequencing was employed to assess changes in immune cell infiltration and communication. Flow cytometric immunophenotyping and immunofluorescent imaging were utilized to confirm single-cell sequencing predicted changes in tumor microenvironment. Results Transcriptomic analysis of patient tumors pre-virotherapy and post-virotherapy with CAN-3110 revealed increased expression of the adenosine receptor gene ADORA2B after treatment. High NT5E gene expression, as well as gene signatures suggestive of adenosine signaling, correlated with a significantly worse prognosis for patients with solid tumors. Single-cell sequencing of immune cells recruited to tumor-bearing brain hemispheres in CD73 knockout mice revealed an increase in macrophage-mediated antigen presentation and CD4+ T cell cross-communication. Intracranial tumor-bearing CD73 knock-out mice treated with oHSV showed significant therapeutic improvement as the result of oHSV compared with wild-type mice. Combination of virotherapy with CD73 antibody blockade also resulted in enhanced antitumor efficacy. Conclusions Here, we identify that immunosuppressive eADO signaling in the TME is a major barrier to oHSV therapy and CD73 blockade prevents tumor immune escape. The combination of oHSV with CD73 blockade supports the development of an antitumor immune memory response in solid tumors. This study supports clinical development of this combination strategy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3c25b7632b9e2aab5320e79e74bc5a8b75449a94" target='_blank'>
              CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation
              </a>
            </td>
          <td>
            Sara A Murphy, Jiaqi Li, Upasana Sahu, J. Swanner, Cole T Lewis, Benedict Anchang, Yan Cui, E. Chiocca, Balveen Kaur, Sara A Murphy
          </td>
          <td>2026-01-01</td>
          <td>Journal for ImmunoTherapy of Cancer</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Background Myeloid-derived suppressor cells (MDSCs) have a dominating presence in the postoperative period, mediating the suppression of natural killer (NK) cells and promoting cancer metastases after surgery. However, their phenotype and effects on postoperative cellular immunity remain incompletely understood. This study aims to functionally characterize surgery-induced (sx) MDSCs and identify potential therapeutic strategies to mitigate their immunosuppressive effects. Methods We used multicolor flow cytometry to characterize sx-MDSCs from n=55 patients with cancer undergoing surgery at various time points. Furthermore, single-cell RNA sequencing was performed on a cohort of patients. Our functional ex vivo sx-MDSC:NK cell suppression assay was used to investigate the activity of sx-MDSCs and to screen a 147 small molecule library to identify sx-MDSC antagonists. Lastly, we used preclinical murine models of postoperative metastases to evaluate the therapeutic potential of the inhibitors identified. Results Sx-MDSCs significantly expanded after surgery and single-cell RNA sequencing identified signatures resembling immunosuppressive monocytes, including an upregulation of PI3K signaling. These sx-MDSCs also suppressed NK cell activity from patient samples and the small molecule screen identified PI3K-γ inhibitors as potent modulators of sx-MDSC activity. In our murine models, inhibiting PI3K-γ with specific inhibitors reduced postoperative metastases, further corroborating the role of this pathway in sx-MDSC-mediated immune suppression. Conclusions Our findings highlight the critical role of PI3K-γ signaling in postoperative sx-MDSC-mediated immune suppression. Targeting this pathway with PI3K-γ inhibitors represents a promising therapeutic strategy to prevent NK cell suppression and reduce postoperative metastases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cb532f80a9f75fcf605458e25b23096cd62d5262" target='_blank'>
              Preventing surgery-induced natural killer cell suppression and metastases by inhibiting PI3K-gamma signaling in myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            L. Angka, G. Tennakoon, David Cook, Andre B. Martel, M. Market, Christiano Tanese de Souza, Emma Cummins, Ismael Samudio, Natasha Kekre, Michele Ardolino, B. Vanderhyden, M. A. Kennedy, Rebecca C Auer
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Osteosarcoma demonstrates limited responsiveness to PD-1 blockade, largely due to its immunosuppressive tumor microenvironment (TME). The specific mechanisms by which cancer-associated fibroblasts (CAFs) contribute to immunosuppression in osteosarcoma are not fully understood. We performed single-cell RNA sequencing (scRNA-seq) on osteosarcoma tissues from patients treated with neoadjuvant chemotherapy and anti-PD-1 therapy to investigate the tumor microenvironment. Cellular composition, gene expression programs, and signaling pathways were analyzed. Functional assays, pull-down and PLA-flow binding validation, and in vivo mouse models were used to dissect the mechanisms by which CAF-derived factors influence CD8⁺ T cell function and contribute to immunotherapy response. We identified a subpopulation of CD36⁺ CAFs, characterized by adaptive uptake of oxidized low-density lipoprotein (OxLDL) and activation of the PPARG–FABP4 axis. This metabolic program promoted ANGPTL4 secretion, which bound integrin on CD8⁺ T cells and activated the JAK2–STAT3 pathway, leading to T cell exhaustion and impaired effector function. In vivo, administration of VitE effectively scavenged OxLDL, reprogrammed the TME, enhanced CD8⁺ T cell infiltration, and synergized with PD-1 blockade to improve tumor control. CD36⁺ CAFs drive immunosuppressive metabolic reprogramming via the OxLDL–PPARG–ANGPTL4 axis, promoting CD8⁺ T cell exhaustion and resistance to immunotherapy in osteosarcoma. Targeting this pathway with VitE alleviated CAF-mediated immune suppression and enhanced PD-1 blockade responses in preclinical models, providing a rationale for metabolism-based combinatorial strategies in osteosarcoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/303965561d945bf130f5cd1a2c422c0f595cd2bb" target='_blank'>
              Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma
              </a>
            </td>
          <td>
            Anyu Zeng, Hongmin Chen, Tianqi Luo, Weiqing Chen, Yihui Song, Yanyang Xu, Zhihao Chen, Q. Tang, Xiaojun Zhu, Chuangzhong Deng, Huaiyuan Xu, Anqi Wang, Hao Wu, G. Song, Jinchang Lu, Jin Wang
          </td>
          <td>2025-12-18</td>
          <td>Molecular Cancer</td>
          <td>2</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4aac0aaca436c5bc7203a87d69b89b490cdfd76a" target='_blank'>
              Mucosal-Associated Invariant T Cells Promote Atherosclerosis Through Monocyte-Driven Inflammation
              </a>
            </td>
          <td>
            Tobias Radecke, Thomas Nipoti, Louise Z. Wang, N. Mouttoulingam, Marc Diedisheim, M. Chajadine, E. Bacquer, Coraline Heron, P. Alayrac, Charles Caër, L. Laurans, Camille Knosp, Pierre Liénart, Kenza Damache, Rida Al-Rifai, Stéphane Camus, Mathilde Lemitre, Marie Piollet, Oliver Soehnlein, Pierre Julia, J. Alsac, S. E. Batti, F. Letourneur, C. Cochain, Alain Tedgui, H. Ait-Oufella, T. Mirault, Z. Mallat, Olivier Lantz, Jean-Sébastien Silvestre, Sophie Lotersztajn, S. Taleb
          </td>
          <td>2026-01-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>94</td>
        </tr>

        <tr id="ABSTRACT Aging is a dominant risk factor for chronic diseases characterized by the functional decline of tissues and organs. During aging, the hematopoietic system declines in regenerative capacity—seemingly attributable to increases in DNA damage, replicative stress, and autophagic flux—resulting in skewing towards a myeloid lineage and away from a lymphoid lineage. Here, we characterized the transcriptomic and cellular landscape of the aged C57Bl/6J mouse hematopoietic system using a combination of bulk RNAseq and single cell RNAseq (scRNAseq). We show that aging leads to global transcriptional alterations in bulk peripheral blood mononuclear cells (PBMCs), lineage marker‐depleted bone marrow cells (Lin‐BM), and in hematopoietic stem and progenitor cells (HSPCs), immunophenotypically lineage marker negative (Lin‐) Sca1+ cKit+ (LSK+). These changes indicate widespread activation of inflammatory processes, namely in PBMCs and Lin‐BM cells. Interestingly, there is also a downregulation of cell cycle genes in HSPCs during aging. ScRNAseq across 39 hematopoietic cell types revealed age‐related skewing in cell composition. Aged PBMCs showed significant decreases in CD4 and CD8 naïve cells concomitant with increases in CD4/8 memory and CD8 exhausted T cell populations. Lin‐BM cells showed significant myeloid skewing in common myeloid progenitor (CMP) cells, as well as in the HSC population. We also identified a unique HSC population marked by increased Vwf, Wwtr1, and Clca3a1 expression that does not exist in young HSCs, thus likely marking true aged HSCs. Collectively, this work should serve as a useful resource for understanding and therapeutically targeting the aged hematopoietic system.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a19cc88f7b5c2f02b7b252356ac23e9d207486aa" target='_blank'>
              A Cellular and Transcriptomic Atlas of the Aged Mouse Hematopoietic System
              </a>
            </td>
          <td>
            Ryan R. White, Kun Xiong, Matthew H. Wakai, Allison Surian, Christina Adler, Nicole Negron, Min Ni, T. Shavlakadze, Yu Bai, David J. Glass
          </td>
          <td>2026-01-28</td>
          <td>Aging Cell</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35d699fa79c5948bd439d7d11d4aa1b44f1e64ec" target='_blank'>
              Macrophage Antigen Presentation Is Unleashed by Pan-RAS Inhibition to Promote Antitumor Immunity
              </a>
            </td>
          <td>
            Jie Shen, Weini Li, Xin He, Lianjun Zhang, Huidi ShuCheng, ChunBo Zeng, Mingtian Che, Wei Fan, Suda Jo, Heping Yang, Yuan Yuan, Zakir Khan, Zhi Chen, DuoYao Cao
          </td>
          <td>2026-02-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Liver cancer incidences increase dramatically beyond 55 years of age, suggesting that age-associated changes contribute critically to tumor initiation. However, the mechanisms linking liver aging and cancer initiation are not well defined. This study investigates the role of CD44, a marker of liver tumor-initiating cells (TIC), in age-associated liver pathophysiology. Aged livers showed accumulation of CD44-expressing hepatocytes exhibiting enrichment of immune modulatory genes and activation of the immunosuppressive IL6/JAK/STAT3 pathway. Indeed, in adoptive transfer assays, antigen-exposed CD8+ T cells mounted a lower IFN-γ response in aged livers than in young livers, indicating an immunosuppressive aged milieu. Concordantly, spatial analyses showed that the proximal neighbourhoods of Cd44-expressing hepatocytes are enriched in T cells exhibiting reduced cytokine and chemokine gene expression. Finally, hepatocyte-specific knock out of Cd44 mitigated the IL6/JAK/STAT3 gene signature in aged livers. Overall, these findings suggest that CD44 expression in aged hepatocytes promotes activation of the immunosuppressive IL6/JAK/STAT3 pathway and this is associated with impaired T cell effector function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b8cfbe41c4f5eea58d4484e39d30b0c559a09da" target='_blank'>
              Aging-induced hepatocyte CD44 drives IL6/STAT3 signaling and associates with impaired neighboring T cell function
              </a>
            </td>
          <td>
            Armin Gandhi, Kathryn Lande, Yichen Li, Filipe A. Hoffman, Michael LaPorte, Shirong Tan, Garrett Evensen, Benji Portillo, M. Teneche, Rouven Arnold, Adarsh Rajesh, Jessica Proulx, Shanshan Yin, Aaron P. Havas, Charlene Miciano, Qian Yang, Elizabeth Smoot, S. Mamde, Andrew Davis, Kevin Y. Yip, Allen Wang, Bing Ren, April E. Williams, S. Kaech, Peter D. Adams
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3541227a821e9e9e6e75e4ddf9b12cd905133ab3" target='_blank'>
              A CD40-Targeted IL-21 Fusokine Enables Rapid Generation of Human IL-10⁺Granzyme B⁺ Regulatory B Cells
              </a>
            </td>
          <td>
            A. Pennati, S. Yuan, Rahul Das, Catigan Hedican, Amar Yeware, Jacques Galipeau
          </td>
          <td>2026-01-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="The remaining unacceptably high mortality of influenza-induced acute respiratory distress syndrome underscores the urgent need to identify key cellular drivers of host responses. Endothelial cells (ECs) are increasingly recognized for their immunomodulatory roles, but whether they function as antigen-presenting cells (APCs) following respiratory viral infection remains unknown. Here, we show that influenza A virus H1N1 restrictively infects pulmonary microvascular ECs (PMVECs) during late-stage acute lung injury, triggering robust MHC class I (MHC-I) upregulation in vitro, in vivo, and in ex vivo human precision-cut lung slices. Infected PMVECs present H1N1 antigens via MHC-I and co-stimulatory CD40 to lung-resident CD8+ T cells, driving their proliferation and effector function (Granzyme B, IFNγ) to promote viral clearance and resolve inflammation. This process is IFNγ-dependent and STAT1-regulated, forming a positive feedback loop that enhances PMVEC antigen presentation and CD8+ T cells activation. By contrast, the emerging H5N1 (A/Texas/37/2024) infect pulmonary ECs earlier and more broadly but elicits weaker pulmonary EC-driven CD8+ T cell responses, potentially contributing to its higher pathogenicity. These findings reveal PMVECs as active APCs in antiviral defense and highlight new avenues for immunotherapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/df01e5b451a6c1d5dc9572e59192186af7ff334d" target='_blank'>
              Pulmonary Microvascular Endothelial Antigen Presentation Activates resident CD8+ T Cells to Restrain Influenza Lung Injury
              </a>
            </td>
          <td>
            Lianghui Zhang, Yuanyun Ao, Kamal Bagale, Sophia Hu, Ahmed Mostafa, C. Ye, Kienan Salvadore, Gregory Gibson, Ricardo Pineda, Jiayue Lu, Rachel Covitz, Dejuanna Chan, Ryan A. Langlois, James Zimring, William Duprex, C. S. Croix, John Alcorn, Jalees Rehman, Melanie Koenigshoff, Luis Martinez-Sobrido, Jianhua Xing
          </td>
          <td>2026-01-08</td>
          <td>Research Square</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Background Antiangiogenics promote immune activation by reducing myeloid-derived suppressor cells (MDSCs) and enhancing natural killer (NK) and T cell functions in metastatic RCC patients. However, these effects are transient, leading to compensatory immunosuppression. Platelets (PLT) and their extracellular vesicles (PLT-EVs) modulate immune and angiogenic pathways, suggesting a role in immune reprogramming during therapy. Methods Circulating EVs were longitudinally profiled in metastatic RCC patients (n=8) undergoing Pazopanib therapy. EVs, isolated by differential ultracentrifugation from baseline, 3- and 6-month plasma samples, were characterized by bead-based multiplex assay and nanoparticle tracking analysis. Results were correlated with blood counts, RNA-seq and flow cytometry immune profiles. Results Pazopanib induced temporally structured EV compartment alterations. After three months, EVs were enriched in immune markers (CD8, CD56, CD19, CD1c, HLA-DR), consistent with immune activation, whereas PLT-derived markers (CD41b, CD42a, CD29) were diminished. By six months, PLT-EV markers recovered, with CD62P+ and CD29+ EVs co-expressing immunoregulatory and angiogenic molecules (CD209, CD105). PLT-EV abundance correlated with the expansion of regulatory T cells (Tregs), PD-L1+ monocytes and MDSCs, together with suppression of NK cells. PLT activation and PDGF signaling pathways decreased in PBMC from patients with clinical benefit. Conclusions Despite the small sample size and absence of functional experiments, our results suggest that Pazopanib promotes cytotoxic immune programs but, by six months, reprograms PLT-EVs towards different adhesion characteristics contributing to Treg and MDSC expansion while suppressing NK activity. PLT-EVs may influence the balance between immune activation and suppression during anti-angiogenic therapy, suggesting PLT-EVs as biomarkers and therapeutic targets in mRCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b6ad24127a68aa48867264bc8f9e8e0c3b3b86d" target='_blank'>
              Pazopanib-associated remodeling of platelet-immune cell crosstalk and immune suppressive platelet-derived extracellular vesicles in metastatic RCC
              </a>
            </td>
          <td>
            Gianpiero Lupoli, Stefano Bergamini, J. Salsetta, A. Mereu, A. Cova, Elisa D’Angelo, Eriomina Shahaj, E. Vergani, Martina Stroscia, Emma Di Carlo, L. Rivoltini, E. Verzoni, V. Huber
          </td>
          <td>2026-01-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>79</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) immunotherapy is limited by antigenic heterogeneity and an immunosuppressive microenvironment. This study engineered chimeric antigen receptor macrophages (CAR-Ms) targeting stress-inducible NKG2D ligands (NKG2DLs), broadly overexpressed in HCC, to enhance phagocytic clearance and remodel immunity. NKG2DL expression in HCC and association with survival were analyzed. CAR-Ms were constructed by fusing the NKG2D extracellular domain to FcγRI signaling. In vitro assays assessed phagocytosis, cytokine secretion, signaling, and T cell interactions. Therapeutic efficacy was evaluated in immunocompetent mice bearing subcutaneous, orthotopic, or metastatic HCC models, with or without anti-PD-L1. Tumor progression, immunity, and survival were analyzed via bioluminescence imaging, flow cytometry, histopathology, and serum biochemistry. Statistics analyses were performed using t-tests, ANOVA, and log-rank tests. NKG2DLs were significantly upregulated in human HCC and correlated with poor prognosis. CAR-Ms selectively engulfed NKG2DL⁺ tumor cells, polarized to an M1 phenotype, and activated PI3K-AKT and cGAS-STING pathways, driving phagocytosis and pro-inflammatory cytokines secretion. They enhanced T cell chemokines (Cxcl10, Ccl5) and antigen presentation, boosting T cell recruitment and activation in vitro. In subcutaneous models, CAR-Ms suppressed tumor growth, reprogrammed tumor-associated myeloid cells toward M1, and induced durable immune memory (100% tumor rejection upon rechallenge), with T cell activation. In orthotopic models, CAR-M monotherapy induced complete regression by week 5 and 100% survival, with elevated CD8⁺ T cells and CAR-M specifically homing to liver tumors. CAR-Ms suppressed metastasis in peritoneal/pulmonary models. Combining CAR-Ms with PD-L1 blockade accelerated tumor clearance and survival versus monotherapies, enhancing T cell cytotoxicity. Safety assessments showed no significant organ toxicity based on histopathology and serum biochemistry. NKG2D-directed CAR-Ms eliminate HCC through integrated innate phagocytosis, adaptive immune activation, and myeloid reprogramming, overcoming key therapeutic barriers. Combination with anti-PD-L1 enhances therapeutic efficacy by leveraging innate-adaptive crosstalk, providing a promising approach for HCC immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/928340f1c482d3cc3031b9813af988a397a41c2c" target='_blank'>
              Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Zihao Zhao, Wenjing Zheng, Yang He, Han Zhang, Lingling Zhang, Yi Huo, Junwei Jiang, Chen Zhang, Haohan Lyu, Weiwei Qin, Chen Liu, Feng Chang, Lequn Shan, Tao Wang, Wenjie Song
          </td>
          <td>2025-12-13</td>
          <td>Molecular Cancer</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9fa5c1ee49d7d4c736812a4f10f208818145e4f" target='_blank'>
              Characterizing cellular subpopulations critical to treatment response in autoimmune diseases
              </a>
            </td>
          <td>
            Siqi Sun, Mulini Pingili, S. Yadav, Zhuoya Wan, Michael Macoritto, Kathleen Smith, Jing Wang, Dan Chang, N. Mahi
          </td>
          <td>2026-01-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c1f647c519c30083006af87ea81f8e90bf0e920" target='_blank'>
              The altered T cell landscape in Systemic Sclerosis patients is characterized by dysfunctional type 1 immunity
              </a>
            </td>
          <td>
            Victoria Volfson-Sedletsky, Hannah A. DeBerg, Mitchell L. Fahning, Ian R. Rifkin, A. Bujor, Daniel J. Campbell, P. Morawski, Anna C. Belkina, H. Dooms
          </td>
          <td>2025-12-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) are key drivers of the immunosuppressive tumor microenvironment (TME), thereby limiting the efficacy of immune checkpoint inhibitors (ICIs). However, the underlying mechanisms remain unclear. Methods Both genetic (Akr1b3 knockout) and pharmacologic (epalrestat) approaches were employed to examine the impact of Aldo-keto reductase family 1 member B1 (AKR1B1) inhibition on TAMs and T-cell function in vitro and in vivo. Mechanistic insights were obtained through RNA sequencing, flow cytometry, immunofluorescence staining, and co-culture assays. To assess therapeutic relevance, 4T1 breast cancer and LLC lung carcinoma mouse models were used to evaluate the effects of epalrestat on tumor growth, immune infiltration, and T-cell responses. Clinical relevance was validated in patient cohorts with triple-negative breast cancer (TNBC) and lung adenocarcinoma (LUAD). Results AKR1B1 is highly expressed in TAMs and correlates with CD8+ T-cell dysfunction. Targeting AKR1B1 enhances antitumor immunity by reprogramming TAMs. Mechanistically, AKR1B1 modulates macrophage metabolism via the glutathione/reactive oxygen species axis, suppressing nuclear factor κB activation and downregulating C-C motif chemokine ligand 5 (CCL5) production, thereby inducing CD8+ T-cell dysfunction and establishing an immunosuppressive TME. Inhibition of AKR1B1, either by gene knockout or selective pharmacologic blockade, reprograms TAMs toward an immunostimulatory phenotype, increases CCL5–CCR5 (C-C motif chemokine receptor 5) signaling, restores CD8+T cell effector function, and strengthens antitumor immunity. Clinically, high AKR1B1 expression is associated with poor prognosis and immune suppression in TNBC and LUAD. Notably, targeting AKR1B1 improves responses to ICIs in both breast and lung cancer models. Conclusions AKR1B1 as a critical regulator of TAM-mediated immunosuppression and highlight its therapeutic potential to enhance the efficacy of ICIs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/160f049c2f738290afe33bc6f397a041f83f45c0" target='_blank'>
              Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity
              </a>
            </td>
          <td>
            Yuqing Liu, Chao Zhou, Yabin Tang, Huimin Lei, Ayinazhaer Aihemaiti, Hongyu Liu, Peichen Zou, Jun-ting Xie, Xu Guo, Ruixue Xia, Bao-Hui Han, Hongzhuan Chen, Liang Zhu
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cd5525dc695c7cab7bc678df063ceac946d09faa" target='_blank'>
              Myeloid cells contribute to bystander CD8 T cell accumulation in metabolic-associated steatohepatitis and are sufficient for fibrosis
              </a>
            </td>
          <td>
            Cynthia Lebeaupin, Katelyn L. Donahue, S. Lal, Stephen M. Christensen, Shoh Asano, Marc H. Wadsworth, Kathryn Bound, Saurav De, James McMahon, Franklin Schlerman, Chang Wang, Xiao Chen, A. M. Barron, Thomas A. Wynn, Kevin M. Hart, Thomas Fabre
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Sialic acid-containing glycans (sialoglycans) on pathological cells interact with Siglecs, glyco-immune checkpoint receptors expressed on myeloid cells, suppressing the cytotoxic functions of these immune cells. Using targeted glycomic analyses and gene editing, we show that HIV infection reprograms the glycosylation machinery of infected cells to increase the expression of the sialoglycan ligands for Siglec-3, −7, and −9. These ligands engage Siglecs on myeloid cells, impairing their ability to target HIV-infected cells. Selective disruption of these interactions using 10-1074-SiaD, an HIV-specific antibody conjugated to sialidase, an enzyme that removes sialic acids, significantly enhances monocyte- and neutrophil-mediated killing of HIV-infected cells in autologous assays. Treatment with 10-1074-SiaD in female humanized mice infected with HIV reduces viral load and decreases inflammation. These findings reveal an immune evasion mechanism exploited by HIV to evade myeloid cell immune surveillance and highlight the potential of targeting sialoglycan-Siglec interactions to improve immune clearance of HIV-infected cells. Immune evasion mechanisms of initial HIV infection are incompletely understood. Here, the authors show that HIV rewires the glycosylation machinery of infected myeloid cells, forming a glycan shield that engages glyco-immune checkpoints and inhibits cell function, and thus targeted killing of infected cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e35cf501834f0c25f5be245e883b980e2b1612af" target='_blank'>
              HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killing
              </a>
            </td>
          <td>
            Shalini Singh, S. M. S. Islam, Rui Liu, Opeyemi S Adeniji, Lacy M. Simons, Pratima Saini, Hiroaki Tateno, Ali Danesh, Paul W. Denton, Leila B Giron, R. B. Jones, J. Hultquist, Han Xiao, Mohamed Abdel-Mohsen
          </td>
          <td>2025-12-13</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="Reprogramming the immunosuppressive milieu in pancreatic cancer (PaCa) remains an important yet unmet therapeutic goal. Although tumor-associated macrophages (TAMs) are known to promote tumor growth and metastasis, little is known about the underlying mechanisms driving macrophage plasticity in PaCa. Herein, we show that extracellular vesicles (EVs) released by PaCa cells as well as circulating EVs in patient plasma, facilitate cellular crosstalk thereby promoting preferential skewing of recipient macrophages towards an M2-like TAM phenotype. PaCa-EV educated macrophages predominantly secrete anti-inflammatory cytokines, adapt an M2-like metabolic phenotype, have a higher expression of PD-L1, and suppress the proliferation of CD8+ T cells. An increased payload of miR-182-5p in PaCa-EV cargo causes a decrease in TLR4 expression in recipient macrophages and a concomitant upregulation of JAK/STAT3 pathway and elevated secretion of IL-10 and TGF-β, leading to increased PD-L1 expression. Most notably, targeted therapeutic delivery of antagomiR-182-5p in pancreatic tumor-bearing mice with varying immunogenic potential results in a significant decrease in tumor volume, increased survival, restoration of M1/M2 ratio, and an overall increase in CD8+ T cell activation in the TME. Taken together, we demonstrate a direct role of EVs in subverting the immune microenvironment and altering macrophage plasticity in a manner conducive to both tumor growth and proliferation. As such, a targeted delivery of microRNA inhibitors as drugs for altering macrophage plasticity may likely achieve better therapeutic response in pancreatic tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/934885801642cb8c2056560a4186551b7da4ccea" target='_blank'>
              Extracellular vesicle-derived miRNA-182-5p educates macrophages towards an immunosuppressive phenotype in pancreatic cancer
              </a>
            </td>
          <td>
            Baldev Singh, Pankaj Gaur, Pritha Bose, Yanjun R. Zhang, Yaoxiang Li, Zihao Zhang, Jeyalakshmi Kandhavelu, William Klotzbier, Meth B. Jayatilake, Shivani Bansal, Mohd Farhan, Sunain Deol, P. Banerjee, Keith Unger, Seema Gupta, Vivek Verma, Amrita K. Cheema
          </td>
          <td>2026-01-16</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7fda0edb364952e5067fda86230619632242ae72" target='_blank'>
              Cancer-Associated Mesothelial Cells Drive Immune Escape and Therapy Resistance in Ovarian Cancer
              </a>
            </td>
          <td>
            M. Chauvin, Julien Roche-Prellezo, Virginie Lafont, Henri-Alexandre Michaud, Estelle Tromelin, Robin Michel, Clara Freixinos, Marie-Charlotte Meinsohn, Pierre-Emmanuel Colombo, Nathalie Bonnefoy, Laurent Gros, David Pépin
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="The contribution of chemotherapy-induced tissue injury to individual susceptibility to metastasis remains largely unexplored. We report that chemotherapy indirectly prevents colorectal cancer (CRC) liver metastases by inducing a lasting systemic “chemomemory”. Chemotherapy-induced intestinal mucositis alters nutrient availability, promoting the expansion of tryptophan-metabolizing bacteria and production of the microbial metabolite indole-3-propionic acid (IPA). IPA reprograms bone marrow myelopoiesis by redirecting common myeloid progenitor fate toward the macrophage lineage, limiting generation of immunosuppressive Ly6ChighCCR2+ monocytes. This shift enhances CD4+ T cell antitumor function by promoting Th1 differentiation and spatially reorganizing CD8+ and CD4+ T cell interactions within the metastatic microenvironment. In a subset of CRC patients, circulating IPA levels increase after chemotherapy and inversely correlate with monocyte abundance, while high monocyte levels were associated with reduced survival. Our findings reveal that chemotherapy-induced intestinal injury normalizes pathological myelopoiesis through a microbiota-derived metabolite and identify IPA as a potential adjuvant to counteract monocyte-driven immunosuppression and metastasis. The microbiota influences the cytotoxicity of chemotherapy in patients with colorectal cancer but the impact on metastatic relapse is less clear. Here, the authors report that chemotherapy-induced intestinal mucositis induces systemic immune changes via production the microbial metabolite, indole-3-propionic acid (IPA), preventing metastases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/15a21dacb8c45e65545bd42db1f0f3a748edfc8e" target='_blank'>
              Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state
              </a>
            </td>
          <td>
            Ludivine Bersier, L. F. Lorenzo-Martín, Yi-Hsuan Chiang, Stephan Durot, Aleksander Czauderna, T. Yarahmadov, Tania Wyss Lozano, I. Roci, Jaeryung Kim, N. Zamboni, N. Vannini, C. Pot, T. Collet, D. Stroka, J. Bernier-Latmani, Matthias P. Lutolf, Simone Becattini, Thibaud Koessler, Tatiana V. Petrova
          </td>
          <td>2025-12-15</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Introduction High levels of extracellular adenosine, highly abundant in the tumor microenvironment, promote immune suppression mainly through the A2AR expressed by tumor-infiltrating immune cells. Given the importance of tumor-infiltrating B and plasma cells (PCs) in antitumor responses, we investigated the effect of A2AR on human B cells. Methods We performed quantitative mass spectrometry imaging followed by GeoMx analysis on 10 tumor samples. Immunohistochemistry, multiplex immunofluorescence and scRNA-seq were used to assess A2AR expression on tumor and tonsillar B cells. In vitro differentiated B cells and sorted tonsillar B cells were stimulated in the presence of the A2AR agonist CGS-21680 with or without the A2AR antagonist inupadenant, and analysed by flow cytometry, LegendPLEX and scRNA-seq. The in vivo effect of inupadenant was assessed using Visium on tumor biopsies from five cancer patients. Results The frequency of PCs was the most negatively affected by adenosine among the immune cells present in the tumor microenvironment. Furthermore, both tonsillar and tumor-associated B cells, including germinal center (GC)-like B cells, PCs and plasma blasts, collectively referred to as antibody-secreting cells (ASCs), expressed high levels of A2AR. Triggering of A2AR inhibited B cell maturation into ASCs and immunoglobulin production in vitro, and impaired upregulation of PC genes upon stimulation. These effects were restored by inupadenant (EOS100850), a potent and highly selective small molecule A2AR antagonist. Spatial transcriptomics analysis of tumor biopsies from patients treated with inupadenant revealed that ASCs specifically increased in tertiary lymphoid structures. Discussion Altogether, these data demonstrate that A2AR plays a key role in adenosine-mediated inhibition of B cell maturation toward ASCs through a B cell-intrinsic mechanism, and that this effect is fully reverted by inupadenant.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/01cfabef3e8622ef099cea933d2e5affa506c5d5" target='_blank'>
              Inhibition of A2AR alleviates adenosine-mediated suppression of plasma cell differentiation
              </a>
            </td>
          <td>
            Paola Tieppo, Hussein Shehade, C. Martinoli, M. Mercier, D. Carbonez, Nicolas Rosewick, Sophie Jung, A. Vezzu, Boris Pirlot, N. Wald, Stephanie Ma, L. Chaible, R. Marillier, Francesco Strozzi, M-C. Dieu-Nosjean, Joao Marchante, M. Brouwer, E. Houthuys, M. Deligny, Yvonne McGrath, Maura Rossetti
          </td>
          <td>2025-12-15</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8d48a09c8bd8763cbb53c10162f6bf4ec34e18bc" target='_blank'>
              Transcriptomic evaluation of immune-infiltrated patient-derived tumor organoids as preclinical models in renal cell carcinoma
              </a>
            </td>
          <td>
            Liangwei Yin, Léonard Lugand, Jules Russick, J. LeMaoult, C. Battail
          </td>
          <td>2026-02-01</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="ABSTRACT Porcine reproductive and respiratory syndrome virus (PRRSV), a major immunosuppressive pathogen, inflicts substantial economic losses on the global swine industry. Despite extensive research into PRRSV pathogenesis, the mechanisms by which PRRSV induces immune dysfunction in vivo remain incompletely understood. Here, we performed single-cell RNA sequencing on cells isolated from the lung of PRRSV-infected piglets, generating transcriptomic profiles for 46,922 single cells encompassing 15 major cell types. We observed a significant reduction in the number of macrophages in lung tissues, which was primarily attributed to the extensive apoptosis of macrophages induced by PRRSV infection. PRRSV infection triggered aberrant differentiation of macrophage, and the SPP1high macrophage subpopulation was identified as the primary target cells for PRRSV infection. Cell-cell communication analysis revealed that PRRSV infection enhanced ligand-receptor interactions between macrophages and other cell types, associated with inflammatory responses, activation of T cells and B cells, and cell adhesion. In addition, monocytes exhibited a tendency to differentiate into macrophages, potentially compensating for the depletion of macrophages caused by PRRSV infection. Moreover, PRRSV infection caused abnormal development of B cells and incomplete activation of cytotoxic T lymphocytes in the lungs. This study provides a comprehensive characterization of how PRRSV perturbs pulmonary immune cell populations, offering valuable insights into the mechanisms underlying PRRSV-induced lung injury. IMPORTANCE Porcine reproductive and respiratory syndrome virus (PRRSV) has consistently posed a significant and enduring threat to the swine industry. However, the virus-host interactions during in vivo infection in vivo remain poorly understood. In this study, we applied single-cell RNA sequencing to characterize the cellular heterogeneity of lung tissues from PRRSV-infected piglets. Through intracellular viral RNA tracking, we identified SPP1high macrophages as the primary reservoir of PRRSV. Furthermore, we analyzed the cell-cell communication between macrophages and other cell types and investigated the immune responses and heterogeneity of monocytes, T cells, and B cells upon PRRSV infection. Our findings provide a comprehensive single-cell landscape of the complex host-pathogen interplay during PRRSV infection. Porcine reproductive and respiratory syndrome virus (PRRSV) has consistently posed a significant and enduring threat to the swine industry. However, the virus-host interactions during in vivo infection in vivo remain poorly understood. In this study, we applied single-cell RNA sequencing to characterize the cellular heterogeneity of lung tissues from PRRSV-infected piglets. Through intracellular viral RNA tracking, we identified SPP1high macrophages as the primary reservoir of PRRSV. Furthermore, we analyzed the cell-cell communication between macrophages and other cell types and investigated the immune responses and heterogeneity of monocytes, T cells, and B cells upon PRRSV infection. Our findings provide a comprehensive single-cell landscape of the complex host-pathogen interplay during PRRSV infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a411b9a7f498fc257495d61e60998a9d94a15046" target='_blank'>
              Deciphering immune features and cellular heterogeneity in PRRSV infection via single-cell RNA sequencing
              </a>
            </td>
          <td>
            Jianda Li, Yue Liang, Yuyu Zhang, Yulin Xu, Fei Liu, Luogang Ding, Yu Wang, Zhihao Zhang, Zhi Chen, Wenbo Sun, Jiang Yu, Jiaqiang Wu
          </td>
          <td>2025-12-30</td>
          <td>Journal of Virology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ce380aea2613d07a2569ea17ef622bcc9b49b6c" target='_blank'>
              Myeloid CD209 impairs T-cell activation by inducing ICAM-2–ERM–dependent cortical stiffening
              </a>
            </td>
          <td>
            Ting Pan, Tingting Wang, Jiaqi Wu, Heping Wang, Bo Zeng, Yangyang Li, Ming Yi, Ruirui He, Lingyun Feng, Zhihui Cui, Guoling Huang, Panyin Shu, Yuan Wang, Xi Li, Yanyun Du, Zhen Li, Xue Xiao, Chenhui Wang
          </td>
          <td>2026-01-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and remains refractory to current therapies. Beyond profound immunosuppression, GBM is characterized by a complex tumor microenvironment (TME) in which neutrophils have emerged as critical yet understudied regulators of tumor progression and immune evasion. Tumor-associated neutrophils (TANs) display marked functional plasticity, acquiring pro-tumor or anti-tumor phenotypes depending on microenvironmental cues. GBM recruits and reprograms infiltrating neutrophils through chemokine-driven trafficking, hypoxia, and tumor-derived cytokines, promoting angiogenesis, glioma stem-like cell support, and immune suppression via vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 release (MMP-9), arginase-1, and neutrophil extracellular traps (NETs). Conversely, under inflammatory or therapeutically modulated conditions, neutrophils can exert cytotoxic and antibody-dependent anti-tumor functions and enhance T-cell responses. Clinically, elevated neutrophil-to-lymphocyte ratios and intratumoral neutrophil transcriptional signatures correlate with poor prognosis and resistance to immunotherapy. Emerging therapeutic strategies aim to modulate neutrophil recruitment, metabolism, polarization, and NET formation, often in combination with immune checkpoint blockade. This review synthesizes current knowledge of neutrophil biology in GBM, highlights their dualistic roles within the TME, and outlines translational opportunities for neutrophil-targeted therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/71108107169540a197f9c1b887db4bdf65a183a9" target='_blank'>
              Neutrophils in glioblastoma: orchestrators of the tumor microenvironment and immune evasion
              </a>
            </td>
          <td>
            Enes Demir, Elham Rahmanipour, Mohammad Ghorbani, Khushal Gupta, Maryam Zeinali, Michael Karsy
          </td>
          <td>2026-02-03</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Despite recent advances in immunotherapy for advanced malignancies, Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to current immunotherapy due to dense fibrosis, limited antigen presentation, and myeloid-driven immune suppression. Here we report the tumor-targeting, immune remodeling, and safety profiles of the attenuated Salmonella enterica serovar Typhimurium strain CRC2631, and of iSTORM, a next-generation derivative engineered for tumor-localized CMTM6 silencing. CRC2631 preferentially colonizes orthotopic and genetically engineered PDAC tumors, with enrichment in primary lesions and metastases. Tumor-localized CRC2631 induces chemokine and adhesion programs consistent with leukocyte recruitment, increases intratumoral activated T-cell fractions, and triggers transcriptional signatures aligned with innate sensing, interferon signaling, antigen-processing and presentation, and apoptosis programs. iSTORM extends this platform by delivering CMTM6-targeting shRNA to modulate a PD-L1-stabilizing, myeloid-associated immune-evasion programs within tumor-colonized tissue. Compared with CRC2631, iSTORM increases intratumoral CD8+ T cells, shifts T-cell state toward activation with reduced exhaustion-prone features, strengthens antigen-presentation programs, and achieves deeper tumor control. A lyophilized formulation preserves immune remodeling while improving deployability. Mechanistically, glycan arrays and functional studies support mannose-rich glycan-guided tumor engagement. iSTORM toxicity studies, including systemic cytokine, hematologic, blood chemistry, and lethality demonstrate a favorable safety profile. Collectively, these findings establish iSTORM as a safe, programmable, CMTM6-silencing microbial immunotherapy platform that selectively targets and penetrate PDAC tumors to unleash anti-tumor immune activities. What is already known on this topic PDAC is highly resistant to immune checkpoint blockade because dense stroma and myeloid-dominated suppression prevent effective T-cell infiltration; attenuated Salmonella strains can selectively colonize tumors but first-generation agents showed limited efficacy and safety concerns. What this study adds This study defines CRC2631/iSTORM as a tumor-selective microbial immunotherapy that exploits surface-exposed, mannose-rich N-glycans to colonize PDAC, delivers CMTM6 silencing, and restores CD8+ T-cell activation and tumor control in models resistant to PD-1 blockade immunotherapy. How this study might affect research, practice or policy These findings provide a mechanistic blueprint for glycan-guided, CMTM6-targeted bacterial “living drugs,” support rational combination strategies for deepening therapeutic effect, and establish a lyophilized, biocontained platform that could be developed into scalable microbial immunotherapies for PDAC and other immunologically cold solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/de69e456272d47e1287958aec83b80a0b830f6b6" target='_blank'>
              CMTM6-Silencing Microbial Immunotherapy Reprograms PDAC Tumors and Restores T-cell Function
              </a>
            </td>
          <td>
            CY Chabu, R. Kazmierczak, M. Hasani, N. Patterson, Q. Wang, L. Canti, M. Tesfay, A. Cios, B. Dhagat, M.Q Pastor, C. De la Nuez, T. Verburg, J. Moyer, K. Gunter, M. Mwanza, O. Moaven, G. Li, P. de Figueiredo, B.M Nagalo
          </td>
          <td>2026-01-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Glioblastoma remains a therapeutic challenge due to its immunosuppressive tumor microenvironment and resistance to immunotherapy. This study investigates the role of CXCL8 signaling in recruiting immunosuppressive neutrophils and driving poor prognosis in glioblastoma. Analysis of TCGA data revealed significant upregulation of CXCL8 in glioblastoma tissues, correlating with reduced survival and neutrophil chemotaxis pathway activation. We identified a distinct low-density neutrophil subpopulation (L-NEUs) in GBM patient blood, characterized by immature markers (CD16low, CD13low, CD10low) and CXCL8-dependent migration. Integrative bioinformatics identified RNASE2 and THBD as L-NEU-specific markers, both upregulated in GBM and associated with poor prognosis. Functional studies demonstrated that CXCL8 overexpression in macrophages enhanced L-NEU recruitment. RNASE2 (secretory) and THBD (transmembrane) emerged as dual biomarkers and therapeutic targets, with pan-cancer survival analysis linking their overexpression to adverse outcomes in glioblastoma, renal carcinoma, and others. These findings define CXCL8-driven neutrophil recruitment as a key immunosuppressive mechanism in glioblastoma and propose RNASE2/THBD-targeted strategies to improve immunotherapy efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a9772d493fa3bf49beedb5af4b793057af3d659" target='_blank'>
              CXCL8-dependent recruitment of neutrophils by the tumor microenvironment drives poor prognosis in glioblastoma patients
              </a>
            </td>
          <td>
            Jiajun Wang, Chao Wang, Zhiming Sun, Antian Zhang, Zihui Niu, Kang Zhang, Shuai Wang, Chao Zhang, Xingjie Shi, Dong Yu, Shiqiang Hou, Ning Lin
          </td>
          <td>2025-12-26</td>
          <td>BMC Cancer</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8be0d6e509dd7791835e7d4c333379b39ded8d02" target='_blank'>
              Immunotherapy with Pro-regenerative Macrophages from Embryonic Stem Cells Ameliorate Osteoarthritis via TNFAIP3-Mediated Chondroprotection
              </a>
            </td>
          <td>
            Zhumei Zhuang, Zicong Liu, Hang Su, Wei Sun, Qiuwen Zhu, Jingyi Xu, Jinghua Fang, Liying Li, Danni Shen, Xiaohui Zou, Hendrik Marks, Xianzhu Zhang, Hua Liu, H. Ouyang
          </td>
          <td>2025-12-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Background Intestinal epithelial stem cells (SCs) and their transit-amplifying (TA) progeny are critical for mucosal repair and regeneration. However, their behaviour under chronic inflammatory conditions, such as those observed in Inflammatory Bowel Disease (IBD), remains incompletely understood. Methods We investigated the impact of chronic inflammation on intestinal stem/progenitor cells by integrating bulk RNA sequencing from the largest IBD biopsy cohort to date with single-cell transcriptomic analysis and experimental assays using patient-derived intestinal organoids. Results Active inflammation was associated with a reduction in canonical LGR5⁺ intestinal stem cells and a concurrent expansion of OLFM4⁺ populations, consistent with an inflammation-induced epithelial repair program. Notably, SC/TA cells from both inflamed and non-inflamed IBD tissues exhibited persistent transcriptional changes that were distinct from those in healthy controls. Single-cell analysis identified transcriptionally heterogeneous SC/TA subpopulations, including a previously uncharacterized inflammation-associated cluster enriched in immune signalling pathways. Pseudotime trajectory analysis demonstrated a shift in differentiation toward deep crypt secretory (Paneth-like) cell lineages under inflammatory conditions. Conclusions Chronic intestinal inflammation reshapes the epithelial stem and progenitor cell compartment, promoting altered differentiation and the emergence of immune-responsive epithelial states. These findings highlight the plasticity of the human intestinal epithelium in IBD and point to new avenues for therapeutic strategies aimed at maintaining epithelial integrity during chronic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e56882b29e98563be8230a7fd202a7abeb1f4acf" target='_blank'>
              Intestinal stem and progenitor cells exhibit distinct adaptive responses to inflammatory stress in IBD
              </a>
            </td>
          <td>
            B. Balasubramanian, Shivam Patel, L. Gall, N. Hannan, W. Dalleywater, Joerg Huelsken, C. Pin, G. Moran, Paloma Ordóñez-Morán
          </td>
          <td>2025-12-14</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="The gut microbiota plays an essential role in mucosal immunity, with secretory immunoglobulin A (IgA) acting as a key effector in neutralizing pathogens and maintaining host-microbiota homeostasis. IgA production occurs via T cell-dependent (TD) and -independent pathways, with T follicular helper (Tfh) cells driving high-affinity, antigen-specific IgA responses. However, the specific microbial taxa and metabolites that regulate Tfh-mediated IgA responses under steady-state conditions remain poorly understood. This study investigated how gut microbiota-derived signals shape Tfh responses and IgA production, with implications for enhancing mucosal vaccine efficacy. We demonstrate that Peyer’s patches (PP)-derived Tfh cells exhibit superior IgA-inducing capacity compared to splenic Tfh cells. RNA sequencing revealed distinct transcriptional profiles in PP-Tfh cells, including upregulation of the genes associated with Tfh differentiation and activation (Bcl6, Cd40lg, Maf), T-B cell interactions (Il21, Sh2d1a, Fyn), and migration (Ccr6, Cxcr5). Functionally, PP-Tfh cells formed larger T-B cell contact areas and induced significantly higher IgA secretion in co-culture than their splenic counterparts. Microbiota depletion experiments revealed that eliminating neomycin-depleted bacteria reduced fecal IgA levels and diminished PP-Tfh cell frequencies. Fecal microbiota transplantation from neomycin-treated mice restored both IgA production and Tfh responses in germ-free (GF) mice. Bioinformatic analysis (PICRUSt2 and LEfSe) identified butyrate-producing Lachnospiraceae and Ruminococcaceae as key drivers of the Tfh-IgA axis. Butyrate supplementation enhanced Tfh differentiation and IgA⁺ germinal center B cell development in vitro and increased fecal IgA levels in vivo. Mechanistically, butyrate promoted IgA production via GPR43 signaling, as its effect was lost in co-cultures with Gpr43⁻/⁻ Tfh cells. Moreover, treatment with tributyrin, a butyrate prodrug, enhanced vaccine-induced IgA and protected mice against Salmonella Typhimurium infection, reducing bacterial burden and tissue damage. These findings define a functional microbiota-Tfh-IgA axis sustained by neomycin-depleted, butyrate-producing bacteria. Our study underscores the crucial role of the gut microbiota, particularly neomycin-depleted butyrate producing taxa, in regulating PP-Tfh cell function and IgA production. Butyrate emerges as a metabolite linking microbial metabolism to Tfh differentiation and IgA class switching. Together, these findings establish a microbiota-metabolite-Tfh cell axis essential for mucosal immune homeostasis and suggest novel strategies for enhancing vaccine efficacy and protection against enteric infections. 65SkT5T5U4s1JHPzYWZphR Video Abstract Video Abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/258f08bfcfc4875278debbc54438c4cb8dd78ba9" target='_blank'>
              Commensal microbe-derived butyrate enhances T follicular helper cell function to boost mucosal vaccine efficacy
              </a>
            </td>
          <td>
            Haeun Ko, Chan Johng Kim, Seungyeon Choi, Jaegyun Noh, Seung Won Kim, Juhun Lee, Seohyun Byun, Haena Lee, J. Park, H. Park, Amit Sharma, Minhyuk Park, Junghwan Park, Choong-Gu Lee, Kwang Hyun Cha, Sin-Hyeog Im
          </td>
          <td>2026-01-21</td>
          <td>Microbiome</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="ABSTRACT Bispecific antibodies are used for the treatment of hematological malignancies as well as solid tumors. One of their main effector mechanisms is the recruitment of effector cells such as CD8+ T cells and CD16A+ NK cells to tumor cells. Bispecific innate cell engagers (ICE®) harnessing CD16A+ NK cells have been shown to induce significant tumor cell lysis in preclinical models, translating to promising signs of clinical activity together with a well-managed safety profile. However, how killing of tumor cells by NK cells influences other innate immune cells in the tumor microenvironment, such as dendritic cells (DCs), instrumental in bridging innate and adaptive tumor immunity, is largely unknown. Thus, we here analyzed whether antibody-dependent cell-mediated cytotoxicity by NK cells affected human DC subpopulations. We could show that killing of tumor cells leads to a strong activation of human conventional DCs type 1 (cDC1), DC2, and DC3 with enhanced expression of co-stimulatory molecules as well as the secretion of proinflammatory cytokines. Further, DC subpopulations as well as surviving tumor cells showed increased expression of the immunoregulatory molecule PD-L1 that is known to dampen T-cell immunity. Nevertheless, ADCC boosted the capacity of cDC1 and DC2 to prime naïve T cell responses but not of DC3. Thus, our data suggests that the therapy with bispecific antibodies targeting NK cells may have the potential to facilitate adaptive antitumor immune responses via activation of cDC1 and DC2.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b68faec76c8019914aaaeb0bb112e3f2ed84b4a" target='_blank'>
              NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells
              </a>
            </td>
          <td>
            L. Heger, Tomasz Kaszubowski, L. Amon, C. H. Lehmann, Susanne Wingert, J. Medina-Echeverz, Joachim Koch, Holger Hackstein, A. Purbojo, Arndt Hartmann, Christoph Alexiou, R. Cesnjevar, J. Pahl, Diana Dudziak
          </td>
          <td>2026-01-18</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Despite advances in surgery and chemotherapy, outcomes remain poor in metastatic cases, with five-year survival rates below 30%. This stagnation highlights the urgent need for novel therapeutic strategies. Growing evidence indicates that the tumor immune microenvironment (TIME) plays a central role in OS progression, metastasis, and resistance to treatment. Immunosuppressive cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), dominate the TIME, while cytotoxic T cells often exhibit exhaustion. Stromal barriers, hypoxia, and metabolic constraints further impair immune activity. Recent single-cell and spatial transcriptomic studies reveal that immune and stromal architectures strongly correlate with prognosis and therapeutic response. These features contribute to the limited efficacy of current immunotherapies, including immune checkpoint inhibitors (ICIs) and CAR-T cells. In this review, we summarize the cellular, molecular, and spatial components of the OS TIME, critically evaluate current immunotherapeutic strategies, and highlight emerging translational approaches aimed at overcoming immune resistance and improving clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f2b045dec1043e90d16aee9ed935ba08b0a4239" target='_blank'>
              Targeting the osteosarcoma immune microenvironment for improved immunotherapy and translational applications
              </a>
            </td>
          <td>
            Jinlin Cai, Shijie Qiu, Biao Sun, Jianbin Ge, Zhe Yu, Chao Wang
          </td>
          <td>2025-12-21</td>
          <td>Discover Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c872e20ed96ce9671cd91e8697d416593c662410" target='_blank'>
              Cellular stress, cell death, and extracellular vesicles: redefining the therapeutic landscape of rheumatoid arthritis
              </a>
            </td>
          <td>
            Barathan Muttiah, A. Wahab
          </td>
          <td>2025-12-24</td>
          <td>Clinical Rheumatology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="CD8⁺ T lymphocytes are pivotal effectors of adaptive immunity, executing cytotoxic mechanisms essential for pathogen clearance, tumor surveillance and tissue protection. Their activity is shaped by antigenic stimulation, cytokine networks and the metabolic and structural architecture of the tissue microenvironment. Physical exercise has emerged as a potent, non-pharmacological modulator of CD8⁺ T cell biology, capable of influencing recruitment, activation, differentiation and functional persistence. Acute exercise mobilizes effector and memory subsets, enhances trafficking to peripheral tissues and transiently alters activation thresholds, while sustained training remodels subset composition, preserves mitochondrial competence and attenuates immunosenescence. These adaptations are orchestrated through integrated neuroendocrine, vascular and metabolic pathways that recalibrate chemokine gradients, nutrient availability and energetic support. However, the magnitude and direction of these effects are highly context-dependent, varying with host physiology, disease state and microenvironmental constraints. This Review integrates mechanistic and translational evidence across physiological and pathological settings—including cancer, infectious, neurological and metabolic diseases—to clarify when and how exercise can be leveraged to reinforce cytotoxic immunity. We highlight key methodological and biological challenges, and propose biomarker-guided, microenvironment-informed and adaptively titrated exercise interventions as a framework for advancing exercise from an adjunctive measure to a modulatory, precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/697b8e18eede93afa0da0c621d293296cae7424c" target='_blank'>
              Modulating CD8⁺ T cell immunity through exercise: mechanistic insights and implications for precision immunotherapy
              </a>
            </td>
          <td>
            Xinyuan Zhao, Xu Chen, Pei Lin, Yunfan Lin, Weiyao Feng, Meiyan Zou, Nina Li, Li Cui
          </td>
          <td>2026-01-01</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="The cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING) pathway acts as a pivotal innate immune sensor that detects cytosolic DNA and links genomic instability to antitumor immune activation. Therapeutic activation of this pathway has garnered substantial interest as a strategy to enhance cancer immunotherapy by promoting dendritic cell maturation, augmenting antigen presentation, and facilitating cytotoxic lymphocyte infiltration. However, the functional outcomes of cGAS–STING signaling are highly context dependent and influenced by both cell type and tumor microenvironmental (TME) conditions. Recent advances in single-cell and spatial transcriptomic profiling have revealed profound heterogeneity in cGAS–STING activation across distinct cellular and regional compartments within tumors. Acute and spatially restricted activation of the pathway can elicit potent antitumor immune responses, whereas chronic or dysregulated signaling may promote immune tolerance and tumor progression. Moreover, metabolic stress, epigenetic silencing, and microenvironmental immunosuppressive factors such as TGF-β and IL-10 can further modulate STING activity, leading to resistance to immunotherapy. Current translational efforts focus on next-generation STING agonists, nanoparticle-based delivery systems, and rational combination strategies with immune checkpoint blockade and metabolic modulators to overcome tumor-intrinsic resistance and minimize systemic toxicity. Understanding the cell-type-specific and spatial dynamics of cGAS–STING signaling is crucial for the rational design of precision immunotherapies. Future research should emphasize context-dependent modulation of STING activity to maximize therapeutic benefit while limiting adverse effects. Integrating multi-omics technologies and spatially guided drug delivery may ultimately enable personalized modulation of the cGAS–STING axis, transforming it into a clinically effective and safe strategy for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7109afa0c002a7c13c763c36487000288fa7135" target='_blank'>
              Cell-type specific activation of the cGAS-STING pathway in tumor immunotherapy: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Lusheng Wang, Sudi Zhu, Zhixian Ding, Jie Hong, Lijie Zheng, Jiting Sun, Yu Tang, Xiaohui Chen, Xiang Yong, Mengxue Hu, Zhimin Jiang, Yan Liu, Dan Wang, Heng Tang
          </td>
          <td>2026-01-07</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="T cells are central components of the adaptive immune system and play key roles in antitumor and antiviral responses. The diverse cell fates of T cells enable them to respond to different durations and strengths of antigen stimulation and various cytokine milieus in a context-dependent manner. During acute infection or vaccination, T cells differentiate into effector cells and later develop into memory cells after antigen clearance, which mediate immune protection against the same antigen. In contrast, during cancer and chronic infection, T cells fail to enter the canonical effector or memory cell differentiation path. Instead, antigen-specific T cells enter a dysfunctional, partially responsive state called exhaustion. Exhausted T cells are heterogeneous. A subset of exhausted T cells exhibits stem cell-like properties. These stem-like T cells sustain immunity through self-renewal and repopulation of terminally differentiated progenies. Stem-like properties are critical for T cell immunity induced by immunotherapy. This review summarizes recent advances in understanding the molecular mechanisms controlling the exhaustion and stemness of T cells and explores the potential of rewiring these circuits to increase the efficiency of T-cell-based immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/01145f359013ec590de5209ce820dcb252b3001d" target='_blank'>
              Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy
              </a>
            </td>
          <td>
            Zeyu Chen, Ziang Zhu, Taidou Hu, Chen Yao, Tuoqi Wu
          </td>
          <td>2025-12-19</td>
          <td>Cellular and Molecular Immunology</td>
          <td>1</td>
          <td>6</td>
        </tr>

        <tr id="Background Mismatch repair deficiency (dMMR) colorectal cancer (CRC) is characterized by abundant tumor-infiltrating lymphocytes and tertiary lymphoid structures (TLSs). However, while B cells are pivotal for TLS formation, their function and the signaling pathways driving their activation in dMMR CRCs remain undefined. Methods Data from The Cancer Genome Atlas (TCGA) database analyzed by XCELL method and multiplex immunofluorescence (MIF) staining tissue slides were used to compare the abundance and distribution of TLSs and B cell populations between dMMR and proficient MMR cohorts. Then MLH1 knockdown models both in vitro and in vivo were used to mimic dMMR/high microsatellite instability (MSI-H) tumors and explore the influence of tumor cells on B cell behavior. Results TCGA analysis and MIF staining revealed a significant association between memory B cell abundance, TLS formation, and improved prognosis in dMMR CRCs. In vivo MLH1 knockdown models showed that B cell depletion enhanced tumor growth and reduced the efficacy of anti-PD-1 treatment in dMMR CRCs. Furthermore, in vitro experiments demonstrated a dsDNA/STING/type I interferon (IFN)/STAT1/ccl19 signaling pathway mediating the dMMR-induced increase in memory B cells. Conclusions In conclusion, these findings show that CCL19 generated by STING/type I IFN/STAT1 pathway in dMMR/MSI-H CRC cells can promote the expansion of memory B cells, which suppresses tumor growth and enhances the efficacy of PD-1 blockade.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb65cbe9f6749b0489caab027f55d644dd2e9a2c" target='_blank'>
              Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers
              </a>
            </td>
          <td>
            Huilin Huang, Zhian Chen, Xinyuan Mao, Jiaqiang Jiang, Yijie Xi, Yihong Wan, Lingzhi Wang, Xinhua Chen, Yanfeng Hu
          </td>
          <td>2026-01-01</td>
          <td>Journal for ImmunoTherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Silicosis is a progressive lung fibrosis lacking effective treatment. Mesenchymal stem cells (MSCs) show antifibrotic potential, but their survival is impaired by the early inflammatory microenvironment. The therapeutic value of repeated MSC administration remains unclear. A murine silicosis model was analyzed by single-cell RNA sequencing, bronchoalveolar lavage fluid (BALF) cytokine assays, and human Bone Marrow-Derived Mesenchymal Stem Cells (hBMSCs) transcriptomics after BALF exposure. Mice received either single or repeated intratracheal hBMSCs doses. Cell retention, lung function, imaging, histology, and fibrosis markers were assessed. The role of ZC3H4 in macrophage activation was examined by in vivo expression profiling, in vitro knockdown, and functional assays. Early silica exposure triggered strong M1 inflammation, high BALF cytokines, and hBMSCs senescence signatures. Repeated hBMSCs dosing improved cell persistence, reduced fibrosis on imaging and histology, enhanced lung function, and decreased collagen deposition compared with a single dose. Mechanistically, MSC therapy suppressed macrophage ZC3H4 expression, while ZC3H4 knockdown reduced macrophage activation and fibroblast migration. Repeated hBMSCs administration enhances therapeutic efficacy in silicosis by improving cell persistence and attenuating fibrosis, partly through ZC3H4-mediated regulation of macrophages.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ac0b00294ed8c4f98e0c63883faa1d16f5193df" target='_blank'>
              Enhanced therapeutic efficacy of repeated bone marrow–derived MSC administration in a murine model of pulmonary fibrosis
              </a>
            </td>
          <td>
            Zihan Zhou, Jiawei Ding, Shuhua Han, Yuanfang Duan, Jie Chao, Jie Huang
          </td>
          <td>2025-12-23</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Glucocorticoids (GCs) regulate diverse physiological processes, comprising metabolism, immune responses, stress adaptation, and inflammation. Synthetic GCs are widely used for their powerful anti‐inflammatory and immunosuppressive effects, in the treatment of autoimmune diseases, allergies, and inflammation. Here, we investigated the role of the glucocorticoid receptor (GR) in B cell development and survival using both B cell‐specific GR‐deficient mice and continuous in vivo GR agonist treatments. Deletion of the GR in B cells altered splenic B cell subpopulations, increasing follicular and CD21lo B cells and leading to the accumulation of IgM−/IgD− B cells. In vivo treatment with GR agonists, such as Dexamethasone (Dex) and Prednisolone (Pred), selectively depleted IgDhi follicular while enriching IgMhi marginal zone B cells. IgMhi B cells, which were more resistant to GC‐induced cell death, showed an increased expression of IL‐10 and genes involved in survival, suggesting a potential regulatory function. In vitro, B cell activation via CpG or lipopolysaccharide (LPS) altered IgM/IgD expression and B cell sensitivity to GR agonists, thereby leading to improved B cell survival and increased plasma cell differentiation. Together, these findings suggest that IgD downregulation and IgM upregulation are critical for B cell survival under GC exposure and that GR agonists promote the enrichment of IgMhi cells resistant to apoptosis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b855ec64e7900b8bc1fa27d67a4d06a01447dadf" target='_blank'>
              IgD‐Expressing Mature B Cells Exhibit Enhanced Sensitivity to Glucocorticoid‐Induced Cell Death
              </a>
            </td>
          <td>
            Kais Almohammad, Marc Young, S. Vettorazzi, Franziska Greulich, Mahmoud Alkhatib, J. Tuckermann, H. Jumaa, Corinna S. Setz
          </td>
          <td>2026-01-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Mesenchymal stem cells (MSCs) are recognized for their capacity to modulate immune responses, including those directed against tumors. In this study, we investigated the temporal effects of MSCs administration on anti-tumor immunity in a murine 4T1 breast cancer model. BALB/c mice were intraperitoneally injected with MSCs either 24 h (MSC1d) or 14 days (MSC14d) after orthotopic implantation of 4T1 mammary carcinoma cells. Early MSC administration (MSC1d) exhibited changes in immune cell phenotypes consistent with enhanced antitumor potential, including increased activity of natural killer (NK) cells, dendritic cells (DCs), macrophages, and T lymphocytes. These immunological changes correlated with reduced tumor growth and prolonged survival. Mice in the MSC1d group exhibited elevated serum levels of pro-inflammatory and anti-tumor cytokines (TNF-α, IFN-γ, IL-6, and IL-17), alongside decreased concentrations of immunosuppressive cytokines (TGF-β and IL-10). Tumor tissue analysis revealed increased infiltration of NK cells expressing markers associated with antitumor activity (IFN-γ-producing CD178⁺), CD80⁺/CD86⁺/I-A⁺ TNF-α-producing DCs, Th1-type CD4⁺ T cells, and Granzyme B-expressing CD8⁺ cytotoxic T lymphocytes (CTLs). Additionally, spleens of MSC1d-treated mice displayed significantly elevated populations of CD11c⁺ DCs, TNF-α/IFN-γ-secreting NK cells, CD4⁺ Th1 and Th17 cells, and CD8⁺ CTLs expressing markers associated with cytotoxic function (TNF-α, IFN-γ, and IL-17). Conversely, late MSCs administration (MSC14d) was associated with immunosuppression. Tumors from MSC14d-treated mice showed a decreased presence of IFN-γ⁺ and IL-17⁺ NK1.1⁺ cells, F4/80⁺ macrophages, IL-12⁺ DCs, and cytotoxic T cells. Spleens from these mice revealed a significant expansion of regulatory T cell (Treg)-like populations, including CD25⁻, FoxP3⁻, CD25⁺FoxP3⁻ cells, and TGF-β/IL-10-producing CD3⁺ and CD4⁺ T cells. Furthermore, serum levels of immunosuppressive mediators TGF-β and vascular endothelial growth factor (VEGF) were significantly elevated in the MSC14d group. Collectively, these findings demonstrate that the immunomodulatory effects of MSCs on breast cancer are highly dependent on the timing of their administration. Mesenchymal stem cells delivered during early tumor development enhance phenotypes consistent with antitumor potential and suppress tumor progression, whereas administration during later stages promotes immune evasion and tumor growth.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c808072251961d94efaa18f265914925e1e7ece9" target='_blank'>
              Temporal dynamics of mesenchymal stem cell administration influence immune modulation in a 4T1 breast cancer model
              </a>
            </td>
          <td>
            Dragana Papic, Dragica Pavlovic, Danijela Nićiforović, V. Jurišić, V. Volarevic
          </td>
          <td>2026-01-01</td>
          <td>Cell Transplantation</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Background Although most studies of anticancer T-cell immunity focus on αβ T cells, γδ T cells are attracting increasing attention due to their involvement in antitumor immune responses in various cancer entities, including melanoma. While immune checkpoint blockade (ICB) using the antagonistic programmed cell death protein 1 (PD-1) antibodies nivolumab and pembrolizumab significantly improved the survival of patients with melanoma with distant metastasis, prognosis remains poor. PD-1 is not only expressed by αβ T cells but also by γδ T cells, making this numerically minor population of unconventional T cells, whose role in melanoma is still elusive, a target of ICB. Methods Here, we present a detailed γδ T-cell profiling study in late-stage melanoma at single-cell level using mass and polychromatic flow cytometry, T-cell receptor repertoire analyses and immunohistochemistry. Results Our analyses link high frequencies of peripheral Vδ1 T cells before the start of anti-PD-1 therapy to a significantly reduced overall survival. In these patients, the Vδ1 compartment is dominated by a late-differentiated senescent-like phenotype that is presumably unresponsive to therapy. This phenotype is less prevalent at the tumor site and analysis of RNA sequencing data revealed that the abundance of Vδ1 T cells within the tumor was positively associated with survival. Conclusions Our study suggests that Vδ1 T cells are associated with clinical outcomes, with a responsive subset expanding under ICB in patients where such a response remains possible. The observed clinical effects may be supported by the infiltration of these cells into the tumor, where they contribute to cancer immunosurveillance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ad77c14a3cfc3aa02688cb2c4360370f794926a0" target='_blank'>
              Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma
              </a>
            </td>
          <td>
            Nicola Herold, Jonas Bochem, Johanna Leyens, Svenja Wingerter, Stephan Forchhammer, Janine Spreuer, M. Deseke, Can Yurttas, Paola Nocerino, Rita Antunes Dos Reis, T. Amaral, N. Wagner, K. Thiel, Daniel Soffel, Kristin Bieber, P. Terheyden, D. Wesch, H. Oberg, Susanne Sebens, Manfred Claassen, Alfred Königsrainer, Claus Garbe, Graham Pawelec, F. Meier, Markus W. Löffler, B. Weide, I. Prinz, S. Ravens, Shahram Kordasti, T. Eigentler, K. Wistuba-Hamprecht
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>61</td>
        </tr>

        <tr id="Immunotherapy has transformed cancer treatments, but the majority of cancer patients would inevitably develop resistance to immunotherapy. Th17 cells play complex but crucial roles in anti-cancer immune response, although their therapeutic potential remains underutilized. Segmented filamentous bacteria (SFB) function as prototypical commensal bacteria that can induce intestinal Th17 cells and impact host immune response. In this study, we investigated how SFB antigen-mediated immune responses modify the tumor microenvironment and enhance anti-tumor efficacy through a coordinated gut–lung immunological axis. We engineered B16F1 melanoma cells to express either the SFB3340 epitope (B16-3340, an I-Ab-restricted epitope derived from SFBNYU_003340 and recognized by 7B8 TCR) or a control vector (B16-MEM) to evaluate SFB antigen effects on tumor immunogenicity. We found that expression of the SFB epitope in cancer cells decreased the number of lung tumor nodules, and SFB colonization further reduced tumor growth in a lung metastasis model. In addition, Th1, Th17, and CD8+ Tc1 cells were all increased in the lungs of the B16-3340 tumor-bearing mice compared with B16-MEM control tumor-bearing mice without triggering a compensatory expansion of immunosuppressive Tregs. Interestingly, SFB triggers systemic metabolic changes and an increase metabolites from aromatic amino acid degradation pathways, providing biochemical evidence for a functional gut–lung conduit, which integrates innate microbial detection with adaptive tumor-specific immunity. Our research provides evidence to further investigate and develop novel cancer immunotherapies that utilize microbial antigens and microbiome modifications to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5429a38be4e5ce2d81f913e703a35d6e85fa2f2" target='_blank'>
              Commensal bacteria antigen-mediated immune response enhances anti-tumor immunity
              </a>
            </td>
          <td>
            Jessica Tzu-Chieh Lee, Soo Ngoi, Brian Deng, Megan Hill, Kai He, Yi Yang, Bei Liu
          </td>
          <td>2025-12-24</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="During the progression of acute myeloid leukemia (AML), extramedullary hematopoiesis (EMH) compensates for impaired bone marrow hematopoiesis. However, the specific cellular dynamics of EMH and its influence on AML progression remain poorly understood. In this study, we identified a substantial expansion of the CD81+ erythroblast subpopulation (CD81+ Erys) in the spleens of AML mice, which promoted AML cell proliferation and reduced survival. Mechanistically, CD81+ Erys secrete elevated levels of macrophage migration-inhibitory factor (MIF), which interacted with the CD74 receptor on AML cells, activating the mTORC1 signaling pathway and upregulating Egln3. Consequently, AML cells cocultured with CD81+ Erys exhibited reprogrammed phospholipid metabolism, characterized by an increased phospholipid-to-lysophospholipid ratio. Modulating this metabolic shift, either by supplementing exogenous lysophospholipids or depleting Egln3 in AML cells, restored the phospholipid balance and mitigated the protumorigenic effects induced by CD81+ Erys. Overall, our findings elucidate the molecular crosstalk between erythroblasts and AML cells, extend our insights into the mechanisms driving AML progression, and suggest potential therapeutic strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ddcd58c64a7ed082f251f1c3eec4cbc61b660c5d" target='_blank'>
              Leukemia-expanded splenic CD81+ erythroblasts potentiate disease progression in mice by reshaping leukemic cell metabolism
              </a>
            </td>
          <td>
            Yue Li, Jiaxuan Cao, Jingyuan Tong, Peixia Tang, Haoran Chen, Guohuan Sun, Zining Yang, Xiaoru Zhang, Fang Dong, Shangda Yang, Jie Gao, Xiangnan Zhao, Jinfa Ma, Ding Wang, Lei Zhang, Lin Wang, Tao Cheng, Hui Cheng, Lihong Shi
          </td>
          <td>2025-12-15</td>
          <td>The Journal of Clinical Investigation</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) therapy can restore T cell function in tumors, but not all patients benefit, and the mechanisms behind this remain unclear. In this study, we used patient-derived organotypic (PDO) cultures from metastatic melanoma to examine transcriptomic and cellular changes following ex vivo T cell stimulation. Genomic and transcriptomic features were preserved during PDO formation, capturing melanoma heterogeneity. PDOs from ICB-responsive patients showed rapid T cell expansion upon T cell stimulation, unlike those from ICB-resistant tissue. Resistant tissue harbored T cells lacking activation and checkpoint markers, suggesting non-tumor-reactive T cells. A T cell-specific transcriptomic score, activated in responsive PDOs, correlated with improved overall and relapse-free survival in metastatic melanoma patients treated with ICB. These findings demonstrate that ex vivo analysis is a viable tool to investigate mechanisms of ICB response and may help identify predictive biomarkers for patient outcome.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ed50cf99fb67ea8136c8c566f1253db09fe9441" target='_blank'>
              Modeling anti-tumor immune responses using patient-derived melanoma organoids
              </a>
            </td>
          <td>
            Kamila Kaminska, B. Phung, Jacob Karlström, M. Lauss, K. Harbst, Teresa Svensson, Kristian Pietras, Kari Nielsen, Ana Carneiro, Henrik Ekedahl, K. Isaksson, G. Jönsson
          </td>
          <td>2025-12-23</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Background Giant cell tumor of bone (GCTB) presents considerable complexity in tumor microenvironment (TME) because of its intricate intercellular heterogeneity and the presence of an immunosuppressive milieu. In order to understand the complex gene expression patterns and cell interactions in GCTB, we carried out a thorough investigation using single‐cell RNA sequencing (scRNA‐seq). Methods We examined scRNA‐seq data from 7091 cells that were collected after surgical removal of GCTB. Following the initial quality control process, 10 separate groups of cells were distinguished, which consisted of dendritic cells, endothelial cells, macrophage cells, mast cells, monocyte cells, neutrophil cells, tumor cells, osteoclast cells, pericyte cells, and T cells. Additional analysis uncovered distinct categories within tumor‐associated macrophages (TAMs), CD8+ T cells, and CD4+ T cells. The differentiation mechanisms of TAMs, CD8+ T cells, and CD4+ T cells were explored using pseudo‐time trajectory analysis. The CellPhoneDB study revealed the interactions between various cell types within the TME of GCTB. Results TAMs have been identified as the main infiltrating cells in GCTB. These TAMs exhibit several subtypes that are characterized by specific marker genes and functional states. The identification of several subgroups within CD8+ T cells that are involved in regulating immunological checkpoints underscores the difficulties encountered when attempting to employ immune checkpoint blockade therapy for GCTB. T cell exhaustion poses a major barrier to the efficacy of antitumor immune responses. Research suggests a strong correlation between TAMs and exhausted T cells (Texs) in the TME. The high number of regulatory T cells (Tregs) highlights the immunosuppressive nature of the immunological environment in GCTB. Significant interactions have been observed between TAMs and tumor cells, highlighting their crucial involvement in immune evasion strategies. Conclusion This scRNA‐seq study provides a general overview of the different cellular compositions and immune interactions within GCTB. The identified subtypes and communication networks provide valuable information about the immunosuppressive environment of GCTB, laying the foundation for prospective therapeutic approaches targeting specific cell types or interactions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e77dc33f2650929ccb5e19eeed4e2c7dc7b4c11a" target='_blank'>
              Single‐Cell Sequencing Reveals the Immunosuppressive Trajectory in the Tumor Microenvironment of Human Giant Cell Tumor of Bone
              </a>
            </td>
          <td>
            Yiming Liu, Wei Luo, Yude Xu, Xiguan Yao, Libing Dai, Qiao Feng, Peigeng Wang, Weichao Yang, Yi Feng, Haixiong Miao, Suixiang Huang, Dongping Ye
          </td>
          <td>2026-01-01</td>
          <td>BioMed Research International</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/92d7ccb154548987305467a7c4fe8a00f89e75f8" target='_blank'>
              SUMO2 Deletion Changes Chromatin Accessibility and Enhances Cytotoxic T Cell Activation and Tumor Infiltration
              </a>
            </td>
          <td>
            Mohottige D Neranjan Tharuka, Dai-Hua Chen, Maria Luisa Jurgensen Amaral, Tianchen Ren, Yixuan Kuang, Shih-Ting Huang, Nikhil Chilakapati, Bing Ren, Stephen P. Schoenberger, Ye Zheng, Yuan Chen
          </td>
          <td>2026-01-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Brain metastasis is a major contributor to mortality in patients with lung cancer. The unique microenvironment of the brain plays a critical role in the initiation and progression of brain metastases (BM), yet the molecular mechanisms underlying tumor-microenvironment interactions remain poorly understood. Here, we demonstrate that upregulation of lipocalin-2 (LCN2) in tumor cells promotes brain metastatic progression by orchestrating crosstalk among metastatic tumor cells, astrocytes, and macrophages. Brain metastatic tumor cells secrete LCN2, which binds to SLC22A17 on astrocytes, activating JAK2/STAT3 signaling and inducing astrocyte activation and chemokine secretion, thereby facilitating macrophage recruitment. In turn, macrophages secrete IL-1β, which further upregulates LCN2 expression in tumor cells. Prophylactic administration of the IL-1 receptor antagonist anakinra inhibits BM formation, whereas therapeutic administration alone is ineffective. However, treatment with the STAT3 inhibitor SH4-54, either alone or in combination with anakinra, significantly suppressed tumor growth in the BM. Furthermore, tumor-secreted LCN2 can bind to SLC22A17 on tumor cells, activating JAK2/STAT3 signaling and promoting VEGF-A expression and release, which enhances tumor neovascularization. Inhibition of this axis with SH4-54, bevacizumab, or their combination effectively reduces the tumor burden in BM-bearing mice. These findings underscore the central role of LCN2 in driving brain metastasis and highlight a potential therapeutic strategy for targeting brain metastatic lung cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29f281e09a6235d0b0b2baf53693c1b005b871ad" target='_blank'>
              Lipocalin-2 drives brain metastatic progression through reciprocal tumor-microenvironment interactions in lung cancer
              </a>
            </td>
          <td>
            Yixiang Zhu, Jian Zhang, DanMing He, Hongqing Cai, Yan He, Li Yuan, Si-Shang Li, Yucheng Dong, Zhuang Wei, Zhijie Wang, J. Duan, Xue Zhang, Zixiao Ma, Hua Bai, Jie Wang
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="In preclinical models, optimum tumor control by radiation therapy incorporates CD8 T cell control of residual cancer cells. Tumor control by these CD8 T cells is negatively regulated by myeloid and T regulatory cell expansions in the tumor following radiation treatment. We demonstrate using ex vivo 3D tumor models and novel in vivo cell tracking models that radiation results in upregulation of the costimulatory molecules CD80 and CD86 on tumor macrophages and on monocytes that enter the tumor following radiation. This regulation of CD80 is not dependent on adjuvant signaling via MyD88 or STING in the myeloid cells. While we would anticipate that CD80 and CD86 would have a positive impact on anti-tumor immunity, we demonstrate that blockade of CD80 and CD86 signaling limits CD4 infiltrates in tumors and prevents the Treg expansion caused by radiation treatment. Importantly, this treatment results in improved tumor control following radiation therapy. These data link the inflammatory activation of myeloid cells in irradiated tumors to the Treg expansion following radiation and ensuing suppression of anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b1ce60db011c72d77a0495e2fb83689f7db3d3d" target='_blank'>
              Radiation therapy causes a STING and MyD88-independent upregulation of CD80 and CD86 in macrophages and monocytes that limits tumor control
              </a>
            </td>
          <td>
            Aanchal Preet Kaur, J. Baird, Alejandro F. Alice, Gwen F. Kramer, David J. Friedman, Eva Moran, M. Crittenden, Michael J. Gough
          </td>
          <td>2025-12-19</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Treatment with anti-CD3 monoclonal antibody (mAb) can delay or prevent type 1 diabetes in mice and humans by modulating the immune-mediated destruction of β cells. A single course of treatment may have lasting efficacy, but the mechanisms that account for these prolonged effects, i.e., "operational tolerance," are not clear. Here, we used paired single-cell RNA and T cell receptor sequencing to characterize islet-infiltrating T cells and their counterpart in paired pancreatic lymph nodes from anti-CD3 mAb-treated nonobese diabetic (NOD) mice in remission. We found that after anti-CD3 mAb treatment, T cells that infiltrate the islets are more heterogeneous and have hybrid features including characteristics of T stem cell-like memory and reduced effector function compared with those from untreated prediabetic NOD mice. Autoantigen-reactive CD8+ T cells persist after treatment, but they also show features of stemness and reduced pathogenicity. Our findings describe the reshaping of islet-infiltrating and autoreactive T cells and β cells that lead to operational, but tenuous, tolerance to autoimmune diabetes following anti-CD3 mAb treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/118beb10b3f3c193540228f7f7cdcdaf0df2f979" target='_blank'>
              Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes.
              </a>
            </td>
          <td>
            Ying Wu, Maxwell Spurrell, Ana Lledó-Delgado, Songyan Deng, Dejiang Wang, Yang Liu, M. Barkestani, A. Perdigoto, Kevan C. Herold
          </td>
          <td>2026-01-23</td>
          <td>JCI insight</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are crucial mediators of tumor-induced immunosuppression, while their heterogeneity and spatial dynamics across malignancies remain poorly understood. By integrating single-cell RNA sequencing data from 576 samples across 19 cancer types and spatial transcriptomics data from three distinct malignancies, we identified a PMN-MDSC population. This cell population demonstrated characteristic upregulation of immunosuppressive genes and was associated with poor prognosis across multiple cancer cohorts. Notably, TREM1 was highly expressed in PMN-MDSCs and may mediate immunosuppressive processes. Multiplex immunofluorescence demonstrated that TREM1+ PMN-MDSCs exhibited significantly higher distribution in tumor regions compared to non-tumor tissues. Spatial transcriptomics analysis revealed their co-localization with fibroblasts and exhausted T cells. Moreover, CellChat analysis showed that TREM1+ PMN-MDSCs remodeled the tumor microenvironment through interactions with diverse cellular components. Collectively, our study revealed the conserved immunosuppressive features and spatial interaction networks of TREM1+ PMN-MDSCs from a pan-cancer perspective, highlighting TREM1 as a pivotal therapeutic target to disrupt PMN-MDSC-mediated tumor immune evasion. A pan-cancer analysis reveals TREM1+ PMN-MDSCs as key mediators of immunosuppression by remodeling the tumor microenvironment, highlighting TREM1 as a therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d5174fd91c2ae4f071c06cfa6c978a0e63d85760" target='_blank'>
              Pan-cancer analysis reveals TREM1+ PMN-MDSCs as critical regulators of immune suppression and tumor microenvironment remodeling
              </a>
            </td>
          <td>
            Yangjie Cai, Shanhang Li, Hening Li, Zhuan Zou, Xinda Zheng, Haijun Tang, Mingxiu Yang, Pintian Wang, Weizhen Wu, Hongcai Teng, Kai Luo, Xinyu Huang, Wenyu Feng, Shijie Liao, Juliang He, Yun Liu
          </td>
          <td>2025-12-18</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f517628343fca7d577007526b6194b2f13cd9d26" target='_blank'>
              Immune checkpoint inhibitors amplify type 2 immune mediated repair by pro-regenerative scaffolds
              </a>
            </td>
          <td>
            Jordan Garcia, Anna Ruta, Frank Haoning Yu, Joscelyn C. Mejías, Alexis N Peña, Natalie Rutkowski, Elise F. Gray-Gaillard, Constance Dubois, Chris C. Cherry, Maria Browne, Katlin B. Stivers, David R Maestas, Kavita Krishnan, Alexander T. F. Bell, E. Fertig, C. Cooney, Damon Cooney, Patrick Byrne, A. Hillel, Kellie N. Smith, Hongkai Ji, Robert Anders, Drew M. Pardoll, Jennifer H. Elisseeff
          </td>
          <td>2026-02-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Small extracellular vesicles (sEVs) including exosomes play an important role in intercellular communication and can exert immunomodulatory effects in recipient cells. We have shown that a single prophylactic intrathecal injection of sEVs from RAW 264.7 macrophages two weeks prior, promotes faster resolution of mechanical and thermal hypersensitivity in the complete Freund’s adjuvant (CFA) mouse model of inflammatory pain. How this long-term memory develops, and how sEVs regulate immune responses are unknown. Recent studies have shown that priming microglia with inflammatory stimuli can enhance or suppress responses to a delayed secondary insult via epigenetic modifications. We hypothesized that prophylactic intrathecal administration of macrophage-derived sEVs confers accelerated resolution of inflammatory pain by reprogramming epigenetic memory in spinal microglia in recipient CFA model mice. To determine whether prophylactic sEVs could attenuate pain in the absence of microglia when administering sEVs, we ablated microglia using a colony-stimulating factor 1 receptor (CSF1R) inhibitor, PLX5622. sEV-induced pain prophylaxis was completely abolished in PLX5622-fed mice, indicating that microglia are required to be present during sEV administration to confer early resolution of inflammatory pain hypersensitivity. ChIP-seq analysis in spinal microglia 14 days after sEV administration (prior to CFA) revealed an increased number of gene loci enriched for H3K4me1, a hallmark of innate immune memory. Furthermore, inhibiting the H3K4 mono-methyltransferase SETD7 abolished sEV-induced pain attenuation. Our findings indicate that both microglia and its epigenetic reprogramming contribute to pain prophylaxis induced by macrophage-derived sEVs, providing novel insights into the development of non-addictive preventive analgesia.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/004641d73bea924af5da1ac51234020dd29f8b8b" target='_blank'>
              Microglial epigenetic memory is associated with accelerated resolution of inflammatory pain induced by prophylactic macrophage-derived small extracellular vesicles
              </a>
            </td>
          <td>
            Xuan Luo, Jason R. Wickman, Jason T. DaCunza, Yuzhen Tian, Ahmet Sacan, Seena K. Ajit
          </td>
          <td>2026-01-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Vaccination is the preferred strategy for preventing infections such as influenza in elderly individuals; however, its efficacy is often suboptimal due in part to age-related declines in immune function. In this study, we discovered that the infusion of mesenchymal stromal cells (MSCs) restored defects in the splenic stromal cell network and lymphocyte architecture in aged mice while also increasing specific antibody levels following vaccine immunization. This significantly protected aging mice from influenza infection. Mechanistically, the delivered MSCs localized in the splenic marginal zones, where they positioned themselves near marginal reticular cells (MRCs) and stimulated MRC proliferation, partially through the action of vascular endothelial growth factor A (VEGFA). This MSC‒MRC interaction orchestrated the reconstruction of the stromal network, thereby restoring lymphocyte homeostasis and germinal center reactions. Importantly, the MSC-mediated enhancement of the vaccine response was further validated in aged cynomolgus monkeys. Collectively, our findings provide new insights into the application of MSCs in addressing age-related immune decline and highlight splenic MRCs as critical therapeutic targets.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a624280664a2bdb72020df258084df4d8fd37533" target='_blank'>
              Mesenchymal stromal cells counteract with age-related immune decline and enhance vaccine efficacy by modulating endogenous splenic marginal reticular cells in elderly models
              </a>
            </td>
          <td>
            Jialing Liu, Zhishan Li, Qiong Ke, Qiuli Liu, Yueming Sun, Rong Yan, Huolin Ye, Yuxi Zhang, Jie Ren, Hong Chen, Gang Li, Tao Wang, Xubo Li, Yuzhe Wang, Yuan Qiu, Xiaoran Zhang, Zhenxiao Yao, Rui Fang, Jianqi Feng, Lili Chen, Weiqiang Li, Xiaoyong Chen, Andy Peng Xiang
          </td>
          <td>2026-01-09</td>
          <td>Cellular and Molecular Immunology</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b5589b0123feca880cf0a4447ac31391eaf80691" target='_blank'>
              Target Fibroblast-B cell crosstalk via MIF signaling drives pathogenic B cell differentiation and joint damage in knee osteoarthritis
              </a>
            </td>
          <td>
            Bizhi Tu, Zhengming Zhu, Yan Li, Zhengming Zhu, Shijie Wang, Peizhi Lu, Ya Li, Shuo Yang, Dingtao Hu, Run Fang, Rende Ning
          </td>
          <td>2025-12-17</td>
          <td>Inflammation Research</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Lymph nodes, brain, bone, and liver are recognized as the four most common metastatic sites for lung adenocarcinoma (LUAD). Metastasis to these locations exhibits some common features, such as immune suppression, and distinct tumor microenvironment (TME) heterogeneity involving differentiation of immune cells, impacting treatment efficacy and prognosis. Lymph node metastases are characterized by immune suppression with exhausted CD8+ T cells, expanded regulated T cell (Tregs), M2-polarized macrophages, and high programmed death ligand-1 (PD-L1) expression. Brain metastases display an “immune desert” phenotype due to blood–brain barrier constraints, reduced T-cell infiltration, and microglia-mediated immunosuppression. Bone metastases involve osteoclast activation, RANKL/OPG pathway dysregulation, and metabolic reprogramming, while liver metastases show Kupffer cell-driven PD-L1/ programmed death 1(PD-1) axis suppression and elevated Treg infiltration. Key biomarkers across all types of metastases include PD-L1, cytokine profiles, immune cell ratios, and metabolic markers. Therapeutic strategies focus on combination therapies such as immune checkpoint inhibitors (ICIs) with metabolic modulators, localized drug delivery, and biomarker-guided approaches. Challenges in this field encompass spatial heterogeneity, dynamic TME evolution, and clinical translation barriers. Future research directions highlight spatial transcriptomics, microbiome interactions, and organoid models to optimize personalized immunotherapy. This article aims to provide a comprehensive review of regarding TME alterations across these four main metastatic locations of LUAD. It will also discuss relevant TME biomarkers and their clinical significance on therapeutic response and prognosis. We expect this article to serve as a source of evidence and inspiration for the future development of treatment strategies based on LUAD TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8eac0fc7ba7c67303e9257f2a2d91aba7b28ddab" target='_blank'>
              Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis
              </a>
            </td>
          <td>
            Chao Guan, Xiangmin Li, Xiaoshan Zeng, Zhenguang Du, Zhicheng Zhou, Jungang Zhao, Lele Song, Li Yu
          </td>
          <td>2025-12-01</td>
          <td>Therapeutic Advances in Medical Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="After birth, the immune system must learn to tolerate a rapidly changing milieu of commensals and self while remaining ready for pathogens. Here we characterize the neonatal liver as a central hub in this process: In postnatal week 1–2, the liver hosts a developmentally encoded, microbiota-independent expansion of regulatory T cells (Tregs) that coexists with microbiota-tuned conventional wave of activated CD4⁺ T cells (Tconvs). Mechanistically, the Treg expansion is governed by MHCII-mediated antigen presentation by CCR7+ cDC1s, which establish tolerogenic DC:T cell clusters in the liver parenchyma, allowing for local expansion and control via PD-L1 checkpoints that selectively increase Tregs without unleashing Tconvs. Importantly, this transient, neonatal program predisposes hepatotropic viral infections to progress toward chronic disease but also protects the adult liver from steatotic disease. These data position the neonatal liver as a unique site of early life T-cell education with timing-sensitive implications for early-life interventions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9487b7d55d4857b031bd0974fcc9aeac38c92126" target='_blank'>
              Neonatal liver niches program T cell tolerance
              </a>
            </td>
          <td>
            Eva-Lena Stange, T. Nguyen, Dustyn Mendoza, Aiara Lobo Gomes, Marlene Sophia Kohlhepp, Jonas Pes, Shahed Al Bounny, Julian Brueck, Yunus Cetiner, Urs Moerbe, Milas Ugur, Cristina Kalbermatter, Jarrett Lopez-Scarim, Aline Dupont, Susan A. V. Jennings, Julia Heckmann, A. Silva-Sánchez, Solveig Runge, C. Kuppe, Oliver Pabst, Thomas Clavel, Dorothee Viemann, S. Rosshart, V. Cerovic, S. C. Ganal-Vonarburg, Adrien Guillot, E. Billerbeck, Mathias W. Hornef, N. Torow
          </td>
          <td>2026-01-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Acne, the most prevalent inflammatory skin condition globally, lacks comprehensive understanding of its cellular and molecular mechanisms. This research integrates single-cell transcriptomics with spatial immunofluorescence to detail cellular composition and functional states in healthy skin, mild acne, and severe acne. Findings indicate that keratinocytes in mild acne secrete antimicrobial peptides and maintain barrier defense, but transition to abnormal differentiation and pathological keratinization in severe acne. Natural killer (NK) cells initially amplify inflammation and activate the immune response, but later become exhausted and apoptotic. This interaction creates a “dual immune-barrier imbalance,” driving acne progression. Functional enrichment and pseudo-time analyses demonstrated a strong association between disease severity and TNF, and chemokine signaling pathways, as well as NK cell-mediated cytotoxicity and Wnt/p53-apoptosis pathways. These findings were corroborated by immunofluorescence validation. This study introduces an innovative pathological model that establishes theoretical foundations for early diagnosis and precision interventions, while also outlining future therapeutic strategies centered on “immune-barrier co-regulation.” The findings provide essential insights into the pathogenesis of acne and open avenues for investigating novel intervention targets.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/46e83afe735e0121344e0a07c8a405ac15ec431c" target='_blank'>
              Single-cell transcriptomics and spatial validation reveal dysfunction of keratinocytes and NK cells driving acne development
              </a>
            </td>
          <td>
            Xinheng Wang, Changzhao Gao, Dandan Yang, Jiahui Pan, Rihua Jiang
          </td>
          <td>2025-12-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fa3ea2bba5477695ec904d1360c6f71b6b797a04" target='_blank'>
              Single-Cell RNA Sequencing Reveals Impaired Regulatory T Cell Function and a Pro-inflammatory Th17 Profile in Systemic Sclerosis
              </a>
            </td>
          <td>
            G. Villanueva-Martin, G. Borrego-Yaniz, M. Acosta-Herrera, J. Callejas-Rubio, Norberto Ortego, N. Mages, S. Börno, María Gutiérrez-Arcelus, Javier Martin, L. Bossini-Castillo
          </td>
          <td>2026-01-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Zika virus (ZIKV) infection can cause severe neurological complications, yet the role of CD8+ T cells in controlling viral pathogenesis in the brain remains unclear. Using Ifnar1−/− mice, which lack type I interferon signaling, we demonstrate that ZIKV infection triggers significant infiltration of CD8+ T cells into the brain, accompanied by neurological defects. ZIKV-experienced CD8+ T cells exhibit enhanced cytotoxic potential, and adoptive transfer of these cells improves survival. In contrast, blocking their infiltration exacerbates brain inflammatory and injury-associated signatures, highlighting their protective contribution. Furthermore, PD-1 blockade worsens ZIKV pathology, suggesting that PD-1 expression reflects an activated rather than exhausted state. These findings underscore an important role of infiltrating CD8+ T cells in reducing ZIKV-induced CNS inflammation and suggest that modulating their response could serve as a potential therapeutic strategy for ZIKV-associated neurological disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/59f92671db8b5cab99c311a3e29cd0630772d86c" target='_blank'>
              Brain-infiltrating CD8 T cells retain functional activity to protect against acute Zika virus infection
              </a>
            </td>
          <td>
            Jaehui Kim, Wooseong Lee, Do Yeon Kim, K. Ku, Young-Chan Kwon, Kyun-Do Kim, Chonsaeng Kim, Dae-Gyun Ahn, Seong-Jun Kim, Sungjun Park
          </td>
          <td>2026-01-05</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/df66cae290474308d3bd343d797357a5e58b1777" target='_blank'>
              Embryonic lympho-epithelial cell interactions play an essential role in the establishment of adult T cell tolerance
              </a>
            </td>
          <td>
            G. Nogueira, A. Chervova, F. Soares-da-Silva, A. Sergé, M. Irla, Cabe C. Moraes, A. Gaudin, P. Ferreirinha, A. Bandeira, N. L. Alves, P. Pereira, A. Cumano
          </td>
          <td>2026-01-19</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Dysfunctional microglia contribute to the pathology of numerous neurological diseases. Depletion of harmful microglia and repopulation with healthy progenitors represents a new therapeutic option for neurodegenerative diseases with an urgent need for effective treatments. However, repopulation with patient-derived progenitors could result in similar dysfunction over time. We therefore propose obtaining microglia-like cells (MLCs) derived from healthy donors for allogeneic transplantation. We hypothesize that the immunosuppressive phenotype of MLCs, combined with the brain´s high immune tolerance, would enable effective engraftment. Additionally, the allogeneic origin of MLCs may increase immune tolerance, with additional therapeutic outcomes, particularly in multiple sclerosis (MS). MLCs were generated from MHC-mismatched mouse strains in vitro and exposed to IL-10/IL-4/TGF-β or LPS/IFN-γ to induce specific immunophenotypes. Phagocytosis and T cell proliferation assays assessed MLC responses to pathogenic insults that could arise in autoimmune contexts. Microglial depletion was achieved using Cx3cr1CreER/−R26DTA/− mice or PLX3397 treatment. A protocol administering MLCs directly into the brain via the intracisterna magna was optimized to facilitate repopulation of the microglial niche. Repopulation with MHC-mismatched IL-10/IL-4/TGF-β-polarized MLCs was tested in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, with immune profiling of cellular populations conducted using flow cytometry. BALB/c- and C3H-derived MLCs developed more pronounced anti-inflammatory profiles than did C57BL/6 MLCs, and promoted tolerogenic phenotypes when encountering MHC-mismatched C57BL/6 T cells. In vivo experiments demonstrated a partial repopulation of an emptied microglia-niche by pre-differentiated MLCs administered intracisternally (i.c) into the CNS. The adoptive transfer of MHC-mismatched MLCs led to enhanced immune tolerance mechanisms and the amelioration of disease progression in the EAE mouse model. Our findings support the therapeutic potential of anti-inflammatory MHC-mismatched MLCs in promoting immune tolerance within autoimmune neuropathologies. Specifically, disease progression was attenuated and tolerogenic mechanisms were activated in the MS mouse model. While a polarization protocol towards an anti-inflammatory phenotype confers MLCs with beneficial features in a pro-inflammatory disease context, the MHC-mismatch interaction within the host´s CNS promotes additional tolerogenic processes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7a7c159393bd71a2aabacfa48a7c4768becbc016" target='_blank'>
              Allogeneic MHC-mismatched microglia-like cell replacement as a therapeutic approach for multiple sclerosis
              </a>
            </td>
          <td>
            Irene Benito-Cuesta, Jin-Hong Min, Yuxi Guo, G. Virgilio, Valerie Suerth, Stefan Bencina, Paula Trigo-Alonso, Keying Zhu, Shin-Yu Kung, M. Pahlevan Kakhki, Heela Sarlus, Robert Harris
          </td>
          <td>2026-01-08</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Immune-mediated intraocular inflammation, called uveitis, is a leading cause of global blindness, with the highest burden of visual impairment falling on older individuals. Immunosenescence, the functional changes in immune cells with aging, impacts the age-associated immune response, but how immunosenescence and the molecular regulators of the age-associated immune response affect the clinical course of uveitis remains unclear. In the murine model of experimental autoimmune uveitis (EAU), aged mice demonstrated a delayed onset and peak of intraocular inflammation compared to young mice. In contrast to the canonical monophasic inflammation that rapidly resolves in young mice, aged mice developed persistent, chronic inflammation. Transcriptomic and flow-cytometric analyses of immune cells and the receptor-ligand interactome revealed a dominant macrophage-CD4+ T cell signature. This signaling pathway was functionally altered on both ends: macrophages from aged mice had an impaired capacity to generate peripherally induced regulatory T cells (pTreg) through an IL-6 regulated pathway, while CD4+ T cells co-cultured with aged macrophages demonstrated increased proliferation. Our study establishes aging as a key regulator of the effector immune response in uveitis. Regulatory T cells, specifically pTreg, are essential for resolving inflammation in uveitis and an impaired ability to induce pTreg led to a sustained, chronic inflammatory uveitis phenotype in old mice, thereby linking immunosenescence to persistent neuroinflammation. These findings highlight potential therapeutic avenues for vision-threatening uveitis, especially in older patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c884624194df8c0680f4019f2ac1093daf979a9b" target='_blank'>
              Macrophage immunosenescence prolongs intraocular inflammation in aged mice via impaired induction of regulatory T cells
              </a>
            </td>
          <td>
            Taku Yamamoto, Keitaro Hase, Joseph B. Lin, Shinobu Yamaguchi, Norihiko Misawa, Jiayi Li, Kenta Kato, Ryo Terao, Brian S. Sohn, Daniel Du, Mitsukuni Yoshida, Charles W Pfeifer, Tae Jun Lee, Jason J. Colasanti, A. Santeford, James T. Walsh, R. Apte
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>51</td>
        </tr>

        <tr id="Despite the promise of immune checkpoint blockade (ICB) in head and neck squamous cell carcinoma (HNSCC), mediators of response are poorly understood. To address this, here we analyzed oropharyngeal HNSCCs treated with neoadjuvant durvalumab (anti-PDL1) alone or in combination with tremelimumab (anti-CTLA4) from the CIAO clinical trial (NCT03144778). We found that only the total abundance of intratumoral bacteria predicted ICB response, which was validated in multiple independent cohorts. High intratumoral bacteria abundance was associated with an immunosuppressive tumor microenvironment, characterized by an accumulation of neutrophils coupled with depletion of T cells and other adaptive immune cells. Experimental elevation or reduction in intratumoral bacteria abundance in orthotopic models of HNSCC in female mice recapitulated immunological associations observed in participant tumors. Increasing intratumoral bacteria abundance was sufficient to induce resistance to anti-PDL1 ICB, irrespective of bacterial species tested. Together, these findings demonstrate that high intratumoral bacteria abundance is a key suppressor of antitumor immunity and promotes immunotherapy resistance. McGrail and colleagues report that high intratumoral bacteria abundance is associated with an immunosuppressive microenvironment and resistance to immune checkpoint blockade in head and neck squamous cell carcinoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ff6bc6b862a40ed54d2a498d13ad74d8fec00fa9" target='_blank'>
              Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma
              </a>
            </td>
          <td>
            Natalie L. Silver, Jin Dai, Travis D. Kerr, Jessica Altemus, Rekha Garg, Hannah Simmons, Tyler J. Alban, Laura Noȅl-Romas, Vladimir Makarov, David J. H. Shih, Shweth V. Kumar, Akeem Santos, Rehan Akbani, Adam Burgener, Mohammed Dwidar, Neil D. Gross, Andrew G Sikora, Elias J Sayour, Apollo R Stacy, Christian Jobin, Timothy A. Chan, R. Ferrarotto, Daniel J. McGrail
          </td>
          <td>2026-01-01</td>
          <td>Nature Cancer</td>
          <td>3</td>
          <td>75</td>
        </tr>

        <tr id="During neuroinflammation, CD11c+CD11b+ myeloid cells accumulate at the cribriform plate, a key cerebrospinal fluid (CSF) and antigen outflow site in mice. At this site, podoplanin (PDPN)-expressing cells, including lymphatic vessels and meningeal layers, expand to create a distinct drainage microenvironment. In this study we sought to characterize myeloid cells which populate this region using a mouse model of neuroinflammation, experimental autoimmune encephalomyelitis (EAE). Utilizing a combination of immunohistochemistry, flow cytometry, and scRNAseq, we report that macrophages and dendritic cells (DCs) from this region display unique expressional signatures related to tolerance, cell death, and reduced inflammatory profile. Together this data supports that myeloid retention at the cribriform plate and olfactory bulb meninges promotes a local immunosuppressive environment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e549a88421337952511a13714c86e5c4e653df94" target='_blank'>
              Cribriform Plate Microenvironment Assembles a Suppressive Myeloid Network during EAE-induced Neuroinflammation
              </a>
            </td>
          <td>
            C. Laaker, Martin Hsu, Andy Madrid, Jenna M Port, Sophia M. Vrba, Melinda Herbath, Cameron M Baenen, Mohan Kumar, Thanthrige Thiunuwan Priyathilaka, Matyas Sandor, Z. Fabry
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4f495b98f4c0f97cebf2e9a7ca186d0b80891a93" target='_blank'>
              CD160+ intraepithelial lymphocytes and CCRL2+ macrophages drive differential repair in cardiac and liver injuries
              </a>
            </td>
          <td>
            Kang Sun, Jia-xin Dong, Xin-tao Mao, Wen-ping Li, Yu Wang, Xiao-Mei Teng, Dan-Dan Liu, Bing Yang, Jiang-yan Zhong, Zhenya Shen, Yi-Yuan Li, Jin Jin
          </td>
          <td>2025-12-24</td>
          <td>Cellular & Molecular Immunology</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs and involving both innate and adaptive immunity. Dendritic cells (DCs) play a crucial role in linking innate and adaptive immune responses, and therefore they deeply participate in the initiation and development of SLE. Deleted in breast cancer‐1 (DBC1) is a negative regulator of deacetylase SIRT1 (the mammalian homolog of silent information regulator 1) and involves in tissue inflammation. Roles of DBC1 in immune cells remain largely unknown, especially in DCs. We here identified that DBC1 is upregulated in activated DCs, and DBC1 deficiency weakened DC maturation while promoting B7‐H1 expression. DC conditional knockout of DBC1 ameliorated murine lupus pathology by decreasing autoantibodies, complement C3, plasma cells, and follicular T helper (Tfh) cells, whereas promoting regulatory T‐cell development. We further demonstrated that Dbc1−/− DC lowered proinflammatory cytokine secretion such as IL‐4, IL‐6, and IL‐12, and reduced signal transducer and activator of transcription 5 (STAT5) signal. With STAT5 overexpression, the protective effect by Dbc1−/− DC was abolished in the lupus model. Therefore, targeting the DBC1‐STAT5 axis in DCs diversifies the therapeutic strategies for SLE.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d1facac1c1eb12f3330a72458012f015712e82b1" target='_blank'>
              Regulation and Mechanism of Deleted in Breast Cancer‐1 on Dendritic Cell Function in Systemic Lupus Erythematosus
              </a>
            </td>
          <td>
            Z X Xiao, Rongzhen Liang, Yan Liu, Changyuan Huang, Qiannan Fang, Xiaojiang Hu, Julie Wang, Nancy Olsen, Dehua Wu, S. Zheng
          </td>
          <td>2026-01-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to chimeric antigen receptor (CAR)-T cell therapy. Insufficient T cell infiltration, a highly immunosuppressive microenvironment, and antigen loss pose major challenges for CAR-T cell therapy. Methods We investigated therapeutic synergies of synthetic 5′-triphosphate RNA (3p-RNA), an agonist of the cytoplasmic double-stranded RNA sensor Retinoic Acid Inducible Gene I (RIG-I), and CAR-T cell therapy using syngeneic and human xenograft PDAC models. Tumor growth, chemokine secretion, immune-cell composition, CAR-T persistence, and endogenous T cell responses were assessed by flow cytometry, multiplex cytokine arrays, Enzyme-linked Immunospot (ELISpot), and vaccination-challenge. Results 3p-RNA provoked rapid type I interferon accompanied with chemokine ligand CCL5 and CXCL9/10/11 secretion, creating chemokine gradients that recruited chemokine receptor CCR5+/CXCR3+ CAR-T cells into tumors. RIG-I activation enhanced CAR-T cell proliferation, activity, and CAR-T persistence. Combination therapy eradicated established tumors in 60%–70% of mice, whereas either monotherapy was largely ineffective. Cured animals rejected CAR antigen-negative tumor cell rechallenge, demonstrating antigen-spreading and endogenous T cell responses. Conclusions Intratumoral RIG-I priming reprograms the PDAC microenvironment, transforming a non-responsive cancer into a CAR-T-permissive one, supporting durable, poly-antigenic immunity. These findings position 3p-RNA as a rapid, clinically tractable co-therapy to extend CAR-T efficacy to solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0740cdf905664a78725635003b567ad13fe803cb" target='_blank'>
              RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma
              </a>
            </td>
          <td>
            Anne Marie Senz, B. Cadilha, Julia Teppert, Simone Formisano, Charlotte Marx, T. Lorenzini, D. F. Boehmer, Christine Hoerth, Simon Delahais, S. Endres, P. Duewell, M. Schnurr, S. Kobold, Lars M Koenig
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Cancer cells employ diverse strategies to evade immune surveillance and resist therapy, including immune exclusion—a phenomenon where cytotoxic T cells fail to infiltrate the tumor microenvironment (TME), severely limiting immune checkpoint inhibitor (ICI) efficacy. Emerging evidence suggests that platelets, traditionally known for their role in hemostasis, may act as key players within the TME. This review introduces a novel perspective on tumor-infiltrating platelets (TIPs) as potential orchestrators of immune exclusion, linking them to the six Delphi-defined criteria, which were established through international cancer experts based on modified consensus Delphi process: lack of chemotactic factors, immunosuppressive cytokines, specific cancer-associated fibroblast (CAF) subtypes, mechanical barriers, disordered vasculature, and increased T-cell apoptosis. We further explore TIP-mediated contributions to related features, such as epithelial-mesenchymal transition (EMT), M2 macrophage polarization, and CXCL12 signaling, which exacerbate exclusion and promote metastasis. Through integration of mechanistic studies and pan-cancer TCGA analyses, we reveal that TIPs exhibit significant, yet heterogeneous, correlations with immune exclusion features across diverse solid tumors. By elucidating these mechanisms, this review underscores the potential role of TIPs as promising therapeutic targets to dismantle immune barriers, enhance ICI responses, and curb metastasis, advocating for platelet-targeted combinations in future immunotherapy trials.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9c997ce4b80550d0a9dd461920b0a62532e9689" target='_blank'>
              Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy
              </a>
            </td>
          <td>
            Atefeh Nasir Kansestani, M. Zare, Jun Zhang
          </td>
          <td>2026-01-29</td>
          <td>Cellular Oncology (Dordrecht, Netherlands)</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Type 1 conventional dendritic cells (cDC1s) are important for generating and sustaining antitumor immunity. Accordingly, the abundance of cDC1s in human tumors correlates with improved outcomes in cancer. Capitalizing on this role, we previously demonstrated that vaccination with in vitro-derived murine cDC1s elicits durable tumor control in multiple preclinical models; however, the immunological mechanisms underlying the efficacy of cDC1 vaccination remain unclear. Here, we examined whether in vitro-derived cDC1s resemble tumor-infiltrating DC populations and whether MHC-I and MHC-II antigen presentation contribute to cDC1-mediated tumor control following vaccination in melanoma. As expected, MHC-I- or MHC-II-deficiency had minimal impact on the transcriptional state of cDC1s in homeostasis or following stimulation with the adjuvant poly dI:dC. Moreover, in vitro-derived cDC1s cultured under steady-state conditions closely resembled tumor-infiltrating cDC1s, whereas their poly dI:dC-stimulated counterparts resembled CCR7+ tumor-infiltrating DC populations, also referred to as mregDCs or LAMP3+ DCs. Our data further show that both MHC-I and MHC-II contribute to tumor control upon cDC1 vaccination, and coexpression of MHC-I and MHC-II on the same cDC1 is necessary for a robust vaccine response. We also identified an important function for host cDC1s in supporting the efficacy of vaccination with in vitro-derived cDC1s, as judged by impaired tumor control in Irf8+32-/- mice, which lack endogenous cDC1s. Overall, these results indicate that effective antitumor responses depend on MHC-I and MHC-II antigen presentation by vaccine-delivered cDC1s, with additional contributions from host cDC1s. Key points In vitro-generated cDC1s resemble intratumoral DC populations found in mice and humans. MHC-I and MHC-II antigen presentation by vaccine-delivered cDC1s contribute to antitumor efficacy. Coexpression of MHC-I and MHC-II on the same cDC1 enhances vaccine responses. Antitumor responses reflect the activity of vaccine and endogenous cDC1s.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a13c6180d1c62c5b4b9f5ea6f97cc1e7fee85670" target='_blank'>
              Antigen presentation requirements for effective cDC1-based cancer immunotherapy
              </a>
            </td>
          <td>
            Josué E. Pineda, Tomoyuki Minowa, Li Shen, Yifan Zhou, Allison M. Dyevoich, B. Patel, Sarah M. Schneider, Sunita Keshari, Akata Saha, Morgan N. Riba, Jing Wang, S. Watowich, Matthew M. Gubin
          </td>
          <td>2026-01-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="Tolerogenic dendritic cells (tolDC) are currently in clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The methods for producing therapeutic tolDC vary widely, with little being known about the commonalities and differences of distinct cell products in terms of their regulatory actions on CD4+ T cells. We compared human monocyte-derived tolDC generated with vitamin D3 alone or in combination with dexamethasone. We found marked differences in the surface expression of HLA-DR and immune regulatory molecules, but also found commonalities, e.g. a strongly reduced capacity to produce interleukin-12 and a concomitant decreased ability to induce interferon-γ secretion by allogeneic CD4+ T cells. To gain a deeper understanding of how these tolDC types exert their regulatory effects, we co-cultured them with CD4+ T cells from rheumatoid arthritis patients or healthy controls and analysed the gene expression profile and function of the responding T cells. We found that tolDC generated with vitamin D3 alone, but not in combination with dexamethasone, induced potent cytotoxic activity in the responding CD4+ T cells as demonstrated by an enhanced cytotoxic gene signature, increased levels of intracellular granzyme B, and superior cytotoxic activity towards myeloid and B cells. These data identify cytotoxicity as an atypical CD4+ T helper cell effector function induced by some but not all tolDC types, with implications for their individual clinical applications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e6376b65c8f61913f7a1c8c2873d5f5d98c5c617" target='_blank'>
              Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4+ T cells
              </a>
            </td>
          <td>
            Gabrielle Barran, N. Naamane, Abdul Mannan Baru, Amy E Anderson, Jane Falconer, C. Hilkens
          </td>
          <td>2025-12-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Mesenchymal stem/stromal cells (MSCs) exhibit broad differentiation capability and strong immunoregulatory potential mediated through intercellular communication and the release of diverse paracrine mediators. They represent a promising but still investigational therapeutic approach for managing complications associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). This review provides an updated synthesis of MSC biology, their bidirectional interaction with immune cells, and their functional contribution to the hematopoietic niche. It also evaluates current clinical evidence regarding the therapeutic roles of MSCs and MSC-derived extracellular vesicles (EVs) in acute and chronic graft-versus-host disease (aGVHD/cGVHD), as well as in poor graft function. Mechanistic insights encompass macrophage polarization toward an anti-inflammatory phenotype, inhibition of dendritic cell maturation, enhancement of regulatory T-cell expansion, and modulation of cytokine signaling pathways. Within the bone marrow milieu, MSCs contribute to stromal restoration and angiogenic repair. Recent phase II/III trials in steroid-refractory (SR)-aGVHD have demonstrated overall response rates ranging from 48 to 71%. Efficacy appears particularly enhanced in pediatric patients and with early MSC administration. Across studies, MSC therapy shows a favorable safety profile; however, heterogeneity in response and inconsistent survival outcomes remain notable limitations. For poor graft function, limited prospective studies indicate hematopoietic recovery following third-party MSC infusions, and combination approaches such as co-administration with thrombopoietin receptor agonists are under investigation. MSC-derived EVs emulate many immunomodulatory effects of their parental cells with a potentially safer profile, though clinical validation remains in its infancy. MSC-oriented interventions hold substantial biological and therapeutic promise, offering a favorable safety margin; however, clinical translation is hindered by product variability, suboptimal engraftment and persistence, and inconsistent efficacy across studies. Future directions should emphasize standardized manufacturing and potency assays, biomarker-driven patient and timing selection, optimized conditioning and dosing strategies, and the systematic appraisal of EV-based or genetically modified MSC products through controlled trials.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/73302ce93894dc67dc4c78b9abd8a8e4bdc0a83f" target='_blank'>
              Mesenchymal Stem/Stromal Cells: A Review for Its Use After Allogeneic Hematopoietic Stem Cell Transplantation
              </a>
            </td>
          <td>
            A. Durdu, U. Hatipoglu, Hakan Eminoglu, Turgay Ulaş, M. S. Dal, F. Altuntaş
          </td>
          <td>2026-01-01</td>
          <td>Biomolecules</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7d1643371c79bb28750e28593c02812612c4ec75" target='_blank'>
              PARP inhibition generates enhanced CD8+ central memory T cells by transcriptional and metabolic reprogramming
              </a>
            </td>
          <td>
            Wael Traboulsi, Pankaj Gaur, Subhadip Kundu, Zainab Ramlaoui, Christopher Priestley-Milianta, Aishwariya Iyengar, Nour Shobaki, Dareen Sarhan, Min-Jung Lee, Jung-Min Lee, G. Pavlakis, M. Mkrtichyan, Viia Valge-Archer, S. Barry, Vivek Verma, Seema Gupta, Samir N Khleif
          </td>
          <td>2026-01-12</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>80</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are key drivers of immunosuppressive inflammation in the breast cancer microenvironment, promoting tumor progression and resistance to immune checkpoint blockade. Our previous work identified extracellular IFI16/IFI202 as tumor-derived damage-associated molecular patterns which activate pro-inflammatory signaling in TAMs via Toll-like receptor 2, thereby facilitating immune evasion. In this study, we investigated the therapeutic potential of a monoclonal antibody (mAb) targeting extracellular IFI202 to suppress tumor-promoting inflammation and to restore antitumor immunity. We developed a mAb against IFI202 and evaluated its functions in bone marrow-derived macrophages (BMDMs) using ELISA and western blotting. In vivo efficacy was assessed in the mouse mammary tumor virus-polyoma virus middle T-antigen breast cancer model by treating with IFI202 mAb, or anti–programmed death-1 (PD-1) antibody, as monotherapies or in combination. Tumor volume, metastasis, cytokine levels, and immune cell infiltration were analyzed. Statistical significance was assessed using Mann–Whitney U test or ANOVA, with P < 0.05 considered significant. Conditioned medium obtained from 4T1 breast cancer cells pre-incubated with IFI202 mAb suppressed secretion of IL-6 and TNF-α, and inhibited activation of ERK and NF-κB in BMDMs. Intraperitoneal injection of IFI202 mAb in mouse mammary tumor virus-polyoma middle T-antigen mice significantly reduced tumor growth and lung metastasis. In addition, IL-1β expression, CD8+ T cell infiltration, and levels of granzyme B and interferon-γ, were enhanced in the tumors of IFI202 mAb-treated mice, indicating that IFI202 mAb restored cytotoxic function of CD8+ T-cells. Combination of IFI202 mAb with PD-1 mAb significantly improved antitumor efficacy compared to monotherapy. Neutralization of extracellular IFI202 suppresses TAM-mediated inflammation and supports a tumor microenvironment favorable for T-cell–mediated immunity. In combination with anti–PD-1 therapy, IFI202 mAb further enhances antitumor responses, suggesting a promising and tumor-selective strategy that may help overcome resistance to immune checkpoint blockade in breast cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc369356ec770be8eb843d59aff9a9f3d18ca8d9" target='_blank'>
              IFI16/IFI202 blockade suppresses tumor growth through CD8+ T-cell–mediated immunity
              </a>
            </td>
          <td>
            G. Lim, Na-Lee Ka, Seung-Su Kim, Mi-Ock Lee
          </td>
          <td>2026-01-03</td>
          <td>Breast Cancer Research : BCR</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized tumour therapy by relieving immunosuppression and restoring effector T cell cytotoxicity. However, its clinical utility is constrained by low response rates and acquired resistance. Tumour‐associated neutrophils (TANs), key players in tumour immunoregulation, have emerged as critical mediators of ICB responsiveness and resistance, highlighting the therapeutic potential of combining TAN‐targeted strategies with immune checkpoint inhibitors (ICIs). This review systematically synthesizes current knowledge of neutrophils in ICB resistance from several dimensions: (1) clinical indicators of neutrophils, such as the neutrophil‐to‐lymphocyte ratio (NLR) and tissue TANs abundance, as predictors of ICI response and patients prognosis; (2) multifaceted TAN‐involved resistance mechanisms, including direct T cell inhibition, antigen presentation impairment, function modulation of other immune cells, promotion of tumour angiogenesis, and elevation of tumour mutation burden (TMB); (3) combination therapeutic strategies targeting TAN generation/ exhaustion, recruitment, phenotypic polarization, activation, proangiogenic functions, and neutrophil extracellular traps (NETs), along with progress in related clinical trials. Combinatorial approaches integrating TAN‐targeted therapies with ICIs hold substantial promise for overcoming resistance by reshaping the immune microenvironment. Elucidating neutrophil‐mediated resistance mechanisms and optimizing combination strategies will pave the way for precision tumour immunotherapy. Key points TANs drive ICI resistance via antitumour immune remodelling, angiogenesis promotion, and elevation of tumour mutation burden Neutrophil biomarkers (e.g., NLR, TAN abundance) show strong predictive value for ICI response and prognosis. Targeting TAN recruitment, polarization, function and NETosis represents a promising strategy to overcome ICI resistance. Numerous clinical trials are evaluating combination therapies targeting neutrophils to enhance immunotherapy efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cb8c196a123899665e6475d21ebf9639c6d4e4b" target='_blank'>
              Targeting neutrophil‐driven immunosuppression: A strategy to overcome immune checkpoint inhibitor resistance
              </a>
            </td>
          <td>
            Ying Ning, Ke Lei, Xinyan Gao, Yan Kong, Yuping Shan, Tian Tian, Zhumei Cui, He Ren
          </td>
          <td>2026-01-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Most colorectal cancers are resistant to immune checkpoint inhibitors due to an immunosuppressive tumor microenvironment. LINC00673, previously classified as a long non-coding RNA, has been implicated in tumor progression, but its role in antitumor immunity remains poorly understood. We used single-cell RNA sequencing, flow cytometry, and functional assays in Linc00673 knockout and wild-type mouse models treated with programmed death 1 (PD-1) blockade to dissect changes in immune landscape and tumor cell behavior. Linc00673 deletion enhanced the efficacy of PD-1 therapy, reducing tumor burden and prolonging survival. KO tumors showed increased infiltration of cytotoxic CD8⁺ T cells, reduced exhaustion, and improved antigen presentation. The tumor microenvironment shifted toward a pro-inflammatory state, with elevated dendritic cell function, reduced immunosuppressive macrophages, and improved T cell–tumor interactions. Linc00673 also promoted tumor cell migration and immune evasion independently of immune cells, suggesting dual tumor-intrinsic and -extrinsic roles. LINC00673 suppresses antitumor immunity and promotes tumor aggressiveness. Its deletion synergizes with PD-1 blockade, revealing a promising therapeutic target to overcome immune resistance in colorectal cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb9ef0a9a3f2685b8b34be389ae9c671f82a1666" target='_blank'>
              Single-cell RNA sequencing unveils enhanced antitumor immunity in colorectal cancer with PD-1 blockade and LINC00673 deletion
              </a>
            </td>
          <td>
            Yifei Zhu, Yanxi Yao, Yaxian Wang, Zhibing Qiu, Dingpei Zhou, Huixia Huang, Keji Chen, Qingyang Sun, Jiayu Chen, Yuxue Li, Jianqiang Tang, Dawei Li, Ping Wei
          </td>
          <td>2026-01-03</td>
          <td>Biomarker Research</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf87d56103e47056c8390c382a196ac0a7304b81" target='_blank'>
              Rasal1 impairment unleashes anticancer immunity - a focus on T cells
              </a>
            </td>
          <td>
            Mark E. Issa, Alejandro Schcolnik-Cabrera
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c51a090a5d78abb279f15d71c3d174a0e1f6dc1c" target='_blank'>
              “Tumor-to-endothelium mitochondrial transfer licenses endothelial cells for CD8+ T cell recognition via mitochondrial neoantigen presentation”
              </a>
            </td>
          <td>
            F. Costabile, Pierini Stefano, Renzo Perales-Linares, N. Leli, Adham Bear, Cameron Koch, Beatriz M. Carreno, Michael T. Lotze, Lerry Singh, Marny Falck, Andrea Facciabene
          </td>
          <td>2026-02-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="The PIM kinase family is critically involved in tumorigenesis, yet its role in primary T cells is understudied. We reported that PIM2, distinct from the other two isoforms, inhibits T-cell responses to alloantigen. Here, we further established PIM2 as a key negative regulator in anti-tumor immunity. Pim2 deficiency in tumor antigen-specific or polyclonal T cells enhanced their ability to control tumor growth in murine breast cancer, melanoma and leukemia models. Pim2 deficiency enhanced cytokine production and metabolic activities in tumor-infiltrating CD8 T cells. Pim2 deficiency increased TCF1 expression and memory-like phenotype in CD8 T cells from lymphoid organs. Mechanistically, PIM2 facilitated LC3 lipidation, P62 degradation and autophagic flux in T cells, leading to impaired glycolysis and effector cytokine production. Furthermore, through modulating VPRBP kinase phosphorylation, PIM2 inhibited histone methyltransferase activity of EZH2 in CD8 T cells, causing disrupted memory-like phenotype. Notably, the PIM2 inhibitor JP11646 markedly enhanced antitumor T-cell response. The immunosuppressive role of PIM2 was validated in human T cells, where inhibition of PIM2 enhanced antitumor responses in engineered human T cells including melanoma-specific TCR-T cells and CD19CAR-T cells. Collectively, PIM2 represents a promising target for improving cancer immunotherapy through enhancing effector differentiation and persistence of CD8 T cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b5cbff6560d4101491df0176143e10a965a0ac36" target='_blank'>
              Targeting Pim2 Improves Antitumor Immunity through Promoting Effector Function and Persistence of CD8 T cells.
              </a>
            </td>
          <td>
            Yongxia Wu, Linlu Tian, Allison Pugel, Reza Alimohammadi, Qiao Cheng, Weiguo Cui, Michael I. Nishimura, Lauren E Ball, Chien-Wei Lin, Shikhar Mehrotra, Andrew S. Kraft, Xue-Zhong Yu
          </td>
          <td>2026-01-27</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a445e1ca795ad9ffc13ccb78dc0d267f18bdd859" target='_blank'>
              Monocyte reprogramming by nociceptors impedes T cell-mediated tumor immunity
              </a>
            </td>
          <td>
            P. Hanč, Adrian Blair, Harold R. Neely, Changwei Peng, I. Mazo, Matthias Mack, Ulrich H. von Andrian
          </td>
          <td>2026-01-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Head and neck squamous cell carcinoma (HNSCC) remains a prevalent epithelial malignancy. Immune-checkpoint inhibitors have reshaped first-line therapy for recurrent/metastatic disease; yet durable benefit is confined to a subset, reflecting myeloid-centric mechanisms—SPP1+ TAM barriers, cDC1/IL-12 insufficiency, and CXCL8–CXCR1/2–driven neutrophil trafficking—distinct from, and complementary to, classical lymphoid exhaustion. In this review we summarize advances from single-cell RNA and ATAC profiling and spatial transcriptomics that resolve macrophage, dendritic-cell and neutrophil programs, and appraise translational opportunities spanning myeloid reprogramming, innate–adaptive combinations and spatial biomarkers. We also discuss enduring challenges—including HPV-status heterogeneity, limited assay standardization and a scarcity of predictive metrics—that temper implementation. By integrating myeloid-informed readouts (e.g., SPP1–TAM burden, cDC1 competency, serum IL-8) with PD-1–based regimens, EGFR-directed antibodies and myeloid checkpoints (CD47–SIRPα, PI3Kγ, CXCR1/2), emerging strategies aim to restore antigen presentation, improve lymphocyte trafficking and remodel tumor–stroma interfaces. Our synthesis provides an appraisal of the evolving landscape of myeloid-informed precision immuno-oncology in HNSCC and outlines pragmatic standards and avenues for clinical translation. We hope these insights will assist researchers and clinicians as they endeavor to implement more effective, individualized regimens.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1e1e89f3eb622744a2cb356a1f52faae72322d69" target='_blank'>
              Myeloid-driven immunosuppression in head and neck cancer: single-cell ATAC/RNA and spatial transcriptomic perspectives
              </a>
            </td>
          <td>
            Rui Luo, Jianzheng Yang, Zimeng Cao, Bing Li
          </td>
          <td>2025-12-18</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c6a4629ecf871286790c31c3ed5cfe1e56e06510" target='_blank'>
              Single-cell RNA sequencing identifies progenitor dysfunction, inflammation and premature aging in ex vivo airway epithelium-derived from transplant recipients
              </a>
            </td>
          <td>
            Louise Bondeelle, Fedor Bezrukov, Grégory Berra, Y. Chalandon, Constant Gensous, Sheryline Loison, Federica Giannotti, Romain Messe, Jérôme Le Goff, Sophie Clément, Caroline Tapparel, Anne Bergeron
          </td>
          <td>2025-12-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Macrophages are pivotal regulators of immunity, with intercellular communication being a central mechanism of their function. Among these communications, chemokines act as critical messengers in macrophage-T cell crosstalk. This review systematically elucidates the notable roles of macrophage-derived chemokines in modulating T cell homeostasis, particularly concentrating on their influence on both CD4+ and CD8+ T cell differentiation, proliferation, exhaustion, secretory activity, metabolic reprogramming (involving glycolysis and OXPHOS), chemotaxis, and memory formation. In the tumor microenvironment (TME), the dualistic nature of chemokines was highlighted: tumor-associated macrophages (TAMs) could secrete immunosuppressive factors, such as CCL22 and CCL5, recruiting inhibitory cells and inducing CD8+ T cell exhaustion. In contrast, M1-like macrophages could produce CXCL9 and CXCL10, activating effector CD8+ T cells, thereby enhancing anti-tumor immunity. Finally, the promising therapeutic potential of targeting specific chemokine signaling axes, such as CCL2/CCR2 and CXCL10/CXCR3, was discussed as a strategy to improve the efficacy of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4a06e8edc357cf9d46cc116733166db76bc166c3" target='_blank'>
              Macrophage-derived chemokines in T cell regulation: implications for cancer immunotherapy
              </a>
            </td>
          <td>
            Kunpeng Zhang, Jingjing Liu, Qi Liu, Ningning Zhu, Baodong Ye
          </td>
          <td>2026-01-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Gliomas with mutant isocitrate dehydrogenase 1 (mIDH1) represent a distinct subgroup of brain tumors characterized by unique metabolic and immunological profiles compared to wildtype IDH1 (wtIDH1) gliomas. Despite recent progress, the cellular mechanisms underlying tumor progression and immune modulation in these subtypes remain poorly understood. In this study, we employed single-cell RNA sequencing (scRNA-seq) to characterize the cellular heterogeneity of wtIDH1 and mIDH1 gliomas, with a particular focus on myeloid cell populations. Our analyses revealed a marked reduction of monocyte-derived tumor-associated macrophages (Mo-TAMs) and lower expression of macrophage migration inhibitory factor (MIF) in mIDH1 gliomas, which was attributable to epigenetic reprogramming. Mechanistic studies using MIF and CD74 knockout mice demonstrated that the MIF-CD74 axis plays a crucial role in regulating the glioma immune microenvironment, thereby driving tumor growth and progression. Importantly, the combination of immune-stimulatory gene therapy (HSV1-thymidine kinase/Fms-like tyrosine kinase 3 ligand; TK/Flt3L) with MIF inhibition significantly extended survival in models of wtIDH1 glioma. These findings highlight the therapeutic potential of targeting the MIF-CD74 pathway and underscore the importance of integrating immunomodulatory strategies for the treatment of glioma. Highlights Mutant IDH1 gliomas exhibit fewer Mo-TAMs and increased Mg-TAMs Mutant IDH1 gliomas have less MIF expression via epigenetic reprogramming. Mesenchymal wtIDH1 glioma cells are main source of MIF. MIF inhibition plus immune stimulatory gene therapy extends survival wtIDH1 glioma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d9d9e99d312aee7d3e8959371325610d5ce9af0" target='_blank'>
              MIF-mediated reprogramming of myeloid lineage within the glioma tumor microenvironment impacts the efficacy of immune stimulatory gene therapy
              </a>
            </td>
          <td>
            Ziwen Zhu, Noah C. Kanis, Anthony E. George, Michael Albdewi, Yingxiang Li, Anzar A. Mujeeb, Brandon L. McClellan, Gurveer Singh, Jialin Liu, W. Al-Holou, J. Heth, Joshua D. Welch, Justin D. Lathia, Pedro Lowenstein, Richard Bucala, Maria G. Castro
          </td>
          <td>2026-01-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and often adopt an M2-like immunosuppressive phenotype that promotes tumor growth. Reprogramming TAMs toward an M1-like pro-inflammatory state is an attractive therapeutic strategy. Tumor Treating Fields (TTFields), an FDA-approved, electric-field–based therapy, has recently been suggested to modulate immune responses in addition to its established anti-mitotic activity. Here, we investigated the direct effects of TTFields on macrophage activation and function. Murine bone marrow–derived macrophages (BMDMs) were polarized toward a pro-inflammatory M1-like phenotype or an anti-inflammatory M2-like phenotype and exposed to TTFields. TTFields rapidly activated guanine nucleotide exchange factor-H1 (GEF-H1), and downstream nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1, via c-Jun N-terminal kinase [JNK]) signaling. Functionally, TTFields reprogrammed M2-like macrophages by increasing major histocompatibility complex class II (MHC-II) and cluster of differentiation 80 (CD80); reducing arginase-1 (Arg1); and elevating secretion of chemokine (C-X-C motif) ligand 1 (CXCL1), interleukin-6 (IL-6), IL-1β, and IL-12 subunit p70 (IL-12p70). In interferon gamma (IFN-γ)-primed macrophages, TTFields provided a secondary signal, driving myeloid differentiation primary response 88 (MyD88)-dependent expression of inducible nitric oxide synthase (iNOS). In vivo, TTFields reduced tumor burden in an orthotopic murine lung cancer model and increased iNOS expression in both M1-like and a subset of M2-like TAMs. These findings demonstrate that TTFields directly reprogram macrophages toward a pro-inflammatory phenotype, suggesting a novel immunomodulatory mechanism that may enhance anti-tumor immunity in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db7963f819719f5d174aa6e308c691c9523b680d" target='_blank'>
              Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)
              </a>
            </td>
          <td>
            T. Kan, Y. Barsheshet, Tharwat Haj Khalil, B. Brant, T. Voloshin, K. Ben-Meir, Simona Zisman Rosen, M. Giladi, U. Weinberg, Y. Palti
          </td>
          <td>2025-12-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor survival. The immunosuppressive tumor microenvironment (TME) drives resistance to therapy, including immunotherapy. This may be, in part, mediated by the formation of neutrophil extracellular traps (NETs), formed when neutrophils release their intracellular contents. NETs are elevated in PDAC and are associated with nearly every stage of tumor progression. We investigated the influence of NETs on the PDAC TME and immunotherapy response. An orthotopic PDAC model was utilized in C57BJ6 or PAD4-/- mice receiving one of the following: control, DNase, anti-PD-1 therapy, or DNase and anti-PD-1. NET markers, fibrosis, and the TME immune profile were evaluated. Human PDAC patients were also evaluated for levels of NETs and tumor-infiltrating T cells. Circulating NET markers correlated with intra-tumoral CD8+ cells in PDAC patients. Patients with high NET levels also experienced more post-operative complications. NET inhibition in mice reduced tumor growth and enhanced survival. Decreased expression of collagen and matrix metalloproteinase (MMP) genes, as well as reduced intra-tumoral collagen deposition were found in NET deficient mice. Additionally, an increase in TCF1+PD-1+CD44+CD8+ progenitor T cells, a subpopulation of T cells responsive to immunotherapy, were identified. These changes resulted in further tumor burden reduction and prolonged survival when anti-PD-1 therapy was given in conjunction with NET inhibition. NETs influence extracellular matrix remodeling and the T cell response to PDAC, allowing for a significant response to anti-PD-1 therapy. These findings support the combination therapy of immunotherapy and NET inhibition in patients with PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c46e4293b48b999ce9a40d9b92499a2b9823b8d" target='_blank'>
              Neutrophil extracellular trap inhibition revitalizes PDAC immunotherapy responsiveness via reduced fibrosis and TCF1+CD8+ progenitor T-cell expansion
              </a>
            </td>
          <td>
            Britney Niemann, Abby D Ivey, Quinn Hopen, Duaa Dakhlallah, Kathleen Brundage, Nicole E Mihalik, Timothy D Eubank, Brian A. Boone
          </td>
          <td>2025-12-01</td>
          <td>OncoImmunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/236386a7fa1ba2562148eaf357471660c9fc4c08" target='_blank'>
              Suppression of CD4 T cells by Tregs dictates metabolic remodeling of CD8 T cells during effector to memory transition
              </a>
            </td>
          <td>
            Adithya Vegaraju, V. Kalia, Surojit Sarkar
          </td>
          <td>2026-02-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0507f17451e85de10486e266478d7f4153cfd4d4" target='_blank'>
              Adipose-Derived Extracellular Vesicles Mitigate Experimental Cutaneous Leishmaniasis Through an IL-10–Dependent Mechanism
              </a>
            </td>
          <td>
            D. B. de Almeida, Camila Nascimento Fernandez, Alisson Amaral da Rocha, Igor Bittencourt dos Santos, João Victor Paiva Romano, Hozany Praxedes dos Santos, Naiara Carla dos Santos Manhães, Renata Trabach Santos, Beatriz Toja de Miranda, L. Covre, Alessandra Marcia da Fonseca Martins, Daniel Claudio Oliveira Gomes, Fernanda Ferreira Cruz, Tadeu Diniz Ramos, P. Rocco, H. L. de Matos Guedes
          </td>
          <td>2026-02-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Immunotherapies have transformed cancer treatment by harnessing the immune system to recognize and eliminate malignant cells, offering durable clinical benefit across diverse tumor types. Despite successes with immune checkpoint inhibitors (ICIs) and other strategies like cytokines, oncolytic viruses, cancer vaccines, bispecific antibodies, and adoptive cell therapies, substantial fractions of patients still fail to respond or develop resistance. The oncogene MYC, deregulated in ~70% of human cancers, has emerged as a central driver of immune evasion and a key contributor to immunotherapy failure. MYC regulates broad transcriptional networks controlling proliferation, metabolism, angiogenesis, and cell survival, while also orchestrating profound remodeling of the tumor microenvironment (TME). Mechanistically, oncogenic MYC suppresses antigen processing and presentation, attenuates interferon signaling, and upregulates immune checkpoints such as PD-L1 and CD47. Concurrently, MYC stimulates secretion of immunosuppressive cytokines and chemokines that recruit regulatory T cells, myeloid-derived suppressor cells, and M2 macrophages, while driving metabolic reprogramming that fosters nutrient competition, hypoxia, and acidosis, impairing effector T- and NK-cell function. Through these pathways, MYC promotes primary, adaptive, and acquired resistance to immunotherapy. Targeting MYC, directly or indirectly, holds promise to restore immune surveillance and potentiate immunotherapeutic efficacy. This review highlights MYC as a master regulator of tumor–immune interactions and underscores the therapeutic potential of MYC inhibition to overcome resistance and expand the clinical impact of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/437ab7ab32dc49430fcd2b151a4005d089060a97" target='_blank'>
              MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance
              </a>
            </td>
          <td>
            Íñigo González-Larreategui, Manrique Valdés-Bango Martín, S. Casacuberta-Serra, Laura Soucek
          </td>
          <td>2026-01-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="The induction of immune responses in tissues and mucosa has emerged as one of the most promising strategies for the development of more effective vaccines and immunotherapies. In this context, CD8+ resident memory T cells (CD8+ TRM) have arisen as key players in local immune surveillance, acting persistently within non-lymphoid tissues. These cells represent a new and promising frontier in local immune responses and as potential clinical tools. CD8+ TRM are being extensively investigated as therapeutic targets against viral infections and cancer, although their clinical applications have yet to be fully established. Understanding the molecular signals that regulate their generation, differentiation, maintenance, and activation is crucial for the precise targeting of their immune functions. This review explores the main mechanisms involved in the formation and maintenance of CD8+ TRM, from the strength of MHC: TCR interactions to the coordinated role of cytokines, chemokines, and transcription factors in tissue retention and the expression of markers such as CD69, CD103, and CD49a. By integrating this knowledge, we discuss strategies to manipulate these pathways with the goal of developing more effective vaccines and personalized therapies based on resident memory T cells. We also examine how these molecular signals and pathways, either independently or in combination, can be explored both in the fight against viral infections and cancer, and in identifying CD8+ TRM predictive biomarkers for response to anticancer immunotherapies across various tumor types.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7a54040a23911cb44878186479043eac242cce4" target='_blank'>
              Keeping it local: how CD8 TRMs regulate viral and cancer immunity
              </a>
            </td>
          <td>
            Luiz Rodrigues Junior, Cristina Bonorino, Alisson F. Haubert, Marvin Paulo Lins, Gabriel Pozo Pereira, Pedro R. Torres Romao, Barry T. Rouse
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Innate immunity has long been viewed as lacking memory capabilities. However, an increasing number of studies are challenging this conventional immunological paradigm. In recent years, innate immune memory has been recognized as an essential component of immune defense, allowing organisms to mount either enhanced or diminished responses to previously encountered stimuli. Increasing evidence suggests that innate immune memory may underlie various lung diseases. In this regard, elucidating the mechanisms of innate immune memory in pulmonary diseases not only aids in understanding the underlying pathophysiology of pulmonary disorders but also holds significant implications for therapeutic interventions. Macrophages, as a central element of the lung’s innate immune system, represent one of the most extensively investigated cell types in terms of innate immune memory. In this review, we first outline the origin and maintenance of lung macrophage homeostasis, alongside the conceptual framework, classifications, and mechanistic underpinnings of macrophage immune memory. Subsequently, we focus on summarizing the distinctive features of macrophage immune memory across diverse lung diseases, including infections, tumors, transplantation, and other immune-related conditions. Finally, we propose potential therapeutic strategies to manage various lung diseases through modulating macrophage immune memory. We hope that these advancements in immunology will uncover novel pharmacological targets and provide valuable theoretical support for researchers to understand the pathogeneses and develop effective treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aa564504a15bfe4b49fddd894ec5c3347d7c1a2b" target='_blank'>
              Recent perspectives on macrophage memory: types, mechanisms, and characteristics in pulmonary diseases
              </a>
            </td>
          <td>
            Shuyong Wang, Bin Wang, Yonghui Qiu, Yiwei Lu, Hongjun Gu, Bo Wang, Jiang Wang
          </td>
          <td>2026-01-15</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Purpose Conventional type 1 dendritic cells (cDC1s) mastermind anti-cancer immunity and play a pivotal role in determining the efficacy of cancer immunotherapies. In this study, we sought to decipher the dynamic changes in the tumor immune landscape during intrahepatic cholangiocarcinoma (iCCA) development and harness the therapeutic potential of targeting cDC1s for cancer therapy. Methods We constructed spontaneous murine iCCAs via hydrodynamic tail vein injection (HDTVi) of plasmids encoding AKT/YAP. To characterize tumor-infiltrating immune cell populations throughout iCCA carcinogenesis and progression, we performed time-of-flight mass cytometry (CyTOF). To expand and activate cDC1s, we combined Flt3L with poly I:C (FL-pIC) therapy and assessed its therapeutic efficacy in both AKT/YAP-induced iCCAs and a subcutaneous tumor injection model. Flow cytometric analyses were used to evaluate intra-tumoral infiltration levels of cDCs and CD8+ T cells. Results CyTOF analysis revealed the progressive formation of an immunosuppressive tumor microenvironment as iCCA advances. Crucially, infiltration of cDC1s dramatically decreases in advanced iCCAs compared to early-stage tumors. Combined FL-pIC therapy preferentially expanded CD103+ cDC1s, powerfully inhibiting tumorigenesis in AKT/YAP-driven murine iCCAs and sensitizing these tumors to anti-PD-1 therapy. Moreover, FL-pIC therapy markedly suppressed the growth of established mIC-23 subcutaneous tumors. Conclusions Our findings demonstrate that recruiting and activating intra-tumoral cDC1s is feasible and essential for driving anti-tumor CD8+ T cell immune responses and enhancing anti-PD-1 therapeutic effectiveness in iCCA.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0302218b55971d224461dce8f8bbf85290ab2de1" target='_blank'>
              Enhancing cDC1-mediated anti-tumor immunity limits tumor progression and potentiates anti-PD-1 therapy in intrahepatic cholangiocarcinoma
              </a>
            </td>
          <td>
            Dong-ni Pei, Yang Song, Yingxia Zhou, Bo Shu, Shao-wei Huang, Fa-zhao Li, Wei-dong Dai, Bao-Ye Sun
          </td>
          <td>2025-12-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has revolutionized the treatment of hematologic malignancies, yet its efficacy in solid tumors remains limited by T cell exhaustion, restricted tumor infiltration, and an immunosuppressive tumor microenvironment (TME). Recent advances in cytokine engineering have introduced innovative strategies to overcome these barriers by modulating CAR cell survival, persistence, and cytotoxic function. This review provides a comprehensive analysis of emerging cytokine-augmented CAR platforms, highlighting mechanistic innovations such as IL-2 superkines that enhance selective CAR-T expansion, IL-15–armed CAR constructs that sustain in vivo persistence, and IL-12 and IL-18 co-expression systems that remodel the TME and recruit endogenous immune effectors. The roles of IL-7, IL-10, and IL-21 in preserving memory phenotypes, mitigating exhaustion, and improving metabolic fitness are also discussed in depth. Furthermore, the review explores synthetic and inducible cytokine circuits that enable spatial and temporal control of cytokine release, improving therapeutic precision and reducing systemic toxicity. Collectively, these innovations represent a paradigm shift toward next-generation, cytokine-engineered CAR therapies with enhanced efficacy, safety, and durability against both hematologic and solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6da7d9a1c0219aac208853d023320a8f5224de41" target='_blank'>
              Frontiers of cytokine engineering in CAR cell therapy for cancer
              </a>
            </td>
          <td>
            Yinghan Wu, Yan-Ruide Li
          </td>
          <td>2026-01-09</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that strongly suppress immunity and expand during tumor progression. Various antitumor chemotherapy agents can induce MDSC accumulation, reducing treatment effectiveness. We investigated the impact of the CHOP regimen and its components (cyclophosphamide (CTX), doxorubicin, vincristine, and prednisolone) on the dynamics of MDSC accumulation and the associated changes in immune cell profiles in the peripheral blood and spleen of healthy and lymphosarcoma RLS40-bearing CBA mice. CHOP induced significant thymic atrophy and splenomegaly, T-cell depletion, and robust accumulation of MDSCs, primarily polymorphonuclear MDSCs. Kinetic analysis in healthy mice revealed splenic MDSC expansion and T-cell depletion peaked 10-day post-CHOP, driven mainly by CTX; whereas doxorubicin, vincristine, and prednisolone exerted minimal immunological effects. To mitigate CTX-induced MDSCs, glycyrrhizic acid (GLZ), a natural triterpenoid with known immunomodulatory properties, and febroxolone methyl (FM), its novel cyano enone derivative, were administered to CTX-treated mice. GLZ significantly attenuated splenic MDSC accumulation, partially restored T-cell function, and improved immune organ morphology. Conversely, FM exacerbated immunosuppression by expanding MDSCs, enhancing their function by upregulation of Nos1 and Ido1 in vivo, and promoting the generation of highly immunosuppressive bone marrow-derived MDSCs in vitro. Thus, our results highlight CTX’s central role in CHOP-induced MDSC expansion. The structure-dependent duality of triterpenoids, countering (GLZ) or promoting (FM) MDSC expansion, offers therapeutic potential for pathologies ranging from chemotherapy-induced side effects to autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7552027a881146da8a9871bda6ded9bf7a0d48b5" target='_blank'>
              Cyclophosphamide-Mediated Induction of Myeloid-Derived Suppressor Cells In Vivo: Kinetics of Accumulation, Immune Profile, and Immunomodulation by Oleanane-Type Triterpenoids
              </a>
            </td>
          <td>
            M. Awad, A. Sen’kova, A. Markov, O. Salomatina, M. Zenkova, O. Markov
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Regulatory B cells (Bregs) are integral to the tumor microenvironment (TME) and influence immune responses through the secretion of immunosuppressive cytokines such as IL-10, IL-35, and TGF-β. This review highlights recent findings on the phenotype and mechanisms of Bregs, emphasizing their dual role in regulating immune responses within the TME. Importantly, we further explored the latest advances in Breg regulatory mechanisms from the novel perspectives of epigenetics and metabolic remodeling, including the effects of DNA methylation, histone acetylation, glycolysis, and oxidative phosphorylation on Bregs. We also investigate the therapeutic targeting of Bregs, with a focus on STAT3 inhibitors such as lipoxin A4, cucurbitacins, and resveratrol, which show promising potential in mitigating the suppressive function of Bregs. Furthermore, this review provides a detailed analysis of the impact of Bregs on tumorigenesis and metastasis, emphasizing the importance of inhibiting specific immune pathways to prevent tumor escape. Finally, this review offers a prospective outlook on immunotherapy strategies based on Bregs, foreseeing a more nuanced understanding of their TME function and the evolution of targeted treatments with enhanced therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/89845b10942cf1fb9d00d8bf5893d8221d0e0a22" target='_blank'>
              Regulatory B Cells in Tumor Microenvironment
              </a>
            </td>
          <td>
            Zhuoyan Cai, Lin Xie
          </td>
          <td>2026-01-01</td>
          <td>Current Issues in Molecular Biology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/954805b24a989a5a800c8a228d8a6b54b8ed322d" target='_blank'>
              Cooperative Interaction Between IL-4 Signaling and FLT3 in Multipotent Progenitors Restore Lymphopoiesis in Inflammation and Aging
              </a>
            </td>
          <td>
            Jingfei Yao, Yuting Wang, Yi Zhang
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Liver metastasis is a primary cause of death in colorectal cancer, yet the role of immune cells called neutrophils in this process remains complex. In this study, we identify three distinct neutrophil subtypes: anti-tumor high-density neutrophils, pro-tumor mature low-density neutrophils, and immature low-density neutrophils. Here we show that tumor-derived GM-CSF converts anti-tumor neutrophils into a pro-tumor state via the AKT–NF-κB–NFAT5 signaling axis. These activated neutrophils, when further stimulated by CXCR2 ligands, release web-like structures known as neutrophil extracellular traps which promote cancer spread by enhancing cancer cell growth, suppressing immune responses, and preparing the liver for metastasis. Importantly, we demonstrate that using antibodies depleting neutrophils or drugs inhibiting their pro-tumor activity effectively reduces liver metastasis in mice. Our work defines specific neutrophil subsets as key drivers of cancer progression and highlights their therapeutic potential in preventing metastatic spread. Liver metastasis remains a leading cause of colorectal cancer mortality. This study identifies different neutrophil subtypes involved in metastasis, highlighting therapeutic potential of neutrophil subset targeting to inhibit tumor progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/72f584b0e84a9c982ad9ec8521c5821285190b9d" target='_blank'>
              Agonist signaling drives neutrophil subpopulations to promote/inhibit colorectal cancer liver metastasis
              </a>
            </td>
          <td>
            Zhuoqing Xu, Haoran Feng, Wenqing Feng, Yuchen Zhang, J. Huo, Zifeng Xu, Fangqian Chen, Han Gao, Zeping Lv, Wangyi Liu, Abudumaimaitijiang Tuersun, Suyue Yu, Wenchang Li, Y. Zong, Xiaohui Shen, Xi Cheng, Jingkun Zhao, Aiguo Lu
          </td>
          <td>2025-12-17</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Abstract Breast cancer is genetically and histologically heterogenous, and is influenced by a variety of factors, including the tumor microenvironment (TME). The PAM50 subtypes; Luminal A, Luminal B, Normal-like, Basal-like and Her2-enriched, are associated with different tumor phenotypes and overall survival. The quantity and quality of immune cell infiltration in breast tumors play a key role in cancer development and progression and are associated with survival and treatment response. We used multiplex immunohistochemistry, single-cell RNA sequencing, and two deconvolution algorithms to explore the immune landscape across PAM50 subtypes. Immunostaining of CD3+ T cells, tryptase+ mast cells, CD20+ B cells, CD68+ CD163+ macrophages, and CD66b+ granulocytes revealed marked differences in tumor immune infiltrates according to breast cancer subtypes. Luminal tumors were relatively deprived of T cells and B cells, while exhibiting sparse to moderate amounts of macrophage infiltration. In contrast, Her2-enriched tumors exhibited a moderate immune presence, with sparse to moderate T cell infiltration and moderate infiltration of B cells and macrophages. At the other end of the spectrum, Basal-like tumors stood out for their strikingly rich immune environment and are heavily infiltrated by T cells, B cells, and macrophages. The results from the single-cell and deconvolution analyses confirmed subtype-specific immune microenvironments, which also allowed us to observe increased levels of natural killer (NK) and CD8+ T cells in Her2-enriched and Basal-like subtypes. In conclusion, our findings demonstrate significant differences in the immune tumor microenvironment between the established breast cancer molecular subtypes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/27c99c23b4dfb7da23c9b0f3a691c05aec9a1b68" target='_blank'>
              Multi-platform analysis of the tumor immune microenvironment associated with breast cancer subtypes
              </a>
            </td>
          <td>
            Lilly Anne Torland, Jürgen Geisler, Y. Azimzade, Astri Frafjord, Hogne Røed Nilsen, Linn Buer, J. Lømo, Ø. Garred, Andliena Tahiri, M. Lyngra, Inger Øynebråten, Alexandre Corthay, Kristine Sahlberg, Vessela N. Kristensen, Xavier Tekpli
          </td>
          <td>2026-01-13</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Dendritic cells (DCs) are crucial in regulating immune responses, making them a compelling target for immunotherapy. While DC vaccines have demonstrated safety and feasibility, their limited clinical efficacy underscores the need for strategies to enhance DC functionality. Emerging evidence highlights the regulatory roles of sialoglycans in DC biology, yet the structure-function relationships of other glycans remain poorly understood. To aid the understanding of DC glycobiology, we recently developed and validated a human model system based on genetically glycoengineered MUTZ-3-derived DCs and showed that ST6GAL1-mediated α2,6-sialylation specifically modulates CD4+ T cell activation. In this study, we knocked-out (KO) mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT1) to investigate how the shift from complex to oligomannose N-glycans affects DC biology and function. MGAT1 KO completely abolished the synthesis of complex and hybrid N-glycans. Differentiation of MGAT1 KO MUTZ-3 cells into immature DCs (iDCs) induced upregulation of DC markers including CD1a, CD80, CD86, CCR6, and CD209, comparable to the upregulation observed in WT iDCs. Interestingly, MGAT1 KO iDCs displayed an enhanced immunostimulatory profile, marked by increased surface densities of CD40, HLA-ABC, and HLA-DR, in combination with elevated mRNA levels of NFKB1 and IFNB1. Consistent with this profile, MGAT1 KO iDCs highly enhanced the activation and proliferation of allogeneic human CD8+ T cells in vitro, resulting in significantly higher levels of secreted proinflammatory cytokines compared to WT iDCs. This enhanced CD8+ T cell activation persisted under PD-L1 blockade, underscoring the robustness of the MGAT1 KO–driven effect. Significantly elevated NFKB1 levels in the MGAT1 KO iDCs suggest enhanced NF-κB activity driving HLA and costimulatory molecule upregulation and robust CD8+ T cell activation. We further demonstrate that MGAT1 KO promotes accelerated DC differentiation, yielding DCs that after three days of differentiation acquire the capacity to activate T cells. Building on previous research into sialic acids in DC biology, our findings reveal a regulatory role for complex and hybrid N-glycans and specifically demonstrate how sialic acids on N-glycans influence distinct functional outcomes in T cell activation. Our findings support cell-based glycoengineering as an effective strategy to improve DC-based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c295253393fc514495236e9da28c6d51c5c72e86" target='_blank'>
              MGAT1 knockout in human dendritic cells enhance CD8+ T cell activation
              </a>
            </td>
          <td>
            Anne Louise Blomberg, Betina L. Henriksen, Weihua Tian, Kerstin Skovgaard, S. L. Skovbakke, Steffen Goletz
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f5b1452c4ea7be36d75cc8466a503f25e2a59f42" target='_blank'>
              IL-12R signaling promotes type 1 regulatory T cell specialization by sustaining T-bet
              </a>
            </td>
          <td>
            Anna Estrada Brull, Ylva M. Carlen, Laura Revert Rubio, P. Zwicky, S. Mundt, Burkard Becher, Nicole Joller
          </td>
          <td>2026-01-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Rheumatoid arthritis (RA) represents a major global public health challenge, with approximately 1% of the world's population suffering from this disease. In the absence of a cure, patients require ongoing and very often lifelong treatment. While environmental, genetic, and epigenetic factors have all been linked to the development of RA, a key, universally accepted initiating factor in disease development is the loss of immunological tolerance to self‐antigens. Currently, most treatment approaches utilise agents that suppress the immune system or inflammatory response. However, there is no currently available treatment to re‐establish self‐tolerance, the key driving factor in the initiation of the disease. In this review, we will explore how peripheral tolerance mechanisms fail in RA, leading to disease initiation and progression. We will explore how dendritic cells (DCs), a central and nonredundant cell type in maintaining immune tolerance, contribute to RA and discuss molecular strategies to switch these immunogenic and self‐reactive cells to tolerogenic cells. Finally, in addition to understanding the fundamental mechanisms of how peripheral tolerance mechanisms are lost, it is also important to know where this dysregulation occurs. Therefore, in this review, we will also discuss emerging research on sites of disease initiation in the context of tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/42e0c982411e47309fe287def4e254144769c5b8" target='_blank'>
              Restoring Immunological Tolerance via Dendritic Cells in Rheumatoid Arthritis
              </a>
            </td>
          <td>
            H. Costello, Andrea Woodcock, Mary Canavan
          </td>
          <td>2026-01-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Glucocorticoids (GCs), such as dexamethasone (Dex), are widely used in breast cancer treatment to alleviate chemotherapy-induced side effects. However, their immunomodulatory effects on the tumor microenvironment (TME) exhibit a dual nature. On one hand, Dex may delay tumor progression by suppressing pro-inflammatory cytokine release, modulating T-cell function, and inhibiting angiogenesis. On the other hand, Dex can promote the formation of an immunosuppressive TME by activating the glucocorticoid receptor (GR) signaling pathway, thereby accelerating breast cancer metastasis. This review summarizes the molecular mechanisms by which Dex influences breast cancer lung metastasis through its regulation of immune cells (e.g., T cells, B cells, myeloid cells), cytokine networks, and metabolic reprogramming in the TME. Additionally, potential strategies targeting GR or combining immunotherapy are discussed.Therefore, this mini review aims to elucidate the complex mechanisms of Dex in the breast cancer TME and ultimately guide the translation of mechanistic discoveries into clinical breakthroughs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c149f170ee7affa8af0416cce619204ab0fcf62f" target='_blank'>
              The dual role of glucocorticoids in the breast cancer immune microenvironment: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Bianping Liang, Xinglan Wang, Yunrui Fu, Mingxue Wang
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Regulatory B cells (Bregs) contribute to immune homeostasis via IL-10–dependent and independent pathways. To dissect additional mediators, we investigated splenic derived GM-CSF/IL-15 fusokine (GIFT15)-induced Bregs in experimental autoimmune encephalomyelitis (EAE) using transcriptomics and functional validation. Bulk RNA-seq of splenic Bregs revealed upregulation of Ccl3, GzmB, and Il27 subunits compared to resting B cells. Functional studies showed that CCL3-deficient Bregs failed to suppress disease, whereas GzmB-deficient Bregs retained efficacy, and IL-27 receptor signaling in recipients was dispensable. Flow cytometry demonstrated that CCL3 expression correlated with FoxP3⁺ Treg and Tr1 expansion, along with CD206⁺ macrophage polarization. In the CNS, transient, tissue-dependent increases in oligodendroglial markers O4 and GalC were detected. Collectively, these findings identify CCL3 as a non-redundant effector of Breg-mediated protection, acting primarily through peripheral T-cell and myeloid remodeling, with secondary CNS impacts. These results highlight the translational potential of CCL3-competent, spleen-derived GIFT15 Bregs for therapeutic modulation of autoimmune demyelination. GIFT15-induced regulatory B cells rely on CCL3 to drive immune modulation and promote recovery in EAE, revealing a key effector pathway with implications for therapeutic remodeling of autoimmune neuroinflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d792b1be1c294b9dc816e115153e9e7bfb3f965d" target='_blank'>
              Regulatory B cell CCL3 competency promotes disease resolution and oligodendrogenesis in experimental autoimmune encephalomyelitis
              </a>
            </td>
          <td>
            A. Pennati, Xingyi Tang, Catigan Hedican, Amar Yeware, Md Mahfuzur Rahman, Owen A Zeitler, S. Yuan, Jacques Galipeau
          </td>
          <td>2025-12-31</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Mesenchymal stem cells (MSCs) are multipotent stem cells with critical functions, including immunomodulation, multidirectional differentiation, anti-inflammatory activity, tissue repair, and regeneration. Recent studies demonstrate that MSCs can enhance hematopoietic stem cell engraftment, mitigate graft-versus-host disease (GVHD), address transplant-related complications, and treat conditions such as immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). These therapeutic effects are largely attributable to the immunomodulatory and anti-inflammatory properties of MSCs. However, in hematologic malignancies, MSCs can exert both pro-tumor and anti-tumor influences. Exosomes, which are extracellular vesicles derived from MSCs (MSC-EVs), not only replicate many MSC functions but also exhibit greater chemical stability and lower immunogenicity. These characteristics make MSC-EVs particularly significant in the context of hematopoietic stem cell transplantation (HSCT). This review provides a detailed overview of the roles and clinical applications of MSCs in hematologic diseases, the properties of MSC-EVs, and their emerging significance in HSCT.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/675b5fd2d3e02a458f9686f5c030ba7046442481" target='_blank'>
              The roles and clinical applications of mesenchymal stem cells and their exosomes in hematologic diseases
              </a>
            </td>
          <td>
            Mengxue Deng, Xiaoying Zhang, Yicheng Zhang
          </td>
          <td>2025-12-24</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Ovarian cancer remains one of the most lethal gynecologic malignancies, largely due to its late-stage diagnosis and the establishment of an immunosuppressive tumor microenvironment (TME). Natural killer (NK) cells, key effectors of innate immunity, exhibit impaired cytotoxicity within this hostile niche. The dysfunction arises from multiple mechanisms, including suppression by immunosuppressive cytokines (TGF-β, MUC16), shedding of activating ligands (MICA/B, B7-H6, CD155), overexpression of inhibitory immune checkpoints (PD-1, TIGIT), and metabolic reprogramming shaped by glucose and lipid competition. Recent advances in NK cell–based immunotherapies—such as cytokine modulation, adoptive NK transfer, and checkpoint blockade—have demonstrated potential to reverse NK exhaustion and enhance antitumor efficacy. In this review, we systematically dissect the molecular and cellular pathways underlying NK cell suppression in ovarian cancer and evaluate emerging strategies to reinvigorate NK-mediated immunosurveillance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0c24208516b5c52a573a3fe8e8a63ee815d757d8" target='_blank'>
              Natural killer cell exhaustion in ovarian cancer: from molecular suppression to therapeutic revival
              </a>
            </td>
          <td>
            Jun Ning, Lan Yao
          </td>
          <td>2026-01-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Background: Lung metastasis is a leading cause of breast cancer (BC)-related mortality, driven by the immunosuppressive traits of the metastatic tumor microenvironment. However, the mechanisms underlying cell–cell crosstalk in shaping immune evasion within the metastatic niche remain poorly defined. Neutrophil extracellular traps (NETs) and their associated proteins, such as cathelicidin, have emerged as key mediators of metastatic regulation in cancer. Here, we aimed to decipher the interaction between a neutrophil subset characterized by high expression of lymphocyte antigen 6 complex locus g (Ly6ghigh) and cluster of differentiation 8-positive T lymphocytes (CD8+ T cells), mediated via cathelicidin embedded in NETs, as well as their synergistic mechanism and cooperative role in promoting lung metastasis of BC. Methods: We characterized neutrophil heterogeneity and functional dynamics by performing single-cell RNA sequencing and flow cytometry on lung tissues derived from murine models of BC lung metastasis. We utilized cathelicidin-related antimicrobial peptide (Cramp) knockout mice to dissect the role of cathelicidin in NETs. The spatial colocalization of apoptotic CD8+ T cells and NETs was analyzed using multiplex immunofluorescence, and the molecular interactions were probed by protein binding assays. Results: Neutrophils in the lung metastatic niche were classified into 2 subsets based on the Ly6g expression: Ly6ghigh and Ly6glow neutrophils. Ly6glow neutrophils, which were recruited in the macrometastatic stage, exhibited myeloid-derived suppressor cell-like characteristics. Notably, Ly6ghigh neutrophils induced CD8+ T cell apoptosis through NET formation, with apoptotic CD8+ T cells spatially clustered within NET-rich areas. Mechanistically, NET-derived cathelicidin (Cramp in mice) directly bound to mitochondrial adenine nucleotide translocator 1 (Ant1) in CD8+ T cells, triggering conformational changes and complex formation with voltage-dependent anion channel 1 (Vdac1). These events resulted in the opening of the mitochondrial permeability transition pore and loss of mitochondrial membrane potential. Conclusions: Our study demonstrates that Ly6ghigh neutrophils play a critical role in immunosuppression and immune evasion through NET-induced apoptosis of CD8+ T cells. These findings underscore the importance of NETs and cathelicidin in BC lung metastasis, suggesting their potential as therapeutic targets in restoring antitumor immunity and in preventing metastatic progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9ef68cd25c376c469635ba05f3d36dd4afd991fe" target='_blank'>
              The Ly6ghigh Neutrophil Subset Dictates Breast Cancer Lung Metastasis via CD8+ T Cell Death
              </a>
            </td>
          <td>
            Rui Wang, Xiaoqi Liu, Yixuan Hou, Shanchun Chen, Yongcan Liu, Zexiu Lu, Chao Chang, Die Meng, Jing Chen, Xiaojiang Cui, Zhengrong Shi, Xueying Wan, Man-ru Liu
          </td>
          <td>2025-12-15</td>
          <td>Cancer Communications</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Inflammation plays a pivotal role in every stage of cancer development, from tumor initiation to progression, largely by influencing the balance between immune surveillance and immune evasion. At the heart of this inflammatory signaling is the transcription factor Nuclear Factor κB (NFκB), widely recognized as a key orchestrator of immune responses in malignancies. Within the framework of cancer immunoediting, comprising the three key phases Elimination, Equilibrium, and Escape, NFκB emerges as a double-edged sword. While it can enhance the activity and infiltration of effector immune cells that promote tumor destruction, it can also reprogram these cells into immunosuppressive subsets, thereby facilitating tumor immune evasion and growth. This dual functionality makes NFκB both a promising and challenging target in cancer immunotherapy. Despite its significance, comprehensive insights into NFκB’s roles across the immunoediting continuum remain limited. This review aims to bridge that gap by systematically exploring the multifaceted contributions of NFκB in modulating tumor-immune interactions, from immune-mediated tumor surveillance to immune escape, highlighting its potential and complexity as a therapeutic target. Plain Language Summary Inflammation has a key role in cancer’s development and spread. It influences whether the immune system can fight cancer or if the cancer escapes detection. NFkB, a protein that regulates the immune system, plays an important role in this process. Within the framework of cancer immunoediting, involving three important phases: Elimination, Equilibrium, and Escape, NFkB emerges as a double-edged sword. It can assist the immune system fight cancer, but it can also suppress immune cell function, allowing cancer to spread. NFkB is a complex target for cancer treatment due to its potential for both beneficial and detrimental effects. This review examines how NFkB influences the immune system's interaction with cancer at various stages, and how a better understanding it could lead to more effective treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc6a1c1a3bf6e0a9c1471ebde9d4748f47774edd" target='_blank'>
              The Role of Nuclear Factor-κB in Cancer Immunity and Immunoediting
              </a>
            </td>
          <td>
            S. Mukherjee, Subhadip Pati, Subhanki Dhar, Tania Sarkar, Silpita Paul, Udit Basak, S. Chakraborty, Gaurisankar Sa
          </td>
          <td>2025-11-01</td>
          <td>Cancer Control: Journal of the Moffitt Cancer Center</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Colorectal cancer (CRC) is a highly prevalent and lethal malignancy worldwide, whose development is closely associated with gut microbiota dysbiosis and immune microenvironment imbalance. Interferons (IFNs) serve not only as pivotal cytokines bridging innate and adaptive immunity but also induce multiple forms of programmed cell death (PCD), playing a crucial role in antitumor immunity. This narrative review examines the core mechanisms of the gut microbiota-IFNs-programmed cell death axis within the CRC immune microenvironment. As upstream regulators, gut microbiota profoundly influence the production and function of type I, II, and III interferons through metabolic products and microbial-associated molecular patterns (MAMPs). Conversely, IFNs, serving as the pivotal link between innate and adaptive immunity, directly participate in tumor immune surveillance while also determining tumor cell fate by finely regulating PCD pathways such as apoptosis, autophagy, pyroptosis, and ferroptosis. In the CRC context, protective microbiota enhances IFN signaling and promote immunogenic PCD, activating effective antitumor immunity. Conversely, carcinogenic microbiota suppresses IFN responses, disrupt immune surveillance, and drive immune evasion and drug resistance. In-depth investigation of the mechanisms by which gut microbiota modulate interferon-mediated programmed cell death in CRC not only offers new insights into CRC immune evasion but also provides a theoretical foundation for developing combined immunotherapy strategies based on microbiota intervention, targeting IFN pathways, or regulating PCD patterns.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4334061aba6b8640bb4bc6883d24bcf7907f7994" target='_blank'>
              Role and mechanism of gut microbiota in regulating interferon-mediated programmed cell death in colorectal cancer
              </a>
            </td>
          <td>
            Qipeng Yao, Shiyin Chen, Weiwei Qian, Chao Yang, Junxian Li
          </td>
          <td>2026-01-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Many inflammatory stimuli can induce progenitor cells in the bone marrow to produce increased numbers of myeloid cells as part of the process of emergency myelopoiesis. These events are associated with trained immunity and have long-term impacts on hematopoietic stem and progenitor cell (HSPC) development but can also compromise their function. While many cytokines support emergency myelopoiesis, less is known about the mechanisms that temper these events. When mice that lack the cytokine IL-27 were infected with Toxoplasma gondii, there was enhanced generation of monocyte progenitors and increased numbers of inflammatory monocytes. In the bone marrow of infected mice, there was increased production of IL-27 that localized with HSPCs, and a survey of cytokine receptor expression highlighted that HSPCs were uniquely poised to respond to IL-27. Furthermore, the use of in vitro differentiation assays and mixed bone marrow chimeras revealed that HSPCs from IL-27-deficient mice are predisposed toward the monocyte lineage. Additional studies highlighted that after infection, loss of the IL-27R resulted in reduced HSPC fitness that manifested as reduced proliferative responses and a decreased ability to reconstitute the hematopoietic system. Thus, the ability of IL-27 to act on HSPC provides a regulatory brake on differentiation to limit monocyte induction and preserve HSPC stemness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4296e880a374b1ca1dccbcbdeb368a411cccee06" target='_blank'>
              IL-27 limits HSPC differentiation during infection and protects from stem cell exhaustion
              </a>
            </td>
          <td>
            D. Aldridge, Zachary R. Lanzar, Anthony T Phan, David A. Christian, Ryan D. Pardy, Booki Min, Ross M. Kedl, Christopher A. Hunter
          </td>
          <td>2025-12-15</td>
          <td>eLife</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Ankylosing spondylitis (AS) is an autoimmune disease that can cause severe deformities, and the immunological patterns associated with its onset and progression remain poorly understood. Here, after recruiting healthy donors and patients in different stages, we performed single-cell RNA sequencing for peripheral blood mononuclear cells to investigate the cytotaxonomic and immunological hallmarks associated with AS onset, aggravation and remission and explore the intrinsic laws causing AS lesions. The results showed that innate antibacterial defense functions were generally enhanced in most cell types at disease onset and were negatively associated with AS severity. The abundance and exogenous antigen presentation scores of the natural killer (NK) cell subset characterized as antigen-presenting cells (APC-NK) increased during disease aggravation but decreased during remission. Generally, APC-NK abundance and their presentation scores were negatively correlated with innate defense scores for multiple cell types. CD4+ effector T cell abundance and cytotoxicity, as well as the enhancement of CD4+ T cell responses by HLA-DRB1+ NK cells (similar to APC-NK), were associated with AS severity. The implantation of HLA-DRB1+ NK cells accelerated AS-like alterations in SKG modeling mice with curdlan induction; this was blocked with CD4+ T cell exhaustion. NK cell exhaustion improved the phenotypes of AS-like mice. HLA-DPB1/DPA1 in APC-NK participated in AS aggravation by mediating antigen presentation targeting CD4+ T cells. Overall, innate defense antigen presentation coupling drives AS lesions and different outcomes. Furthermore, the trade-off between innate defense and NK-dependent exogenous antigen presentation results in CD4+ T cell activation or inactivation, thereby contributing to AS aggravation or remission; this reveals that APC-NK is a crucial factor causing ankylosing deformities. Ankylosing spondylitis (AS) is a chronic disease affecting the spine and joints, often leading to disability. Current treatments mainly focus on symptom relief, but understanding the disease’s underlying causes is crucial for better therapies. Researchers aimed to explore the immune processes involved in AS using advanced techniques such as single-cell RNA sequencing. The study involved 14 patients with AS and 3 healthy donors. Researchers collected blood samples and analyzed immune cells to understand their roles in AS. They found that certain immune cells, including T cells and natural killer cells, behave differently in patients with AS compared with healthy individuals. These differences are linked to the disease’s progression and severity. The study revealed that immune responses, particularly those involving NK cells, play a significant role in AS. These findings suggest that targeting specific immune pathways could improve treatment strategies. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bf4a8beff5e28b3fc841aa6c1bf981b8e9e08ab6" target='_blank'>
              Single-immunocyte transcriptomics reveal the role of natural killer cell-dependent exogenous antigen presentation in ankylosing spondylitis severity
              </a>
            </td>
          <td>
            Dianshan Ke, Hanhao Dai, Yibin Su, Hongyi Zhu, Xiaofeng Liu, Xiaochun Bai, Changqing Zhang, Jie Xu, Jinshan Zhang
          </td>
          <td>2026-01-28</td>
          <td>Experimental & Molecular Medicine</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Abstract Unconventional T cells expressing the γδ T cell receptor (TCR) are abundant within the intestine and largely function as ‘first responders’ to injury, infection and inflammation. To this end, murine γδ T cells are highly compartmentalized within the intestinal mucosa based on the expression of their Vγ chain and their effector function. The activation status also differs among these γδ T cell populations to ensure a timely and appropriate response within their local microenvironment. In this review, we will examine the role of γδ T cell populations in the epithelium (i.e. intraepithelial lymphocytes), the lamina propria and Peyer's patches and discuss the influence of the gut microbiota on the maintenance and effector function of each compartment. We will also highlight how γδ T cells contribute to the host response to luminal bacteria and how this reciprocal crosstalk is disrupted in the context of inflammatory bowel disease (IBD). An enhanced understanding of how γδ T cells function within distinct mucosal compartments and their regulation by commensal bacteria may lead to the development of novel microbiome-based therapies for IBD.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05c0bab1b59e7852efa3b798e6fb5e0fbd1f5eaa" target='_blank'>
              Crosstalk between the microbiota and intestinal γδ T cell compartments in health and IBD
              </a>
            </td>
          <td>
            Ananya Parthasarathy, Tingting Li, Karen L. Edelblum
          </td>
          <td>2025-12-29</td>
          <td>Gut Microbes</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Autologous stem cell transplantation (ASCT) involves harvesting hematopoietic stem and progenitor cells (HSPCs) prior to chemotherapy and subsequent repopulation of the bone marrow. This process imposes a bottleneck, providing a framework to dissect the unresolved short- and long-term clonal dynamics during hematopoietic reconstitution. By integrating bulk error-corrected targeted sequencing of clonal hematopoiesis (CH)-associated genes with mitochondrial single-cell Assay for Transposase-Accessible Chromatin sequencing (mtscATAC-seq), we characterized mutational trajectories in frequently altered hematological genes and traced clonal evolution through somatic mitochondrial DNA variants, revealing post-transplant cellular heterogeneity and clonal architecture. Among 60 patients (multiple myeloma, n = 51; non-Hodgkin lymphoma, n = 6; Hodgkin lymphoma, n = 3), CH-associated mutations were identified in 53% pre-ASCT, predominantly involving DNMT3A. A transient increase in mutation counts and gene diversity occurred 10-25 days post-ASCT, with a gradual clonal expansion two years post-transplantation. Tandem ASCT amplified clonal complexity, with a twofold increase in mutation count and gene-level diversity, while preserving clonal trajectories across both transplant courses. Mitochondrial single-cell profiling in longitudinal samples of 3 patients showed patient-specific immune reconstitution and clonal dynamics, with balanced multilineage output from graft HSPCs. Collectively, our findings provide a firsthand comprehensive view of ASCT-induced clonal dynamics and immune reconstitution, paving the way for targeted gene-specific post-transplant monitoring.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6fa98043059e18d9fd50446cb2c494c87e5e2054" target='_blank'>
              Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation
              </a>
            </td>
          <td>
            Catarina M Stein, Raphael Hablesreiter, F. Christen, P. Löwe, Coral Fustero-Torre, Klara Kopp, B. Locher, Lena Nitsch, Robert Altwasser, Johanna Franziska Kerschbaum, L. Bullinger, Leif S. Ludwig, Paulina M Strzelecka, Frederik Damm
          </td>
          <td>2025-12-19</td>
          <td>Leukemia</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related deaths. Immune checkpoint inhibitors (ICIs) of programmed death-1 (PD-1)/programmed death ligand-1 signaling induce tumor regression in some patients with NSCLC, but most patients with NSCLC exhibit resistance to ICIs therapy. NSCLC shapes the potent tumor immunosuppressive microenvironment (TIME) that underlies tumor immune tolerance and acquired resistance. Therefore, elucidating the cellular and molecular mechanisms by which NSCLC establishes and sustains the TIME is essential for developing novel strategies to overcome immune resistance and enhance the clinical benefit of ICIs. Methods The correlation between sterile alpha motif domain and histidine-aspartate domain-containing protein 1 (SAMHD1) expression and ICIs was analyzed via immunohistochemistry. Cell migration assay was performed to assess the effect of SAMHD1 on macrophage recruitment. Multicolor flow cytometry was performed to analyze the effect of SAMHD1 knockdown on the tumor microenvironment. SAMHD1 regulation of the dual specificity phosphatase 6-extracellular regulated protein kinases 1/2 (DUSP6-ERK1/2) pathway was verified by RNA sequencing and western blotting. Results Here, we identify the SAMHD1 as a potential therapeutic target and a major determinant of poor response to ICIs in patients with NSCLC. Tumors with high SAMHD1 expression show resistance to anti-PD-1 antibody (αPD-1) treatment, whereas tumors with low SAMHD1 expression are highly sensitive. SAMHD1-dependent resistance to αPD-1 is characterized by increased tumor-associated macrophages (TAMs) infiltration and reduced CD8+T cell numbers. Mechanistically, SAMHD1 regulates the expression of macrophage-associated chemokines by influencing the activation of the DUSP6-ERK1/2 pathway, which contributes to TAMs aggregation within NSCLC tumors to shape an immunosuppressive microenvironment. The HIV accessory protein viral protein-x (VPX) specifically degrades SAMHD1 to promote HIV replication. Similarly, the vpx-engineered oncolytic adenovirus (oAd-vpx) targets SAMDH1 degradation to enhance oncolytic adenovirus replication and weaken the hostile immune microenvironment shaped by TAMs, thereby triggering a CD8+T-cell-dependent antitumor immune response. The combination of oAd-vpx and αPD-1 inhibits tumor growth and enhances sensitivity to ICIs in both mouse and human NSCLC. Conclusions This research identifies a key mechanism of SAMHD1-driven immunosuppression and highlights its important role in oncolytic adenovirus therapy. This study provides a theoretical basis for targeting SAMHD1 as a drug therapy strategy in patients with NSCLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/372d10aa91d60fc17880ac962111bea4e207ee3b" target='_blank'>
              SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication
              </a>
            </td>
          <td>
            Shichuan Hu, Jian Xu, Zhiwu Wang, Yong Zhang, C. Zhao, Yu Liu, Feng Luo, Pi-Yun Cheng, Jiantao Wang, Jing Zhao
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Macrophages are innate immune cells that extensively infiltrate and play a key role in the tumor microenvironment (TME). Tumor cell–secreted factors recruit monocytes into the TME, where they differentiate into tumor‐associated macrophages (TAMs), which can polarize into distinct phenotypes: M1 and M2. M1 TAMs promote antitumor immunity through cytokine secretion and antigen presentation, whereas M2 TAMs support tumor progression by facilitating angiogenesis, invasion, and immune escape. Despite these dual roles, the specific mechanisms governing macrophage plasticity and polarization remain insufficiently understood. This review comprehensively summarizes the origin, polarization, and functional diversity of macrophages in the TME, with emphasis on pathways that regulate TAM‐mediated immune responses. Furthermore, this article examines current TAM‐targeted therapeutic strategies, including recruitment inhibition, phenotypic reprogramming, and the development of chimeric antigen receptor macrophages (CAR‐Ms), as well as macrophage‐based drug delivery and exosome therapy. By integrating recent advances in cell engineering and immunometabolism, this review highlights the translational potential of TAM‐targeted therapies and their value in reshaping the immunosuppressive TME to enhance cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7215a076e2ef0687c2a7e70ce9deca69722be237" target='_blank'>
              The Role of Macrophages in Cancer: From Basic Research to Clinical Applications
              </a>
            </td>
          <td>
            Zhimei Liu, Yan Li, Jingchao Cao, Yefeng Qiu, Kun Yu, Shoulong Deng
          </td>
          <td>2025-12-19</td>
          <td>MedComm</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Fibroblasts, once considered merely passive structural components of tissues, are now recognized as dynamic regulators of the immune microenvironment. Recent advances in single-cell and spatial multi-omics have revealed their profound heterogeneity, spatial organization, and functional plasticity, positioning them as a ‘ruler’ that measures, defines, and shapes local immune responses. In both homeostasis and disease contexts—such as cancer, autoimmune disorders, and fibrosis—distinct fibroblast subpopulations exhibit specialized roles: some drive immunosuppression via PD-L1 expression, TGF-β secretion, or metabolic reprogramming; others promote inflammation or fibrosis through cytokine and chemokine secretion; while a subset supports immune resolution and tissue repair. Spatially, fibroblasts organize immune territories by forming physical and chemical barriers, orchestrating tertiary lymphoid structures, and partitioning inflammatory zones. Their bidirectional crosstalk with immune cells—including T cells, macrophages, and B cells—further fine-tunes immune activation or suppression. The dysregulation of fibroblast subsets is a hallmark of disease progression and therapy resistance. Emerging therapeutic strategies aim to ‘recalibrate’ this dysfunctional ruler through targeted depletion, phenotypic reprogramming, or disruption of pathogenic signaling. Integrating fibroblast-centric metrics into clinical practice may enable precise assessment of the immune microenvironment and personalized interventions, heralding a new era in immunotherapy and fibrotic disease management.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a5b61a7cf749a3d3b53564921ffb11c2d17b261b" target='_blank'>
              Fibroblasts as a ruler of the immune microenvironment: measurement and modulation in tissue homeostasis and disease
              </a>
            </td>
          <td>
            Yanling Zhang, Xinyi Fang, Lian Yan, Lin Wang
          </td>
          <td>2026-01-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="ABSTRACT Tumor‐associated macrophages (TAMs) represent the most abundant immune cell population within the tumor microenvironment and are central drivers of malignant progression and treatment resistance. High TAMs infiltration in solid tumors consistently correlates with poor clinical outcomes, largely due to their role in establishing an immunosuppressive milieu that supports tumor growth, metastasis, and undermines the efficacy of chemotherapy, radiotherapy (RT), and immune checkpoint inhibitors. Although TAMs are well‐recognized promoters of tumor progression, the development of effective strategies to therapeutically target them remains an unmet clinical need. In this review, we examine the multifaceted mechanisms through which TAMs contribute to malignancy, including phagocytic signaling modulation, metabolic reprogramming, exosomal communication, and crosstalk with other immune cells. We also evaluate three key therapeutic strategies: blocking TAMs recruitment and survival, reprogramming TAMs toward antitumor phenotypes, and the emerging approach of chimeric antigen receptor macrophage therapy. Furthermore, we highlight the synergistic potential of integrating TAMs‐targeted strategies with conventional chemotherapy, RT, and immunotherapeutic approaches. By synthesizing current clinical evidence, this review aims to inform the rational design of next‐generation TAMs‐targeted interventions and to propose novel strategies for overcoming treatment resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f8d44c15cdc93900836129bceb89040bd162694" target='_blank'>
              Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation
              </a>
            </td>
          <td>
            Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li
          </td>
          <td>2026-01-28</td>
          <td>MedComm</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="The endothelium promotes a non-adherent vascular surface that facilitates tissue perfusion, prevents clotting, and limits inflammation. Endothelial cells (ECs) execute these tissue-specific functions through the integration of signaling pathways promoted by growth factors, cytokines, extracellular matrix components, and signals from mechanosensory complexes. Furthermore, ECs secrete various molecular signals, leading to the establishment of a specific niche microenvironment. Importantly, ECs can serve as sentinels against invading viral pathogens, propagating anti-viral responses such as the secretion of type I interferons (IFNs). Identification of mechanisms that alter immunity and inflammation at this critical barrier is important to understanding endothelial dysfunctions and the endothelium’s overall role in disease. To investigate the regulation and function of IFN signaling in endothelial cells, we used a conditionally immortalized human cell line. We analyzed IFN gene expression by RT-qPCR and used an Mx2 promoter-dependent bioassay to quantify the levels of secreted IFN during homeostatic conditions. Multiple cell types were screened for the ability to enhance tonic IFN production by endothelial cells in a direct coculture model. The role of direct cell-cell interactions in this behavior was studied using cell culture insert settings and inhibitors specifically targeting gap junction communication. The antiviral effects of endothelial tonic IFN production were determined with SARS-CoV-2 and HCMV infections. We demonstrate that endothelial cells can generate a type I IFN response in absence of infection under homeostatic conditions. These tonic IFN levels rise dramatically when endothelial cells are in direct contact with epithelial cells, though not when cultured with other cell types. The transcriptional induction of type I IFN genes occurs only in endothelial cells and requires direct cell-cell contacts. We further show that IFN induction can be blocked by interfering with gap junction communication and is partially dependent on the cGAS/STING pathway. Notably, the IFN activity derived by this cell type-specific interaction efficiently protects neighboring lung epithelial cells against SARS-CoV-2 infection. We propose that the upregulation of tonic IFN production by the endothelial-epithelial cell axis can contribute directly to pathogen defense and/or strengthens the innate immune response by elevated priming. While the contributing molecular signaling pathways underlying this activation have not been fully identified, this newly described mechanism has potential relevance during acute or chronic lung injuries, as it enhances the level of tonic antiviral activity. Furthermore, excessive lung inflammation in nonviral pathologies may be dampened by elevated levels of tonic IFNs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7299efbc5679df86bc6d932101b25a63c99b6011" target='_blank'>
              Cell type-specific interactions induce tonic interferon production in endothelial cells in a pathogen-independent manner
              </a>
            </td>
          <td>
            Timothy Surette, Fiamma Serra, Ulfert Rand, T. May, Luka Čičin-Šain, Mario Köster, Dagmar Wirth
          </td>
          <td>2026-01-13</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Gastric cancer (GC) is a highly heterogeneous malignancy and the formation of an immunotolerant tumor microenvironment (TME) is an important promoter of tumor progression, treatment resistance and a poor prognosis. The TME is composed of cellular components including immune cells as well as non-cellular elements (such as the extracellular matrix) which induce immune tolerance through numerous mechanisms. Comprehensive exploration of TME regulatory pathways in GC has established the theoretical foundation for targeted immunomodulatory strategies. TME-targeted immunotherapies have demonstrated efficacy in reversing immune tolerance and enhancing antitumor immunity. Additionally, when combined with chemotherapy, radiotherapy and/or targeted agents, these therapies notably improve response rates in patients with GC. The present review evaluates the impact of the TME on the development of immune tolerance in GC and the therapeutic implications of immunomodulation. The components of the GC TME were systematically characterized, and the present review discusses the contributions of cellular components to establishing an immunosuppressive microenvironment, investigates the molecular mechanisms underlying immune tolerance in GC, identifies key immune cells and their crosstalk within the TME and summarizes current treatments targeting TME-mediated immune tolerance, all with the aim to provide insights into optimized immunotherapeutic strategies and improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a552cdba1e0fda5662c793b6d423a20532cde08d" target='_blank'>
              Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review)
              </a>
            </td>
          <td>
            Zihe Guan, Lichao Han, Baojiang Chen, Yijia Ma, Qianyue Ni, Zijian Wang, Jingyu Yang, Zheng Liu
          </td>
          <td>2026-01-13</td>
          <td>Oncology Letters</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Background: Hepatocellular carcinoma (HCC) harbors a dynamic tumor microenvironment (TME) in which macrophages are highly abundant and plastic. Under physiological conditions, macrophages switch between inflammatory and resolution/tissue-repair programs to maintain homeostasis; however, during hepatocarcinogenesis these programs are reprogrammed into tumor-associated macrophage (TAM) states that foster immune suppression, angiogenesis, and tumor progression. Purpose: To summarize macrophage heterogeneity and polarization mechanisms in HCC, and to highlight omics-informed therapeutic opportunities for targeting TAMs and improving precision immunotherapy. Research Design: This review summarizes physiological macrophage polarization and the mechanistic basis of macrophage reprogramming in the hepatocellular carcinoma immune microenvironment, integrating evidence from recent advances in single-cell sequencing, multi-omics, and spatial transcriptomics, with a focus on macrophage subset diversity, key regulatory pathways governing polarization and function, and emerging macrophage-targeted interventions and biomarkers. Results: Recent single-cell and spatial multi-omics studies reveal substantial TAM heterogeneity and plasticity in HCC. Macrophage-targeted strategies—including TAM depletion, phenotypic reprogramming, and exosome-mediated drug delivery—show encouraging preclinical efficacy. Macrophage-associated prognostic models and biomarkers may support individualized immunotherapeutic approaches. Conclusions: Macrophage polarization in HCC represents a dynamic continuum that is essential for homeostasis but is co-opted by tumors to drive immunosuppression and tissue remodeling. Advances in single-cell and spatial multi-omics are redefining TAM subsets and actionable pathways, enabling more rational macrophage-targeted therapies. However, challenges remain in standardizing TAM definitions, identifying robust predictive biomarkers, minimizing off-target effects, and optimizing combinations with immunotherapy. Integrating longitudinal multi-omics with AI-based modeling may help predict macrophage state transitions, guide patient-specific regimens, and advance precision medicine in HCC. Plain language summary Hepatocellular carcinoma is a highly aggressive cancer. Studies have found that immune cells within tumors—particularly macrophages—play a crucial role in cancer development and therapeutic response. Macrophages have two main “personalities”: the M1 type, which can kill cancer cells, and the M2 type, which supports cancer growth. They shift between these states in response to signals from the tumor microenvironment. Both liver-resident Kupffer cells and infiltrating macrophages are involved in this process. Various molecules, such as cytokines, enzymes, and exosomes, influence their polarization. This polarized state of macrophages, in turn, affects key tumor processes such as stemness, proliferation, metastasis, and angiogenesis. In recent years, scientists have been exploring drugs that specifically target macrophage polarization to suppress liver cancer, offering new directions for future therapy. Graphical Abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b9c3d3369daa7c8bd747ff210bf91cca4945570" target='_blank'>
              Macrophage Polarization in the Tumor Microenvironment of Hepatocellular Carcinoma: From Mechanistic Insights to Translational Therapies
              </a>
            </td>
          <td>
            Xiaoqing Fu, Mingquan Pang, Zhixin Wang, Haijiu Wang
          </td>
          <td>2025-11-01</td>
          <td>Cancer Control: Journal of the Moffitt Cancer Center</td>
          <td>1</td>
          <td>2</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is an aggressive malignancy that is often refractory to chemotherapy and immune checkpoint inhibitors. This therapeutic resistance is driven in part by the persistence of cancer stem-like cells (CSCs) and the development of an immune-cold tumor microenvironment. However, the upstream regulators that coordinate these malignant features remain poorly defined. In this study, we identified dysadherin as a novel upstream activator of YAP that promotes both CSC plasticity and immune evasion through the FAK/YAP/TEAD2 signaling axis. Using single-cell transcriptomic analysis, in vitro assays, and multiple in vivo models including a humanized immune mouse system, we showed that dysadherin enhances the expression of pluripotency genes, such as OCT4 and upregulates PD-L1. These changes support stem-like tumor behavior and contribute to T-cell exclusion, fostering an immunosuppressive niche. Notably, genetic knockdown or peptide-based pharmacologic inhibition of dysadherin effectively restored antitumor immune activation, suppressed metastasis and improved therapeutic responsiveness. Our findings reveal a mechanistic link between dysadherin-mediated cell adhesion signaling and the transcriptional regulation of both stemness and immune escape. Collectively, these findings establish the dysadherin/YAP axis as a key driver of HCC progression and resistance, and highlight it as a compelling therapeutic target that could overcome treatment failure in advanced liver cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29884335d480102826ec8b793e157ba0b7881a1e" target='_blank'>
              Dysadherin/YAP axis fuels stem plasticity and immune escape in liver cancer
              </a>
            </td>
          <td>
            T. Jang, So-El Jeon, H. Yun, Choong-Jae Lee, Da-Ye Lim, Sang Hoon Lee, Dajun Lee, Seungwon Lee, Jungmin Choi, Hyung-Sik Kim, Jeong-Seok Nam
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Background: Radiotherapy (RT) remodels the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are key mediators of TME, yet how RT reprograms TAMs toward a programmed death ligand- 1(PD-L1)⁺ immunosuppressive phenotype remains unclear. Materials and Methods: Esophageal squamous cell carcinoma (ESCC) subcutaneous xenografts in immunodeficient mice received localized RT or sham treatment. Tumor-infiltrating PD-L1⁺ TAMs were quantified via multiplex immunofluorescence and flow cytometry. Extracellular vesicles (EVs) derived from irradiated ESCC cells (IR-EVs) were isolated and characterized by nanoparticle tracking analysis and transmission electron microscopy. Functional assays included co-culture of IR-EVs-educated macrophages with autologous CD8⁺ T cells. RNA sequencing identified DYNLL1-AS1 as the most upregulated lncRNA in IR-EVs. Mechanistic studies employed RNA pull-down, mass spectrometry, RNA immunoprecipitation, and dual-luciferase reporter assays. Clinical validation utilized ESCC specimens for RNA in situ hybridization. Prognostic significance was assessed via Kaplan-Meier and Cox regression analyses. Results: RT triggered ESCC cells to secrete DYNLL1-AS1-enriched EVs, which reprogrammed macrophages into PD-L1⁺ immunosuppressive TAMs. IR-EVs-educated macrophages suppressed CD8⁺ T cell proliferation and IFN-γ/ Granzyme B secretion. Mechanistically, DYNLL1-AS1 bound SEC22B, enabling its interaction with FOXP1 to activate PD-L1 transcription via promoter binding. In vivo, EVs carrying DYNLL1-AS1 counteract anti-PD-L1 therapy by suppressing CD8+ T cell function and promoting tumor growth. In ESCC patients, high DYNLL1-AS1 expression correlated with PD-L1⁺ TAM density, poor immunotherapy response, and reduced survival. Multivariate analysis confirmed DYNLL1-AS1 as an independent prognostic factor. Conclusions: Radiation-induced DYNLL1-AS1 in ESCC EVs drives PD-L1⁺ TAMs immunosuppression via SEC22B/ FOXP1 signaling. Combining DYNLL1-AS1 inhibition with PD-L1 blockade may reverse RT-induced immunosuppression, offering a transformative strategy for ESCC radio-immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/62c9c29a3e6d1b11c8904cf92b1d7f9e8f201bd1" target='_blank'>
              Extracellular vesicles derived from irradiated tumor cells foster immunosuppressive macrophages formation to promote esophageal squamous cell carcinoma immune evasion
              </a>
            </td>
          <td>
            Shanshan Jiang, Y. Pang, Yue Zhou, J. Ni, L. Chu, X. Chu, Jianghong Zhang, Yan Pan, Yida Li, R. Ye, Hongru Chen, Silai Yu, T. Guo, Chunlin Shao, Xi Yang, Zhengfei Zhu
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Biological Sciences</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Decorin (DCN) predominantly produced by fibroblasts is a small leucine-rich proteoglycan with tumor-suppressive property. However, whether DCN has a role in shaping the tumor immune microenvironment remains elusive. The TCGA and GEO databases were analyzed to identify fibroblast-specific secretory proteins that are downregulated in most types of human tumors, positively correlate with CD8⁺ T cell infiltration, and associate with improved response to immune checkpoint blockade (ICB) therapy. The function of DCN in vivo was assessed using cell lines with stable DCN overexpression in both immunocompetent and immunodeficient mice. The changes in the composition and function of immune cell subpopulations in tumors were analyzed by flow cytometry analysis (FCM) and immunofluorescence staining. The role of CD8⁺ T cells in the DCN-mediated tumor suppression was further elucidated by utilizing B2m-knockout tumor cells and CD8⁺ T cell depletion assays. The in vitro co-culture system of tumor cells and T cells was applied to dissect the effects of DCN on CD8+ T lymphocyte activation and functions. Finally, the therapeutic efficacy of DCN in combination with anti-PD1 antibody was evaluated in mouse tumor model. DCN-mediated tumor suppression was present in immunocompetent mice, wherein either depletion of CD8⁺ T cells in mice or ablation of β2M in tumor cells abrogated the tumor-inhibitory effects mediated by DCN, indicating the importance of CD8⁺ T cells in the DCN-antitumor activities. DCN overexpression promoted CD8⁺ T cell infiltration into tumors and increased the production of TNF-α, IFN-γ, and perforin in infiltrating T cells, and DCN expression substantially enhanced the tumor-suppressive efficacy of anti-PD1 therapy. More importantly, integrative analyses of clinical data indicated that DCN expression is downregulated in multiple types of human tumors and positively associated with the presence of CD8⁺ T cells and their expression of cytotoxic genes. Furthermore, high DCN levels were correlated with favorable prognosis in certain types of cancer patients with ICB therapy. Our study reveals that DCN functions as a tumor-suppressive factor by enhancing T cell response, and proposes the potential of exogenous DCN as a supplement to cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1d5b6eb80a5279f1cd41ac2e3910968815e0cfd4" target='_blank'>
              Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy
              </a>
            </td>
          <td>
            Ningqian Zheng, Lvzhu Xiang, Guiqin Xu, Yun Liu, Chengming Xu, Li Zhang, You Zuo, Zhiqian Ye, Yongzhong Liu, Zhaojuan Yang
          </td>
          <td>2026-01-27</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Liver fibrosis, characterized by the excessive deposition of extracellular matrix (ECM) driven by hepatic stellate cells (HSCs) activation, remains a critical challenge due to its progression to cirrhosis and hepatocellular carcinoma (HCC). This review clarifies the complex crosstalk between the immune system and HSCs, highlighting key cellular players including macrophages, natural killer (NK) cells, regulatory T cells (Tregs), and their cytokine‐mediated signaling pathways that regulate fibrogenesis and fibrosis resolution. We describe pivotal molecular mechanisms such as transforming growth factor (TGF)‐β, platelet‐derived growth factor (PDGF), Wnt/β‐catenin, and NF‐κB signaling in HSCs modulation, emphasizing their interplay with immune responses. Novel therapeutic strategies targeting this complex immune–HSCs interaction, ranging from immunomodulatory agents, macrophage polarization, and NK cell‐based therapies, to stem cell‐derived exosomes, offer promising opportunities for preventing and reversing fibrosis. We further discuss innovative combination therapies integrating immunotherapies with antifibrotic agents, personalized strategies based on immune profiling, and the challenges of immune heterogeneity in fibrosis management. This review discusses recent advances in molecular interplay of immune system and HSCs, highlighting novel therapeutic targets, and future perspectives for managing chronic liver diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5022b23a68cf2c2cfdfb9468e2f2ae355d75f27a" target='_blank'>
              Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential
              </a>
            </td>
          <td>
            Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, F. H. Zahiroh, Aris Muhammad Nurjamil, T. Wargasetia, I. M. Nainggolan, Rizal Azis, Elham Rismani, Dr. Massoud Vosough
          </td>
          <td>2026-01-01</td>
          <td>Journal of Immunology Research</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Cancer is a disease with a very high fatality rate. immunotherapy is a promising way to treating cancers, of which CTLs are important for the host immune system against tumor, directly killing tumor cells. However, the relative immunotherapy is limited by many factors that suppress the function and activity of CD8+ CTLs. This review aims to study the mechanisms by which CD8+ CTLs are suppressed in the tumor microenvironment. By collecting preclinical and clinical studies, this paper summarized the main factors that suppress CD8+ CTLs including the following factors: immune cells like regulatory T cell (Tregs), tumor-associated macrophage (TAM), myeloid-derived suppressor cells (MDSCs); metabolic factors like hypoxia, lactic acid accumulation, glucose competition, and immune checkpoints molecules (ICM) PD-1 and CTLA-4. The complex mechanisms of suppressing CD8+ CTLs in the tumor microenvironment are discussed in these findings, which may give clues to the relative treatment and help overcome these suppression effects on CD8+ CTLs in tumorigenesis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e0a3c8667fb5c07636fc20ce12f9301e91ee0bab" target='_blank'>
              Suppressed Factors to CD8+ Cytotoxic T Lymphocytes in Cancer Immunotherapy
              </a>
            </td>
          <td>
            Zeyu Zhou
          </td>
          <td>2025-12-19</td>
          <td>MedScien</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Background Lipocalin-2 (Lcn2) is a sensitive early marker for acute kidney injury, delayed graft function and acute rejection of kidney transplants. We previously showed the renoprotective effect of recombinant Lcn2:Siderophore: Fe3+ (rLcn2) in a mouse kidney transplantation (KTx) model. Here, we investigate the molecular and cellular mechanisms underlying these effects. Methods Male C57BL/6 mice (10–12 weeks) received BALB/c kidney allografts, with or without rLcn2 treatment (250 µg, s.c.). To examine the immunomodulatory function of rLcn2, immune cells from graft, spleen, lymph nodes and blood were analyzed by flow cytometry at post-operative days (pod) 3 and 7. Syngeneic C57BL/6 grafts were used to investigate the impact of rLcn2 on alloimmune-independent tissue injury and inflammation through multiplex signaling assays, functional readouts, cytokine profiling and histopathological analyses. Results rLcn2 treatment markedly reduced frequencies of distinct T cell subsets, including effector memory T cells and their cytotoxic (Tc) and helper (Th) subsets across grafts, lymphoid tissues and blood by pod-7 following allogeneic KTx. In graft infiltrating CD8+ T cells, rLcn2 decreased degranulation capacity and diminished expression of interferon-γ and perforin. rLcn2 also lowered the proportion of NKG2D+ CD8+ T cells, an activating Tc subset, in spleen and blood. In contrast, its impact on innate immune cells was modest and selective, influencing only neutrophils, macrophages in lymph nodes and intermediate mature NK cells in spleen and blood. No significant effect of rLcn2 treatment was observed on alloimmune-independent tissue injury or inflammation in syngeneic kidney grafts. Conclusion rLcn2 selectively modulates T-cell activity after KTx without affecting alloimmune-independent injury pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ed180d49cdbfb39ec89a170f0fe6750f292b2bde" target='_blank'>
              Lipocalin-2 modulates recipients alloimmune responses to the murine kidney transplants
              </a>
            </td>
          <td>
            A. M. Pfefferkorn, R. Fritsche-Guenther, Angelika Kusch, Hubert G. Schwelberger, Shiqian Liu, R. Klopfleisch, Yuhuan Li, R. Catar, Shaokun Liu, Felix Aigner, Johann Pratschke, Igor M. Sauer, Muhammad-Imtiaz Ashraf
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Immunity during cancer progression involves critical responses that may be harnessed to augment anti-tumor cytotoxicity. A potent arm of immunity in cancer involves cytotoxic T cells (a key CD8+ T-lymphocyte subset): Anti-tumor responses by such cells optimally involve sensitization and acquired responses to tumor antigens by antigen presenting cells. Many tumor microenvironment (TME) biophysical and functional limitations in carcinomas limit robust achievement of this ideal cellular-immunologic pathway. This is especially challenging in lung carcinoma, on which we focus mechanistically and with an eye to therapeutic translation. Localization of tumor-sensitized and activated CD8+ T cells to tumor “nests” with efficient tumor cytolysis involves many challenging steps. Amplifying and sustaining such responses is also a unique challenge. The variety of homeostatic and immunosuppressive obstacles often becomes overwhelming. Measuring the state of this response during lung cancer progression is also challenging, making it difficult to mount (and/or predict) T-cytotoxic responses in the heterogeneous and dynamic carcinoma antigen landscape. We investigate these challenges herein, while examining strategies to boost T-cytotoxic immunity in lung cancer through novel and emerging immunotherapeutic approaches. Beyond current immune checkpoint blockade approaches that are relatively non-specific with respect to antigen recognition by the T-cell receptor, we highlight ongoing and translational vaccines, cell-therapies, antigen-presenting cell boosting approaches, T-cell therapies, and biophysical considerations with an eye to overcome key barriers of this powerful arm of anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d405cc42ae9819222b3a3a0b50f4e0cc2451158" target='_blank'>
              The challenge of cytotoxic T cell responses in carcinoma with a focus on lung carcinoma
              </a>
            </td>
          <td>
            Aditya Dash, Afsheen Banisadr, Donivian Al Dikka, Scott C. Johns, Mark M. Fuster
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Oncology</td>
          <td>1</td>
          <td>10</td>
        </tr>

        <tr id="Systemic sclerosis (SSc) is a disease in which malfunctioning immune cells lead to the formation of autoantibodies that damage blood vessels and body tissues. Fibrosis then develops in the affected organs. Its complex pathogenesis involves multiple immune and stromal cell types, soluble mediators, and dysregulated tissue repair, resulting in heterogeneous clinical manifestations and poor prognosis. Current disease-modifying therapies provide only modest benefits, often slowing but rarely reversing disease progression, and are associated with considerable adverse effects. These limitations have spurred the development of cell-based therapeutic strategies aimed at restoring immune tolerance and promoting tissue repair. In this review, we summarize recent advances in hematopoietic stem cell transplantation, mesenchymal stem cell therapy, and adoptive regulatory T cell transfer and highlight the emerging role of chimeric antigen receptor (CAR)-T cell therapy as a transformative approach for SSc. Collectively, these evolving strategies hold the potential to improve survival, achieve durable remissions, and significantly enhance quality of life for patients with SSc.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f1fdf87d9868eaf91720753e565ce61e3ed90045" target='_blank'>
              Emerging Cell-Based Therapies for Systemic Sclerosis: From Stem Cells to CAR-T Cells
              </a>
            </td>
          <td>
            V. Chasov, S. Mukhametshin, Elvina Gilyazova, Damir Davletshin, Mariya Tikhomirova, Iuliia Topchu, A. Valiullina, Marcella Prete, E. Bulatov
          </td>
          <td>2026-01-01</td>
          <td>Current Issues in Molecular Biology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with poor overall survival. Understanding how dysregulated immunity contributes to the development and progression of AML is an active area of investigation. Prior work has demonstrated functional defects in natural killer (NK) cells; however, the role of non-NK innate lymphoid cells (ILCs) in AML is incompletely understood. Conventional ILC3s are non-cytotoxic and regulate mucosal immunity through cytokine secretion. In this study, we discovered an expansion of ILC3s in both a murine model of AML and in AML patients. The transcription factor, aryl hydrocarbon receptor (AHR) is required for ILC3 development and function, and AML blasts have been shown to secrete AHR ligands. Modeling studies demonstrated ILC3 expansion was mediated by AHR activation in ILC precursors. ILC3s developed in leukemic settings had increased cytokine production, and co-culture of ILC3s significantly increased AML colony formation, which was mediated by ILC3-derived TNFα and GM-CSF. Furthermore, co-transfer of ILC3s with AML led to more rapid disease progression in vivo and human ILC3 frequency was associated with adverse risk stratification in AML patients. These data support a model in which AML promotes ILC3 expansion and function via an AHR-dependent mechanism to aid AML growth and survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9a83a3f8e625be3b71c4e7fbb7f5ebf620217514" target='_blank'>
              Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia
              </a>
            </td>
          <td>
            T. T. Dinh, Matthew R. Lordo, Amy Y Zhang, C. Goda, Nikolas Shilo, Ekaterina Altynova, Michael Ruesch, Parker Kronen, Megan Broughton, Erin Jeremy, Victoria L Sellers, Xiaoli Zhang, Karilyn T. Larkin, Patrick L Collins, Adrienne M Dorrance, A. Freud, Christopher C Oakes, Bethany L. Mundy- Bosse
          </td>
          <td>2025-12-22</td>
          <td>Leukemia</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC), the most common primary liver cancer, continues to rank among the leading causes of cancer-related death despite improvements in early detection and systemic therapies. Therapeutic advances, including immune checkpoint blockade, cancer vaccines, and adoptive cell therapies, have broadened treatment possibilities. However, their efficacy and durability are often limited by immune evasion within a metabolically challenging tumor microenvironment (TME). This review consolidates current knowledge on how metabolic reprogramming in immune cells influences HCC progression, therapy resistance, and clinical outcomes. We discuss the roles of glycolysis, oxidative phosphorylation, fatty acid oxidation, and amino acid metabolism kynurenine pathways—in regulating the differentiation and function of T cells, regulatory T cells, macrophages, dendritic cells, natural killer cells, and B cells. Environmental factors such as hypoxia, lactate accumulation, adenosine signaling, and lipid remodeling act as key TME cues that suppress antigen presentation, impair cytotoxic responses, and promote immunosuppressive myeloid phenotypes. Building on these mechanisms, current strategies focus on targeting metabolic checkpoints in immune cells, reshaping the TME, and integrating metabolic modulation with checkpoint inhibitors to enhance therapeutic efficacy. In addition, candidate biomarkers (including circulating metabolites, multi-omics profiles, and liquid-biopsy indicators of immune metabolism) offer opportunities for patient stratification and dynamic monitoring. Together, these insights provide a conceptual framework in which precise modulation of immune metabolism can potentiate existing immunotherapies and guide rational combination strategies, warranting further clinical investigation to achieve sustained benefit in HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3e43a3cd7e997e6b0d1b868223afcfca36efc08" target='_blank'>
              Immune cell metabolic reprogramming in hepatocellular carcinoma: mechanisms, tumor microenvironment, and future immunotherapeutic directions
              </a>
            </td>
          <td>
            Lichen Zhou, Wenjie Zhang, Zhuoran Liu, Yaming Xie, Kangyi Jiang
          </td>
          <td>2026-01-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Transdifferentiation, also known as direct reprogramming, is the transformation of one terminally differentiated cell type into another mature cell type, while bypassing the stage of pluripotency. In leukemia, this phenomenon has a dual significance: on the one hand, it is an adaptive mechanism driving tumor survival and resistance to treatment, and on the other, it offers a potential opportunity for innovative therapies. Of particular interest is the directional transdifferentiation (mostly partial) toward dendritic cell-like phenotypes, which increases the immunogenicity of cancer cells. Mastering this process could define a new generation of immunotherapies that leverage the inherent plasticity of leukemic cells to achieve therapeutic benefits. In this brief review, we attempt to gather information concerning the molecular mechanism of this process and point to the role of dendritic cells as a crucial element of anticancer, particularly anti-leukemia innate and acquired, immunity. Thus, in vitro and in vivo techniques of inducing transformation of the leukemia cells into cancer antigen-presenting cells and the application of these technologies in current and future therapies are discussed.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cb4860b12b5b1e05e4c6dca4a179939d6e410810" target='_blank'>
              Leukemic Transdifferentiation: From Pathological Plasticity to Dendritic Cell-Based Immunotherapy
              </a>
            </td>
          <td>
            Joanna Dubis, Aleksander Czogalla, Kazimierz Kuliczkowski, Aleksander F. Sikorski
          </td>
          <td>2025-12-01</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Macrophages play a key role in immunity against solid tumors. However, their development and clinical applications are limited by their difficult-to-transfect nature, low proliferative capacity, and easily changing polarization states. The combination of chimeric antigen receptor (CAR) technology with macrophages to form chimeric antigen receptor macrophages (CAR-Ms) is an emerging strategy for adoptive cell therapy. In our previous study, we confirmed that anti-CD47 CAR-Ms have potential for ovarian cancer treatment. Here, we demonstrated that the introduction of IL-21 significantly increases the tumor-suppressive effect of anti-CD47 CAR-Ms against ovarian cancer. Specifically, IL-21-modified CAR-Ms with second-generation CARs targeting CD47 showed potent tumor cell-killing activity, both in vitro and in vivo, through direct and indirect pathways (direct phagocytosis and activation of cytotoxic T lymphocytes). In addition, an IL-21 modification significantly enhanced the tumor microenvironmental regulation of immunosuppression mediated by anti-CD47 CAR-Ms in vivo, thereby improving their therapeutic efficacy in a mouse model of ovarian cancer, without any obvious adverse effects. Taken together, these results suggest that anti-CD47 CAR-Ms combined with IL-21 is a promising treatment strategy for ovarian cancer. The anti-tumor effects of a co-expression strategy of chimeric antigen receptor macrophages with IL-21 was validated in both in vitro and in vivo models of ovarian cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1287e633e565f0f44deb23e07481a37084e0b41a" target='_blank'>
              IL-21 promotes the anti-tumor effect of anti-CD47 chimeric antigen receptor macrophages in ovarian cancer
              </a>
            </td>
          <td>
            Yizhao Chen, Xiangling Zhu, Yu Chen, Zhaoyi Yang, Zhaolei Shen, Mengchen Chen, Chong Liu, Yuanyuan Zhou, Huihui Wang, Mengjuan Zhu, Jiaqi Qiu, Jinhua Huang, Xintong Han, Wei Wei, Ruilin Li, Wenming Hong, Jiajie Tu
          </td>
          <td>2025-12-23</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Background Hepatocellular carcinoma (HCC) is a global health challenge with high mortality rates, particularly in patients with advanced disease and lung metastasis. T-cell receptor (TCR)-T cell therapy based on specific neoantigens, is an emerging treatment with potential for HCC. However, the prognosis of patients remains poor, underscoring the need for novel targets and strategies. Methods We conducted a comprehensive study to investigate the role of C7orf50 and its neoantigens in HCC. We evaluated the functional impact on HCC progression and metastasis in vitro and in vivo, and further explored the mechanism by which C7orf50 promotes cancer metastasis and remodels tumor immune environment. Using exome and transcriptome sequencing, we identified neoantigens associated with C7orf50 and assessed their potential in TCR-T therapy. Results Our in vitro experiments revealed that C7orf50 overexpression enhances HCC cell proliferation, migration, and invasion, while knockdown inhibits these processes. In vivo, C7orf50 promoted tumor growth and lung metastasis, with a significant correlation between C7orf50 expression and poor clinical outcomes in patients with HCC. We further demonstrated that C7orf50 activates the NF-κB/PAI-1 pathway by binding to AEG-1 and facilitating its nuclear translocation, thereby promoting tumor-associated macrophage recruitment. Meanwhile, we found that TCR-T from C7orf50-related neoantigen could obviously realize the killing effect on HCC cells, revealing its great role in cell therapy. Conclusion C7orf50 is a critical mediator of HCC progression and lung metastasis, acting through the NF-κB/PAI-1 pathway and AEG-1. Its expression levels, along with those of PAI-1 and CD68, serve as independent prognostic markers. And C7orf50-related neoantigen shows great application potential in TCR-T therapy. These findings provide a foundation for developing C7orf50-targeted therapies and highlight its potential in precision medicine and immunotherapy for HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f45092ca1b38a8cc8160edb18c4c6caef60aaa8e" target='_blank'>
              Tumor neoantigen gene C7orf50 remodels the immune microenvironment by recruiting tumor-associated macrophages to promote hepatocellular carcinoma progression and lung metastasis
              </a>
            </td>
          <td>
            Jia Li, Xinming Ye, Sheng Su, Zhiqiang Hu, Changzhou Chen, Yu Gong, Zehuan Li, Feng Qi, He Li, Li Mao, Xiaowu Huang
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="T cells and B cells are central components of the adaptive immune system, orchestrating immune responses through a complex network of interactions. This review explores the dynamic interplay between T and B cells, focusing on their development, activation, and functional coordination in immune defense. T cells provide essential help to B cells through cytokine signaling and direct cell–cell interactions, facilitating antibody production and affinity maturation in germinal centers. Conversely, B cells contribute to antigen presentation and cytokine modulation, influencing T cell differentiation and function. The regulation of these interactions is critical for maintaining immune homeostasis, preventing autoimmunity, and enhancing vaccine efficacy. Dysregulation of T-B cell crosstalk is implicated in various immune disorders, including autoimmune diseases and immunodeficiencies. Recent advances in immunotherapy have targeted these pathways to modulate immune responses in conditions such as cancer, infections, and inflammatory diseases. This review synthesizes current knowledge on T and B cell physiology, highlighting emerging research on their cooperative mechanisms.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6e0fe2e9313e995df86d94ce3fd1fb0de65940c3" target='_blank'>
              B and T Cell Interplay, Germinal Center Dynamics and Role of Regulatory T Cells (Tregs) in B Cell Modulation and Immune Tolerance: A Narrative Review
              </a>
            </td>
          <td>
            Mohammad Shahid Iqbal, A. Arbaeen, M. A. Bendary, H. Qadi, Aisha Tabassum, Othman Fallatah, Sami Melebari, Nadeem Ikram, Mohammed Parvez, Kamal H. Alzabeedi
          </td>
          <td>2025-12-18</td>
          <td>Immuno</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7c4f1d7c9259c917480b33109eb2eb505069fe2" target='_blank'>
              Gatekeepers of immunity: mechanisms and regulation of immune checkpoints and their role in immune-privileged sites
              </a>
            </td>
          <td>
            Reza Nejad Shahrokh Abadi, Zahra Shahrokh Nejad Abadi, Sara Hooshmand
          </td>
          <td>2025-12-18</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Deficient mismatch repair (dMMR) in gastric cancer is associated with a high tumor mutation burden (TMB) and increased neoantigen load, which may enhance sensitivity to immunotherapy. Nevertheless, heterogeneous responses among patients with dMMR suggest complex tumor immune microenvironment (TIME) regulation. The present study aimed to integrate a case of dMMR gastric cancer with multi-cohort bioinformatic analyses to assess TIME determinants of immunotherapy outcomes, focusing on hematological immune cell subsets. Pre- and post-immunotherapy TIME changes were evaluated in a patient with dMMR gastric cancer using immunohistochemistry analysis [CD8+, CD4+, forkhead box P3 (FoxP3)+ regulatory T cells (Tregs), M1/M2 macrophages and programmed death-ligand 1 (PD-L1)]. Moreover, bioinformatics analyses assessed microsatellite instability (MSI) status, immune checkpoints [cytotoxic T-lymphocyte-associated protein 4 (CTLA4), CD274 and programmed cell death protein 1 (PDCD1)], TMB and TIME cell infiltration across The Cancer Genome Atlas (TCGA)-stomach adenocarcinoma (STAD; n=383), Kim (n=45), Peking University Cancer Hospital (n=31) and Esophagogastric Cancer-Memorial Sloan Kettering-2017 (EGC-MSK-2017; n=28) cohorts using CIBERSORT (LM22) and R-based statistical approaches. The case report demonstrated that, prior to treatment, the tumor was deemed ‘immune cold’, characterized by low levels of CD8+ T cells, M1 macrophages and Tregs. Post-treatment, total T cell infiltration increased, driven primarily by CD4+ T cells, while CD8+ T cell levels remained low. FoxP3+ T cell density (0.18 cells/mm2) indicated potential immune suppression; B cell infiltration (CD20+, 17.07 cells/mm2) did not markedly increase, with no tertiary lymphoid structures (TLS) detected. Moreover, bioinformatics cross-cohort analyses revealed favorable immunological features in microsatellite instability (MSI)-high (MSI-H) gastric cancer compared with in MSI-low (MSI-L)/microsatellite stability (MSS) gastric cancer. In TCGA-STAD dataset, MSI-H tumors had significantly higher TMB, neoantigen load, infiltration of memory-activated CD4+ T cells, activated natural killer (NK) cells, mast cells, M1 macrophages and immune checkpoint markers (CTLA4, CD274 and PDCD1; all P<0.05); CD8+ T cells differed significantly between MSI-H and MSI-L (P<0.05), but not between MSI-H and MSS cancer. MSI-H was associated with a higher TMB in the Kim and EGC-MSK-2017 cohorts, a higher immunotherapy response rate in the Kim cohort (P<0.05) and trends toward improved OS in TCGA-STAD [hazard ratio (HR), 0.68] and EGC-MSK-2017 (HR, 0.42) cohorts. All survival differences were non-significant (P>0.05). In conclusion, the results demonstrated that in dMMR/MSI-H tumors (which typically exhibit high TMB and neoantigen load), a TIME characterized by low CD8+ T cells, high Tregs, absent TLS and low PD-L1, could be indicative of immunotherapy resistance. Cross-cohort analysis further revealed that despite favorable immunological features (higher TMB, neoantigen load, memory-activated CD4+ T cells, activated NK cells, mast cells, M1 macrophages and immune checkpoint expression), MSI-H gastric cancers have heterogeneous immunotherapy outcomes. Collectively, dMMR/MSI-H status alone is insufficient for outcome prediction, highlighting the need for individualized TIME evaluation in patients with gastric cancer receiving immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b6f62df1304732fe74cacfd42d44f79517715f3a" target='_blank'>
              Immune microenvironment and treatment response of dMMR gastric cancer: Heterogeneity and implications for immunotherapy
              </a>
            </td>
          <td>
            Liping Wang, Xinliang Zhong, Mengxing Diao, Wei Deng
          </td>
          <td>2026-01-27</td>
          <td>Oncology Letters</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) are recognized as a key mediator of immunosuppression in aging, which induce immunosenescence and increase elderly people’s susceptibility to infections, cancers, autoimmune diseases, and degenerative diseases. However, the commonly used MDSC markers overlap with those defining healthy and normal neutrophils or monocytes, which makes it challenging to distinguish MDSCs from their myeloid counterparts, and hampers deeper understanding of the pathophysiological functions of MDSCs. In this study, we compared MDSCs from aged mice to young controls using single-cell RNA sequencing. We established MDSC-specific gene signature, which revealed the general characteristics of MDSCs during aging, and thus facilitating distinguishing them from normal myeloid cells. Experimental study revealed that CD300c may serve as a specific marker for improved detection and enrichment of MDSCs in aging. CD11b+Gr1+CD300c+ cells demonstrated a robust ability of T cell suppression. The universality and applicability of MDSC-specific gene signature have also been demonstrated in human myeloid cells. We also found that MDSCs from aged individuals shared the similar developmental trajectory with their myeloid counterparts, and may develop from mature myeloid cells, both in mice and human beings, which has been reported by a limited number of studies. Overall, our work extends the understanding of MDSCs in aging process.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7343d247742e2514c816d82197f3a4e427bbbd1" target='_blank'>
              Defining the marker and developmental trajectory of myeloid-derived suppressor cells in aging by single-cell transcriptomics
              </a>
            </td>
          <td>
            Yaru Su, Ruimin Wu, Haochen Ai, Zhaoming Zhong, Lin Zou, Zihan Wang, Kewu Tu, Lingzheng Tang, Jiawen Gao, Yusheng Huang, Congrui Liao, Guanhai Zeng, Hongyang Zhang, Jian Jin, Siyuan Zhu
          </td>
          <td>2025-12-24</td>
          <td>NPJ Aging</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/41c90be54d0c8300380663bf0b722bf4b28986ad" target='_blank'>
              Divergent myelopoiesis and macrophage polarization underlie host susceptibility to chronic Chlamydia trachomatis infection
              </a>
            </td>
          <td>
            Naveen Challagundla, Shivani Yadav, Reena Agrawal Rajput
          </td>
          <td>2025-12-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Cerebral malaria (CM) is associated with dysregulated immune response against the blood stage of malaria parasite that often leads to serious organ damage, ultimately causing fatal pathological complications. Conventional treatments, although effective in controlling the parasite, often fail to address the severe immunopathology associated with the disease. Herein, we investigated the therapeutic potential of Mesenchymal stem cells (MSCs) in managing the excess proinflammatory response and maintaining immune homeostasis in Plasmodium berghei ANKA (PbA) infected C57BL/6 mice, an experimental cerebral malaria (ECM) disease model. Parasitemia and survival were monitored regularly, along with the neurological complications associated with the disease. Immunophenotyping, along with programmed cell death analysis of splenocytes, was also done via flow cytometry, and cytokine levels were analyzed at different time points in serum, as well as spleen, through bioplex assay and qRT-PCR. It was found that MSC effectively reduced parasitemia, increased survival, and decreased hemozoin accumulation in spleens of PbA-infected mice, along with improving brain pathology by preventing vascular leakage and protecting the blood–brain barrier (BBB). MSCs not only rescued the lymphocytes from apoptosis by downregulating PD-1/PD-L1 and ROS levels but also effectively modulated the Th17/Treg imbalance and maintained immune homeostasis by downregulating Interleukin-6 (IL-6) and Interleukin-17 (IL-17) cytokines and upregulating Interleukin-10 (IL-10) cytokine in infected mice. For the first time, we reported that MSCs were able to induce a dual phenotype effector Treg cell subset (Tr17), which are known to express both RoRγt and Foxp3 transcription factors, which were highly suppressive against pathogenic Th17 cells as they significantly downregulated IL-17 expression in Th17 cells. In conclusion, our findings offer insight into how the infusion of MSCs reduces the severity of experimental CM by modulating Th17/Treg balance and inducing Tr17 effector Treg response against Th17 cells. Thus, MSCs could potentially be used as an adjunct therapy for addressing the immunopathological complications of CM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cfad3db5aafc238b499630bbfa250ef3d8fd50bd" target='_blank'>
              Mesenchymal stem cells alleviate experimental cerebral malaria disease severity by inducing RoRγt+ Foxp3+ T regulatory (Tr 17) cells and modulating the dysregulated Th17/Treg axis
              </a>
            </td>
          <td>
            Indu Sharma, R. S. Thakur, Amrendra Chaudhary, Rubika Chauhan, Kuldeep Singh, Srikanth Sadhu, Amit Awasthi, Jyoti Das
          </td>
          <td>2026-01-30</td>
          <td>Cell Death Discovery</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Exhaustion of T cells, characterized by their compromised function and cytokine production, was first discovered in chronic infections and later redefined in the context of immunosuppressed tumor microenvironment (TME). Exhaustion markers include the immune checkpoints PD-1, TIM-3, LAG-3, and TIGIT. Colorectal cancer (CRC), which ranks among the highest in global prevalence, has been associated with exhaustion of T cells. While many trials have focused on anti-PD1 therapeutics in clinical trials, results indicate suboptimal efficacy. A robust approach involved dual blockade of other immune checkpoints together with PD-1. Interestingly, novel exhaustion markers could be used as prognostic markers for the development and progression of CRC. The present work discusses the basics of T cell exhaustion markers and their signaling in CRC. Also, novel combination therapy approaches and challenges in the field are discussed.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a02631f965c15b2749164cf5ae55f1cc2908741" target='_blank'>
              Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance
              </a>
            </td>
          <td>
            Pardis Zamani, Erfan Barootchi, Ayda Firouzabadi, Maryam Sadat Tonekaboni, Kiarash Saleki, Niloufar Yazdanpanah, N. Rezaei
          </td>
          <td>2026-01-05</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Phage therapy (PT) is a promising alternative for antibiotic-resistant infections, but its immunomodulatory effects in clinical settings remain poorly understood. This exploratory observational study aimed to characterize pro- and anti-inflammatory gene response patterns in ten patients undergoing personalized PT at the Phage Therapy Unit in Wrocław. Peripheral blood mononuclear cells (PBMCs) and granulocytes were analyzed to assess changes in the expression of 22 selected immune-related genes associated with innate and adaptive immune signaling pathways. While no uniform pattern of immune gene expression was observed across the cohort, individual cases exhibited significant up- or downregulation of specific genes. Interestingly, we identified biological age as a potential determinant of the host response. Specifically, older patients showed higher activation of the innate sensing machinery in PBMCs, characterized by a higher TLR4 fold change which may reflect the “inflammaging” phenomenon. These findings suggest that chronic exposure to bacterial viruses (bacteriophages), unlike many viral infections, does not trigger a predictable, significant systemic immune activation and that immune responses to PT are highly individualized by host- and phage-related biological factors. By documenting this spectrum of real-world responses, our work provides baseline data and hypotheses to guide the rational design of future preclinical and clinical investigations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5ab2b289866cbc1eb0a98219b4968f109c16e453" target='_blank'>
              Analysis of Pro- and Anti-Inflammatory Gene Response Patterns in Patients Receiving Phage Therapy
              </a>
            </td>
          <td>
            Hubert Kasprzak, Maciej Przybylski, W. Fortuna, Sławomir Letkiewicz, Paweł Rogóż, B. Bubak, Andrzej Górski, R. Międzybrodzki
          </td>
          <td>2025-12-23</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c515ee3e9e86703752ec072206a806bfdf0f76b3" target='_blank'>
              SLAMF1-peptide mediated epigenetic priming reprograms innate immune responses in sepsis
              </a>
            </td>
          <td>
            Sindre Ullmann, Birgitta Ehrnström, Jørgen Stenvik, S. Pinto, Yashwanth Subbannayya, Victor Boyartchuk, I. Mestvedt, Mahamaya Dhaware, Siddhesh S. Kamat, L. Ryan, Hilde Vagle, T. Dahl, B. Halvorsen, J. K. Damås, T. Espevik, Maria Yurchenko
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>72</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/72f3e3fb83d6da5da12fbd024325e0282875f616" target='_blank'>
              Single-cell analysis identifies monocyte signatures of disease activity and clinical subtypes in Behcet disease
              </a>
            </td>
          <td>
            E. Carmona, R. Deniz, C. Bes, H. Direskeneli, A. Gul, A. H. Sawalha
          </td>
          <td>2025-12-27</td>
          <td>None</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Endometrial carcinoma (EC), particularly high-risk molecular subtypes like p53abn and NSMP, is frequently characterized by a tumor immunosuppressive tumor microenvironment (TME) that drives progression, metastasis, and resistance to therapy. This immunosuppressive milieu is orchestrated by key cellular components, including M2-polarized tumor-associated macrophages (TAMs), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), PD-L1-expressing tumor cells, and pro-fibrotic cancer-associated fibroblasts (CAFs), which collectively inhibit effector T cell function and promote immune exclusion/desert phenotypes. Natural products offer promising multi-targeted strategies to remodel the TME. This review comprehensively summarizes the potent immunomodulatory effects of the phytosterol β-sitosterol (BSS) and the flavonoid luteolin (Lut) specifically within the EC TME. We detail how BSS and Lut synergistically reprogram TAMs towards an M1 phenotype, inhibit Treg differentiation/function and MDSC expansion, enhance CD8+ T cell recruitment, activation, and cytotoxicity (e.g., by downregulating PD-1/TIM-3), and suppress CAF-mediated immunosuppression and fibrosis. Mechanistically, these effects are achieved through targeting critical signaling pathways (STAT3, NF-κB, PI3K/AKT, Wnt/β-catenin) and modulating key chemokines/cytokines (e.g., reducing TGF-β, IL-10, CXCL12; increasing CXCL9/10, IFN-γ). Critically, BSS and Lut demonstrate significant potential to overcome resistance to immune checkpoint inhibitors (ICIs), particularly in immune-cold EC subtypes. By remodeling the immunosuppressive TME, BSS/Lut combinations can enhance ICI efficacy, as evidenced by preclinical data showing increased tumor suppression rates and T cell infiltration. While challenges remain, including EC-specific validation, bioavailability optimization, and molecular subtype stratification, BSS and Lut represent promising natural adjuvants for combinatorial immunotherapy, offering novel strategies to improve outcomes for patients with aggressive or treatment-refractory EC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7104edd872a0f11fcab8f2569253c5f8ba5f95ef" target='_blank'>
              Remodeling the tumor microenvironment: regulatory effects of β-sitosterol and luteolin on the immunosuppressive milieu in endometrial carcinoma and implications for combinatorial immunotherapy
              </a>
            </td>
          <td>
            Guojie Ji, Pengbo Wang, Zhihong Kong, Xiangxiang Cao, Xiaowei Shi, Huigen Feng, Huanhuan Hu
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Glioblastoma (GBM), the most aggressive and lethal subtype of glioma, remains therapeutically intractable despite advances in surgical and chemo-radiotherapy interventions. The highly immunosuppressive tumor microenvironment (TME) contributes significantly to treatment resistance and tumor recurrence. Among the predominant immune constituents, glioma-associated microglia and macrophages (GAMs) constitute a major cellular compartment, exerting profound influence on tumor progression, immune evasion, angiogenesis, and therapeutic response. These myeloid populations, derived from both yolk sac–origin microglia and bone marrow–derived macrophages, exhibit remarkable functional plasticity and are actively recruited, polarized, and reprogrammed by tumor-intrinsic and environmental cues. Recent studies have elucidated a range of molecular pathways, including chemokine signaling, metabolic reprogramming, and epigenetic modulation, that govern GAM behavior and sustain their tumor-supportive phenotype. Therapeutic strategies targeting GAM recruitment, depletion, or functional re-education toward an anti-tumor state are emerging as promising adjuncts to conventional and immune-based therapies. This review comprehensively explores the ontogeny, regulatory networks, and pathological roles of GAMs in GBM, with particular emphasis on novel immunotherapeutic approaches, including CSF-1R blockade, nanoparticle-mediated reprogramming, and oncolytic virotherapy. A deeper understanding of GAM–TME interactions will be critical to overcoming immunotherapy resistance and advancing precision immunomodulation in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/25eca6f21a304c01a3b2302212396bd448e3361e" target='_blank'>
              Targeting glioma-associated microglia and macrophages: a new frontier in glioblastoma immunotherapy
              </a>
            </td>
          <td>
            Bingyang Wang, Cong Li, Jiatong Gu, Xiaojie Wang, Mingjuan Xun, Bin Jiang, Jun Yan
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>1</td>
        </tr>

        <tr id="Tumor-associated neutrophils (TANs) exhibit highly functional heterogeneity across cancers. Although TANs promote inflammatory responses and contribute to tumor clearance, they frequently undergo context-dependent reprogramming within the tumor microenvironment (TME) into highly immunosuppressive phenotypes that facilitate cancer dissemination and immunotherapy resistance 1,2 . We contend that an underappreciated, upstream determinant of this divergence is the maturation stage of TANs 3,4 . The developmental stage of TANs determines the migration patterns and constrains the functional capacity, and the developmental stage also constrains the extent of TME-driven re-education, together shaping pro-or anti-tumor outcomes 3-5 . In this Perspective, we place maturation at the core of TAN biology and discuss current definitions for TAN developmental stages and the measurable markers that researchers and clinicians can use ( Figure 1 ). In addition, spatial and temporal transitions in TAN maturation stages and the factors that govern these transitions are elucidated. We explain how maturation status shapes TAN function and articulate the key differences between mouse and human TAN maturation systems to highlight the value of human immune system (HIS) mouse models. Based on this framework, functional biomarkers and signatures of TAN maturation are introduced and we show how to embed them into patient stratification and longitudinal monitoring. Finally, we outline immunotherapy strategies targeting TAN maturation, selecting interventions guided by maturation markers to reinforce treatment benefits for">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d662ed678180365badf4da6ebe8288f142877d8a" target='_blank'>
              From bone marrow to the tumor microenvironment: how neutrophil maturation shapes cancer immunity
              </a>
            </td>
          <td>
            Tao Shi, Yiran Cai, Hanbing Wang, Jia Wei
          </td>
          <td>2025-12-15</td>
          <td>Cancer Biology & Medicine</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="A recent publication by Qin et al. in Cell reported on the ﬁ rst-in-human application of anti-BCMA chimeric antigen receptor (CAR)- T cell therapy in patients with treatment-refractory progressive multiple sclerosis (MS) with a good tolerability and ef ﬁ cacy. 1 CAR-T cells rank among the breakthrough therapeutic approaches, transforming the ﬁ eld of cancer and autoimmune conditions including neuroimmunological disorders. B-cell maturation antigen (BCMA) and CD19 antigen are B-cell target antigens frequently used in CAR constructs for autoimmune diseases. 1,2 In addition to the B-cell depletion in the peripheral blood, CAR-T cells allow deep depletion of tissue-resident B cells e.g., in lymphoid tissues and hard-to-reach compartments such as the central nervous system (CNS), an effect that has not been observed with antibody-based B-cell depletion therapies. However, little is known about direct and indirect effects of CAR-T cells on microglia, even though CNS-resident microglial cells are involved as one of the key drivers and maintainers of the compartmentalized neuroin ﬂ ammation and neurodegeneration during MS progression. This is con ﬁ rmed by emerging evidence that smoldering neurodegenerative processes are hallmarked by chronic microglia-mediated neuroin ﬂ ammation with progressive axonal injury, resulting in disability progression independent of relapse activity (PIRA) and brain atrophy. 1 To date, none of the available therapies for MS are fully effective at preventing disease progression and PIRA. The emerging study by Qin et al. showed, for the ﬁ rst time, signi ﬁ cant functional improvement during a 9-month">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aadbe175bb178ba56f15991ba7d572d20c6623b1" target='_blank'>
              Anti-BCMA CAR-T cells attenuate microglial activation in progressive multiple sclerosis: indicating a plasma cell-microglia crosstalk
              </a>
            </td>
          <td>
            F. Ismail, Hans-Peter Hartung, Nico Melzer
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Highlights What are the main findings? Neonatal hearts display a distinct post-infarction immune profile characterized by the accumulation of CD4+Foxp3+ T (T-reg) cells with reparative transcriptional programs. Reticulocalbin 3 (Rcn3) is selectively upregulated in neonatal T-reg cells and is required for functional recovery and suppression of fibrosis after myocardial infarction. What are the implications of the main findings? Neonatal T-reg cells actively contribute to cardiac repair by modulating endoplasmic reticulum stress responses and paracrine anti-fibrotic signaling. Targeting T-cell-specific pathways such as Rcn3 may represent a novel immunomodulatory strategy to enhance myocardial repair in the adult heart. Abstract The neonatal heart possesses a unique capacity for reparative healing after myocardial injury, unlike the adult heart. While immune cells, particularly T cells, regulate post-infarction inflammation, their role in age-dependent cardiac repair remains unclear. This study aimed to characterize the temporal activation of T cell subsets and their contribution to immune homeostasis and myocardial repair. Myocardial infarction was induced in mice of different ages, and T cell subsets (CD4+ T cells, CD8+ T cells, and CD4+Foxp3+ T [T-reg] cells) were analyzed using flow cytometry and RNA sequencing. Neonatal hearts exhibited CD4+ T cells, CD8+ T cells, and T-reg cells that gradually increased until seven days post-injury. Transcriptome analysis identified Rcn3 as a neonatal-specific, injury-responsive gene in T-reg cells, with minimal induction in adult and aged hearts, promoting a reparative microenvironment and exerting anti-fibrotic effects via the PI3K/Akt pathway. Under endoplasmic reticulum stress, Rcn3 activated unfolded protein response genes, and Rcn3-conditioned media reduced fibrosis-associated gene expression in adult cardiac fibroblasts. In a conditional knockout mouse model (Lck-cre; Rcn3fl/fl), Rcn3 deletion in T cells led to impaired cardiac function recovery and increased fibrosis post-injury. These findings suggest that neonatal T-reg cells play a crucial role in cardiac repair, with Rcn3 as a potential therapeutic target for enhancing immune-mediated cardiac repair and limiting pathological remodeling in the adult heart.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0089581412a45d753304f07125a1ffc0f79e817d" target='_blank'>
              Neonatal Regulatory T Cells Mediate Fibrosis and Contribute to Cardiac Repair
              </a>
            </td>
          <td>
            Tabito Kino, Sadia Mohsin, Yumi Chiba, Michiko Sugiyama, Tomoaki Ishigami
          </td>
          <td>2026-01-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Abstract Introduction The cytokine CD137 (TNFRSF9, 4-1BB) is best known as a T cell costimulatory molecule. However, CD137 is also part of a negative feedback mechanism that limits T cell activation, and that is employed by regulatory T cells (Tregs) to prevent an overstimulation of T cells and subsequent autoimmune damage. CD137 has been identified as the gene that most significantly distinguishes intra- from extratumoral Tregs. CD137+ Tregs are more immunosuppressive than CD137− ones, and CD137 levels on intratumoral Tregs correlate with a poor prognosis for cancer patients. In addition, CD137 is also ectopically expressed on several types of malignant cells that usurp this physiological feedback mechanism to evade immune surveillance. This suggests CD137 as a target for eliminating or changing intratumoral Tregs. Here we demonstrate that a murine CD137-specific aptamer can bind to CD137 on malignant cells and T cells and be internalized. Methods and Results We fused the aptamer to short hairpin (sh) RNAs that are specific for Enhancer of zeste homolog 2 (EzH2) or neuropilin-1 (Nrp1), and demonstrated their uptake into CD137+ malignant cells and Tregs, and the subsequent downregulation or EzH2 and Nrp1. Conclusion This study confirms CD137 as a target for tumor immunotherapy and introduces CD137 aptamer-shRNA chimeras as novel tools to be evaluated for their usefulness in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1541323ab972d605301367d616f74090104c8314" target='_blank'>
              Targeting intratumoral regulatory T cells by CD137 aptamer-shRNA chimeras
              </a>
            </td>
          <td>
            Kang Yi Lee, Yu Mei, Haiyan Liu, Herbert Schwarz
          </td>
          <td>2025-12-22</td>
          <td>Immunotherapy Advances</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by dysregulated megakaryopoiesis and expansion of neoplastic hematopoietic stem cells (HSCs). Megakaryocytes (MKs) not only regulate HSC function but also shape immune responses within the marrow niche. Using an aging murine model of MPN with MK-restricted JAK2V617F expression, we investigated the immunomodulatory roles of mutant MKs. Compared to wild-type MKs, aged mutant MKs exhibit enhanced antigen uptake and MHC I presentation, secretion of pro-inflammatory cytokines (PF4, TGFβ, IL-1β), and induction of T cell dysregulation in the marrow niche. In chimeric murine models with co-existing wild-type and JAK2V617F mutant hematopoietic cells, enhanced MK immune activity correlates with mutant cell expansion and MPN development. Single-cell RNA sequencing revealed that aging amplifies JAK2V617F MK-driven immune remodeling. Notably, aged mutant MKs showed marked upregulation of LINE-1 (long-interspersed element-1) retrotransposon transcripts alongside elevated innate immune sensors cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING), implicating retrotransposon activity in niche inflammation. In human MPN marrow, immunohistochemistry detected LINE-1-encoded protein ORF1p in MKs from 12 of 13 MPN patients, but not in orthopedic controls (n=5). These findings identify MKs as active immune regulators in MPNs, with JAK2V617F mutation and aging synergizing to reprogram MKs into inflammatory, immunemodulatory niche cells. LINE-1 activation emerges as a potential driver of chronic marrow inflammation and a targetable mechanism in clonal hematopoiesis and MPN progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/00078a7009ffc9e9c106b868442d3f41d8397509" target='_blank'>
              Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.
              </a>
            </td>
          <td>
            Xiaoxi Yang, Sandy Lee, Kyla Masarik, Tameena Ahmed, Lei Zheng, H. Zhan
          </td>
          <td>2026-01-22</td>
          <td>Haematologica</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Cellular senescence is a complex biological process that contributes to the progression of age-related diseases. Senescent cells accumulate over time and secrete proinflammatory factors that disrupt tissue homeostasis and promote chronic diseases. Initially created for cancer immunotherapy, chimeric antigen receptor (CAR) T cell therapy has recently been repurposed at the preclinical level to eliminate senescent cells by recognizing senescence-associated surface markers. Recent preclinical studies have demonstrated the feasibility of anti-uPAR and anti-NKG2D CAR T cell-based approaches for eliminating senescent cells in preclinical models of fibrosis, metabolic disorders, and natural aging, resulting in reduced fibrotic burden, improved metabolic parameters, and enhanced tissue function. However, several challenges remain in their clinical applicability, including the identification of specific and universal senescence markers, potential off-target effects, and long-term safety concerns. Additionally, immunosenescence, an age-related decline in immune function, poses challenges for CAR T cell therapy in elderly patients. This review discusses recent advancements in CAR T cell therapy for senescence clearance, highlighting key molecular targets, preclinical findings, and future research directions. Despite their promise, a significant translational gap persists, and further research is required to improve the specificity, efficacy, and readiness for future human clinical trials.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d113132250c19579664d9a3c7b6b4e41c0e7cbb7" target='_blank'>
              Above and beyond senescence and CAR T cell: advances and future perspectives
              </a>
            </td>
          <td>
            R. Rosas-Campos, Scarlet Arceo-Orozco, A. Sandoval-Rodríguez, Jose Alejandro Madrigal, Juan Armendariz-Borunda
          </td>
          <td>2025-12-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b364384029e8332616bd3d0f1e05609ce0723cb3" target='_blank'>
              [Research progress of Type II immune responses in cancer therapy].
              </a>
            </td>
          <td>
            Yunfei Dong, Ying Sun, Hongqian Guo, Ke Zeng, Rong Yang
          </td>
          <td>2026-02-01</td>
          <td>Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="ABSTRACT Introduction The immunosuppressive microenvironment of hepatocellular carcinoma (HCC) is shaped by multiple oncogenic pathways, but howosteopontin (OPN), a molecule frequently overexpressed in HCC, regulates anti-tumor immunity remains unclear. Methods To define the mechanism by which OPN modulates the HCC immune microenvironment, with a focus on its regulation of CD155 and its impact on CD8+ T-cell – mediated anti-tumor responses. Results We identified that OPN activates the p65/NF-κB – c-Myc/CD155 signaling axis, leading to robust upregulation of CD155 and impaired intratumoral CD8+ T-cell infiltration and effector activity. These immunosuppressive effects occurred independently of changes in tumor stemness markers or Treg accumulation. Genetic suppression of p65 abrogated OPN-induced CD155 expression and mitigated tumor progression in vivo, demonstrating the pathway’s functional requirement. Discussion OPN drives HCC progression by suppressing CD8+ T-cell immunity through the NF-κB (p65)/c-Myc/CD155 axis. Targeting this pathway may enhance anti-tumor immunity and represents a promising therapeutic strategy for HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/241c4fb9ee39fefaef3e7ced0898ca89a09ca3d0" target='_blank'>
              OPN Promotes Hepatocellular Carcinoma Progression Through the p65/c-Myc/CD155 Axis by Suppressing CD8+ T Cell Infiltration and Activation
              </a>
            </td>
          <td>
            Jincun Fang, Liwei Liu, Zhiying He, Mingqiang Ling, Jiajun Liang, Yingying Lei, Zhenzhen Wen, Jingfeng Guo
          </td>
          <td>2025-12-19</td>
          <td>Immunological Investigations</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Bispecific T-cell Engagers (BITEs) are a novel form of immunotherapy that overcome a deficiency of immune checkpoint inhibitors (ICI) by targeting a preidentified tumor associated antigen and redirecting a polyclonal population of effector T-cells against the tumor. High grade serous ovarian cancer is a lethal disease in the recurrent setting and has not been amenable to ICI therapy. MUC16/CA125 is overexpressed in high grade serous ovarian cancer. BITEs targeting the tumor-retained portion of MUC16/CA125 have recently been described and are in early-phase clinical trials. To identify mechanisms of resistance to BITEs, we collected serum, peripheral blood mononuclear cells, and ascites samples from patients with disease progression on MUC16-directed bispecific antibodies. Analysis of these samples showed downregulation of MUC16/CA125, elevated secretion of VEGF, and epithelial-to-mesenchymal transition in tumor cells. Interestingly, hypoxia was determined to be a driver of these changes. These findings were prospectively validated in ovarian cancer cell lines with CRISPR/Cas9 knockout of MUC16/CA125 and VEGF. Peripheral blood mononuclear cells from patients with disease progression were capable of effective cytolysis ex vivo, suggesting that resistance to therapy was primarily tumor driven. Restoration of MUC16/CA125 expression did not restore cytotoxicity in the presence of increased VEGF secretion. Combination treatment with a VEGF inhibitor rescued cytotoxicity in hypoxia-conditioned ovarian cancer cell lines with preserved target antigen expression. Collectively, these data outline a link between hypoxia and the development of resistance to BITEs and posits inhibition of VEGF inhibition as a potentially important therapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/50276863592076e01725c57fe1f33a7b17e06d98" target='_blank'>
              Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers
              </a>
            </td>
          <td>
            Mengyao Xu, S. Barakzai, Raj Kumar, Irva E Veillard, Eugene Kim, Amy Bregar, Eric Eisenhauer, Richard Penson, S. Bouberhan, Jennifer Filipi, T. Colella, Timothy S. Bond, Caroline Clark, Lawrence H Lin, Jinpeng Ruan, Cheng Wang, Xing-Lei Qin, K. Sarosiek, Bo R Rueda, Cesar M Castro, David R. Spriggs, O. Yeku
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Glucocorticoids (GCs) are known for their anti-inflammatory potential, which includes the macrophage polarization into an anti-inflammatory and tissue remodeling state. GCs are routinely co-administered to cancer patients to alleviate the side effects of chemotherapy. However, it is not well known if GCs can modulate tumor-associated macrophages (TAMs) to promote tumor progression. Here, we show that dexamethasone (DEX) induces dose-dependent differentiation of THP-1 monocyte-derived anti-tumorigenic (M1) macrophages into pro-tumorigenic (M2-like) macrophages, even in the presence of M1 cues, and that DEX can repolarize fully differentiated M1 macrophages into an M2-like state. These macrophages have a cytokine profile similar to the pro-tumorigenic (M2) macrophages and can stimulate the proliferation and invasion of triple-negative breast cancer (TNBC) cells in vitro. DEX treatment of an orthotopic mouse model of TNBC attenuated paclitaxel-mediated tumor growth inhibition, increased M2-like TAMs in primary tumors, and enhanced lung metastasis. Transcriptomic analysis of DEX-treated M1 macrophages revealed not only transcriptomic overlap with M2 macrophages, but also with human breast cancer TAM transcriptomic data, and further to a specific TAM signature associated with aggressive estrogen receptor-negative breast cancer. Our study illustrates a remarkable macrophage repolarization plasticity upon DEX exposure that can promote tumorigenesis, warranting care in prescribing high doses of GCs to breast cancer patients, especially to those considered for chemotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/13ba2aca7a65c995d23e6a0cfbaa06b3762a101f" target='_blank'>
              Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness
              </a>
            </td>
          <td>
            Mohamed M. Shamekh, Birgitta Lindqvist, I. Nalvarte
          </td>
          <td>2025-12-19</td>
          <td>Cell Death & Disease</td>
          <td>1</td>
          <td>22</td>
        </tr>

        <tr id="Beyond their traditional role as short-lived antimicrobial cells, neutrophils are increasingly recognized as key regulators of adaptive immunity and tumor progression. This AI-assisted integrative review investigated the neutrophil–T-cell axis, particularly the role of Galectin-9 (Gal-9), across adult T-cell leukemia/lymphoma (ATL), Sézary syndrome (SS), coronavirus disease 2019 (COVID-19), and psoriasis. Leveraging AI tools (GPT-5 and Adobe Acrobat AI Assistant) for literature synthesis (2000–2025) and expert validation, we aimed to identify common immunological mechanisms. Across all conditions, neutrophils displayed persistent activation, elevated Gal-9 expression, and modulated T-cell interactions. In ATL and SS, neutrophilia correlated with poor survival and TCR signaling dysregulation, suggesting Gal-9-mediated immune modulation. In COVID-19 and psoriasis, neutrophil-derived Gal-9-linked innate hyperactivation to T-cell exhaustion and IL-17-driven inflammation. These findings define a recurring neutrophil–Gal-9 regulatory module connecting innate and adaptive immune responses. This study underscores the feasibility of combining AI-driven literature synthesis with expert review to identify unifying immunological mechanisms and therapeutic targets across malignancy and inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f09c2cd18cebd70f857746a605633d6065276e4" target='_blank'>
              Neutrophil–Galectin-9 Axis Linking Innate and Adaptive Immunity in ATL, Sézary Syndrome, COVID-19, and Psoriasis: An AI-Assisted Integrative Review
              </a>
            </td>
          <td>
            Toshio Hattori
          </td>
          <td>2025-12-31</td>
          <td>Reports - Clinical Practice and Surgical Cases</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Multiple myeloma (MM) develops in the hypoxic bone marrow (BM) microenvironment, which alters tumor behavior and immune responses. While hypoxia is known to directly suppress immune function, its effect on immunotherapy-relevant antigen expression and the MM secretome remains underexplored. Here, we investigated how hypoxia affects BCMA expression and BCMA-targeted CAR T cell responses. MM cells were cultured under normoxia (21% O₂) or hypoxia (1% O₂). BCMA surface and total expression were analyzed. Anti-BCMA CAR T cells were co-cultured with normoxic or hypoxic MM cells to assess cytotoxicity and cytokine release. Conditioned media and small extracellular vesicles (sEVs) were isolated, quantified, and RNA-profiled. MM cells cultured in hypoxia showed reduced BCMA surface and total protein expression, resulting in reduced CAR-mediated signaling. Importantly, the hypoxic tumor secretome further reduced BCMA levels and significantly impaired CAR T cell killing and cytokine production, which was partially reversible by γ-secretase inhibition. To dissect the suppressive nature of the hypoxic secretome, we identified an increase in small extracellular vesicle (sEV) release under hypoxia. RNA profiling of sEVs revealed a hypoxia-induced RNA signature with potential immunomodulatory roles. This study shows that hypoxia diminishes BCMA expression and enhances secretion of immunosuppressive factors, including sEVs, thereby limiting the efficacy of BCMA CAR T cell therapy in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/32804a5eae759659f84b5610dc79fafee9f0e914" target='_blank'>
              Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
              </a>
            </td>
          <td>
            Chenggong Tu, A. Van der Vreken, Fien Meeus, Lauren van den Broecke, Jack Brons, K. De Veirman, K. Vanderkerken, E. De Bruyne, Karine Breckpot, E. Menu
          </td>
          <td>2026-01-08</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="CD38 is a transmembrane glycoprotein involved in NAD+ metabolism, calcium signaling, and immune cell activation. Its role in the inflammatory response has been studied extensively in innate immune cells; however, its contribution to the activation of memory T lymphocytes under inflammatory conditions is less understood. Additionally, recent studies have shown an age-related increase in the expression of the protein CD38 in various human and murine tissues. Moreover, CD8+ bystander T cells have been shown to contribute to inflammation during the aging process. Given the importance of its potential role in age-related pathologies, we examined the effect of CD38 on bystander activation of CD8+ memory T cells in aged mice following lipopolysaccharide challenge. CD38-deficient mice exhibited attenuated serum cytokine responses (IL-1β, IL-6, IFN-γ, and IL-10) and a distinct CD8+ T cell profile, characterized by a decrease in activated T cells. Wild-type mice displayed a significant expansion of CD69+TCM cells after LPS inoculation, an effect that was absent in CD38-deficient animals. LPS also promoted the expression of CD69 and CD38 in TEM/EFF subsets. Thus, our findings reveal a CD38-dependent mechanism underlying bystander activation of memory CD8+ T cells in aging. Highlighting the potential contribution of CD38 to age-related diseases, such as autoimmunity, and in the face of inflammatory conditions in aged people.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2543f635ae92595d3f140c2ea47a35fc4eab9dd" target='_blank'>
              CD38 promotes LPS-induced innate-like activation and proliferation of CD8+ T lymphocytes in aged mice
              </a>
            </td>
          <td>
            Wendolaine Santiago-Cruz, Enrique Espinosa, Jocelyn C Pérez-Lara, Héctor Romero‐Ramírez, Priyadharshini Devarajan, Fabio García-García, J. C. Rodríguez-Alba
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Aging</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Hypoxic tumor microenvironment (TME) is a common occurrence in the development of solid tumors, which activates hypoxia-inducible factors (HIFs) and their downstream signaling pathways in cancer cells to facilitate tumor progression and immune escape. However, among the various immune cells that constitute innate and adaptive immune systems, HIFs have a more intricate function; moreover, different isoforms of HIFs play different functions under spatial and temporal conditions. HIFs are conducive to the adaptation of various immune cells to the hypoxic TME. The stability of HIF-α can regulate metabolism and directly regulate the expression of immune genes. Additionally, the activation of HIF signaling may also inhibit the development of immune cells in some tumor environments, affecting the antigen recognition and killing processes to assist cancer cells in immune escape. Therefore, understanding the relationship between HIF signaling and immune cells more comprehensively may yield substantial benefits for the immunotherapy of various types of cancer. The present study reviewed the role of HIFs in immunity, including their role in T cells, B cells, macrophages, neutrophils, dendritic cells and natural killer cells. It also discussed the effectiveness of HIF targeted therapy in clinical application, the challenges associated with it and the development of a precise targeting drug delivery system. The present review may help researchers comprehend the tumor immune process in a hypoxic microenvironment. It aimed to offer novel strategies for cancer immunotherapy and prolonging the overall survival of patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2f2959e24720a9bfcd6ba812398c12fc625e1637" target='_blank'>
              Regulatory networks of HIFs in tumor-infiltrating immune cells: From molecular mechanisms to therapeutic implications (Review)
              </a>
            </td>
          <td>
            Chaoqun Li, Chenge Qin, Xingchen Li, Jinzhu Wang, Yang Li, Qin Sun
          </td>
          <td>2026-01-12</td>
          <td>International Journal of Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Aging is a complex biological process, often characterized by increased vulnerability to disease, infection, and death. This increased vulnerability is mechanistically linked to a progressive and functional decline of the immune system. In humans, aged lymphocytes lose their capacity to effectively surveil within diverse microenvironments, decreasing their capability for clearing infections and maintaining physiological homeostasis. However, specific mechanisms by which aged lymphocytes, specifically T cells, lose this capacity to surveil remain unclear. We profiled three core characteristics of T cell surveillance at single-cell resolution, specifically migration, deformability, and sensing. While aged T cells retained their capacity for spontaneous migration, they exhibited impaired cellular deformability and deficiencies in sensing local signaling cues. To modulate this surveillance defect, we performed mechanical reprogramming using elevated fluid viscosity. Results showed that acute priming of aged T cells with elevated fluid viscosity recovered a transient young-like surveillance phenotype, which was mechanistically linked to membrane tension, cortical F-actin, and Arp3 expression. These findings reveal a key source of surveillance defects in aged T cells and provide an effective mechanical approach to tuning their single-cell behaviors. Teaser Recovery of ‘young-like’ surveillance phenotypes in aging human T cells via viscosity priming">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f2221a7b923d3654545a592b6523d97b8c79656c" target='_blank'>
              Acute priming using elevated fluid viscosity recovers ‘ young-like ’ single-cell surveillance behaviors in aged human T cells
              </a>
            </td>
          <td>
            Y. Dance, Alice Amitrano, Annaka Saffron, Chanhong Min, Ladaisha Thompson, Zhuoxu Ge, Ian M. Smith, Nico Macaluso, Charles Ezenwanne, Nicholas Milcik, Abigail Fennell, Kendall A. Pyndell, K. Stroka, Jeremy Walston, Sean X. Sun, K. Konstantopoulos, Jude M. Phillip
          </td>
          <td>2026-01-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a85afdff22ae96afa7e975dddb2b63ea9aa9cd29" target='_blank'>
              Microbiota-induced T cell plasticity enables immune-mediated tumour control.
              </a>
            </td>
          <td>
            T. Najar, Yuan Hao, Yuhan Hao, Gabriela Romero-Meza, Alexandra Dolynuk, Emma Almo, Dan R. Littman
          </td>
          <td>2026-01-14</td>
          <td>Nature</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Infections remain a key challenge during treatment of multiple myeloma (MM) patients with anti-BCMA and -GPRC5D bispecific antibodies (bsAbs). However, the underlying mechanism behind different rates and severity of infections induced by the two bsAbs remains poorly understood. Single-cell RNA-sequencing performed in bone marrow aspirates of 11 MM patients and 8 healthy donors revealed BCMA expression on mature B cells and, surprisingly, in small pre-B cells within B-cell precursors. By contrast, GPRC5D expression was restricted to normal and malignant plasma cells (PCs). Next-generation flow cytometry immune profiling showed that anti-BCMA bsAbs severely depleted bone marrow (BM) mature B cells (4.9%→0%; p<0.001) and normal PCs (0.17% → <0.0002%; p<0.001) during treatment of 62 relapsed MM patients. This was observed in early and late time points of therapy. Additional flow cytometry (N=31) and single-cell RNA-sequencing studies (N=8) demonstrated that, in contrast to anti-GPRC5D, anti-BCMA bsAbs also depleted immature and small pre-B cells. The MIcγ1 mouse model was used as a negative control of BCMA expression in all stages of the B-cell lineage, which confirmed no depletion of any B-cell subset after anti-BCMA treatment. In conclusion, we show that while GPRC5D bsAbs selectively target PCs, anti-BCMA bsAbs target both PCs and B cells from the small pre-B stage onwards. Our study provides mechanistic insight into the increased infection risk with anti-BCMA therapy and lays a foundation for individualized bsAb strategies in MM. Moreover, dual targeting of B cells and PCs may have therapeutic potential in other B cell malignancies or autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3f82e6f29f4eaa2729da3c53cfa2b6609a13def" target='_blank'>
              Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.
              </a>
            </td>
          <td>
            T. Jelínek, D. Žihala, A. Zabaleta, Ioannis V. Kostopoulos, Ondřej Souček, O. Venglar, Cristina Moreno, D. Fotiou, Eva Radova, L. Tamariz-Amador, F. Theodorakakou, L. Muroňová, A. Manubens, O. Tsitsilonis, T. Popková, Carmen González, A. Anilkumar Sithara, Francesco Corrado, Nayda Bidikian, C. Guerrero, V. Kapustová, D. Bilek, Patrick Hagner, M. Larrayoz, Jose-Al Martinez-Climent, L. Broskevičová, J. Mihalyova, Maximillian Merz, T. Ševčíková, Irene M. Ghobrial, Jesús F San-Miguel, M. Dimopoulos, P. Rodríguez-Otero, J. Radocha, E. Kastritis, B. Paiva, R. Hájek
          </td>
          <td>2025-12-17</td>
          <td>Blood</td>
          <td>0</td>
          <td>76</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a hematologic malignancy driven by clonal expansion of malignant plasma cells. Despite the long-term disease control achieved with immunotherapies in some patients, treatment resistance remains a major cause of disease relapse. Accumulating evidence highlights the tumor immune microenvironment, especially macrophages, as a key contributor to immunotherapy failure in MM. Herein, we identified a subset of MM-associated macrophages with high expression of fibroblast activation protein alpha (FAPα), defined as FAPα+ macrophages. Clinical data showed that FAPα+ macrophages were enriched in the bone marrow versus peripheral blood of MM patients, and their abundance positively correlated with tumor burden. In MM mouse models, depletion of FAPα+ macrophages significantly boosted the efficacy of anti-PD-1/PD-L1 antibody therapy but not anti-CTLA-4 therapy; this combinatorial strategy also exerted enhanced anti-tumor effects in EL4 lymphoma and CT26 colorectal carcinoma models. Mechanistically, FAPα stabilized PD-L1 expression by maintaining its N-glycosylation and inhibiting proteasomal degradation, and induced PD-L1 synthesis via promoting vimentin (VIM) phosphorylation at the S72 residue. Additionally, FAPα+ macrophages accelerated T cell senescence by secreting soluble FAPα. Collectively, our findings demonstrate that FAPα+ macrophages mediate MM immune evasion via dual mechanisms, positioning them as promising therapeutic targets to potentiate anti-tumor immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4fdd98a62af104734c7d9ca3e69d0c38a4399f57" target='_blank'>
              FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence.
              </a>
            </td>
          <td>
            Huiyao Gu, Zhenfeng Dai, Xi Huang, E. Zhang, Xinyuan Dai, Haoguang Chen, Wen Cao, Jinna Zhang, Yifan Hou, Haimeng Yan, Yang Yang, Li Yang, Yi Li, Wenlong Lin, Zhen Cai, Jingsong He
          </td>
          <td>2026-01-30</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>22</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025', '2026'],
    y: [9, 4],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>